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Abstract 
 
The chalcone motif is a privileged structure present in an extensive range of 
biologically active molecules. The chalcone structure can also serve as a versatile 
starting material for more complex molecules in medicinal chemistry. 
 Eleutherobin, isolated from the Australian coral Eleutherobia and sarcodictyin, 
isolated from the Mediterranean coral Sarcodictyon roseum are natural products 
displaying nanomolar cytotoxicity against a range of cancer cell lines including  
Taxol®-resistant cell lines. Both natural products act as microtubule stabilising agents 
and will be valuable additions to the clinic, however their limited availability and 
lengthy total syntheses prevent further development. The urocanic ester side chain 
present in eleutherobin and sarcodictyin was identified as being critical for biological 
activity. We discuss the design, synthesis and biological evaluation of fourteen 
chalcone analogues based on this urocanic motif with the lead chalcone displaying 
promising antiproliferative activity in a range of cancer cell lines. 
 Combretastatin A-4 is a promising microtubule destabiliser under clinical 
development. The Z configuration is vital for biological activity, however it can 
isomerise to the inactive E configuration. We report a library of twenty pyrazolines 
synthesised from chalcones as “Z restricted” combretastatin analogues with the lead 
pyrazoline displaying potent antiproliferative activity in cancer cell lines due to the 
disruption of tubulin. 
 Tissue engineering is a diverse interdisciplinary field that applies engineering 
principles to the biological sciences with the aim of maintaining or replacing tissue 
function. Recent developments have revealed metal chelation to be a valuable tool to 
control the architecture of tissue engineering scaffolds. We report a library of ten 
novel pyrazolines and their potential as metal chelators. Maltol is a well established 
Fe3+ chelator with a low toxicity profile. We report a novel maltol hydrazide which can 
be attached to the cell surface which upon addition of Fe3+ results in cellular 
aggregation due to metal chelation. Further studies revealed that this process can be 
applied to form heterocellular aggregates composed of two different cancer types 
with valuable applications in tissue engineering and cancer research. 
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Chapter 1: Introduction to Cancer Research 
 
1.1 Cancer Research 
 
Cancer is one of the most feared diseases in the modern world with an estimated 
12.7 million cases in 2008 resulting in 7.6 million deaths worldwide.1 Cancer is 
characterised by uncontrolled cellular proliferation involving most, if not all, of the 
hallmarks of cancer as proposed by Hannah and Weinberg (Figure 1A).2,3 With over 
100 different types of cancer, arising from multiple cell types, research into the 
molecular biology and treatment of cancer is one of the most extensively studied 











      Figure 1: A) The hallmarks of cancer,
2,3
 B) common chemotherapy approaches. 
  
There are three traditional approaches to treating cancer: surgery, 
radiotherapy and chemotherapy of which chemotherapy (Figure 1B) is the most 
commonly employed both in initial cancer treatment and in preventing reoccurrence 
in the future.4 The majority of agents target the increased cellular proliferation of 
cancer cells with alkylating agents,5 antimetabolites6 and microtubule binding agents7 
commonly used in combination to target multiple cellular pathways. The continued 
development of new therapies is of paramount importance with the microtubule 
binders set to continue to play a critical role in combination chemotherapy in the near 
future. 
        Chemotherapy   Hallmarks of 
Cancer 
A B 
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1.2 Targeting Microtubules 
 
Microtubules are highly dynamic biological polymers performing key cellular 
functions including maintaining cell shape, cell signalling, transport of materials 
within the cell and provide the scaffold for cell division and mitosis to occur.7,8 
Microtubule assembly is highly regulated and critically involved in coordinating newly 
synthesised chromosomes during mitosis (Figure 2).8  
 
 




A microtubule is a hollow tubular structure composed of α-β tubulin 
heterodimers comprising one α and one β tubulin unit bound in a head to tail 
arrangement (Figure 3A). Heterodimers assemble into a microtubule nucleus (B) 
acting as a nucleation site for additional heterodimers forming a microtubule (C).7 
Microtubule formation is completely reversible enabling microtubules to expand and 
contract on demand to perform the functions required by the cell.  
 
Figure 3: The three stages of microtubule formation, (A) heterodimer, (B)         microtubule 
nucleus and (C) microtubule, all stages are fully reversible. 
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1.3 Tubulin Binding Sites 
 
The critical role of microtubules in cellular processes inspired the search for novel 
compounds which interact with microtubule assembly providing valuable tools to 
inhibit cellular proliferation. There are three recognised binding sites in which agents 
can interact with tubulin and include the i) vinca and ii) taxane site located on β 




Figure 4: The three binding sites on tubulin are vinca, taxane and colchicine sites B) A crystal 




A diverse range of natural and synthetic compounds interact with tubulin and 
either disrupt the formation of microtubules, classed as microtubule destabilisers or 
interact with tubulin within a fully formed microtubule and prevent its disassembly 
classed as microtubule stabilisers.10 Due to their distinct mode of action, microtubule 
binding drugs are commonly used alongside other cytotoxic drugs in combination 
chemotherapy for a range of different cancers and are set to continue to play a 
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1.4  Microtubule Stabilisers 
 
Microtubule stabilisers commonly bind to the taxane site on β tubulin within a 
formed microtubule resulting in a subtle conformation change preventing the α-β 
tubulin heterodimers from disassociating from the formed microtubule.11 The success 
of this class of compounds is exemplified by the taxane natural product Paciltaxel 
(Taxol®) (1) isolated from the Pacific yew tree (Taxus brevifolia) (Figure 5) approved in 
1992 for breast and ovarian cancers and later for use in lung cancers.12 However 
despite the success of Taxol®, the poor water solubility and emergence of drug 
resistance are major limitations and have inspired the search for improved agents to 
overcome these complications.13  
 
 
Figure 5: Microtubule stabilisers. 
 
 Ixempra® (2) is derived from the gram negative bacteria (Sorangium 
Cellulosum) and binds to the taxane site on tubulin and was approved by the FDA in 
2007 for use in metastatic breast cancer and in Taxol®-resistant cancers.14 Ixempra® 
(2) demonstrates the importance of developing the next generation of drugs with 
improved biological profiles to replace existing treatments in the clinic. 
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 Two further additions to this library are eleutherobin (3) isolated in 1993 from 
the Australian coral Eleutherobia15,16 and sarcodictyin A (4) and B (5) isolated in 1987 
from the Mediterranean coral Sarcodictyon roseum.17 Eleutherobin (3) and 
sarcodictyin (4,5) were shown to be microtubule stabilisers which bind to the taxane 
binding site with potent antiproliferative activities exemplified by eleutherobin (3) 
displaying IC50 values of 11 nM and 14 nM in a colon (HCT116) and ovarian (A2780) 
cell lines respectively.18 The most promising property of these natural products are 
their activities in  Taxol®-resistant cell lines suggesting they may be valuable additions 
to the clinic.18,19 One major problem limiting the further development of these 
compounds is the limited availability from natural sources and the complex total 
syntheses currently available (>35 steps).20-25  
 
1.5 Sarcodictyin SAR Study 
 
An extensive structure activity relationship (SAR) study by Nicolaou et al.26 highlighted 
the importance of the urocanic ester side chain (Figure 6) inspiring the design of 
simplified structurally related analogues in an attempt to pursue the clinically 
potential of these natural products.  
 




Numerous research groups incorporated the urocanic ester side chain into 
simplified analogues in attempts to confer the nanomolar activity of the sarcodictyins, 
however they met with limited success. Gennari et al. reported an analogue (6) 
synthesised in 21 steps from carvone displaying low micromolar activity in human 
ovarian (A2780) and two colon cancer cell lines (HCT116 and HT29 Figure 7).27 
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Figure 7: Simplified sarcodictyin analogues.
27-29 
 
The simplified analogue (6) was confirmed as a tubulin stabiliser with an ED90 
value of 2.0 μM (concentration required to induce 90% tubulin polymerisation). 
Gennari et al. suggested that the failure to confer the potent tubulin stabilisation 
properties of (6) to antiproliferative activity in vitro may be due to esterase mediated 
hydrolysis of the urocanic ester side chain previously identified as vital for biological 
activity.27 Gennari et al. also reported a further analogue (7) synthesised in 22 steps 
from carvone with improved tubulin stabilising and antiproliferative activities.28 
Analogue (7) displayed an ED90 value of 0.5 µM however the antiproliferative 
activities in vitro remained in the low micromolar range. This inability to translate 
tubulin stabilisation properties to potent antiproliferative activities within cancer cell 
lines highlights the potential weakness of the ester linkage. Holmes et al. reported a 
much simplified analogue (8) synthesised in 9 steps from 2-deoxy-D-ribose which had 
an ED90 value of 6.0 μM however no IC50 values were reported.
29 
 
 To pursue the clinical potential of simplified eleutherobin (3) and sarcodictyin 
(4,5) analogues we envisaged replacing the ester linkage with an isostere less 
susceptible to hydrolysis. We wished to simplify the synthesis of simplified 
eleutherobin (3) and sarcodictyin (4,5) analogues (<3 steps) overcoming the long 
syntheses previously reported (>20 steps) enabling rapid screening for useful 
biological activities, as outlined in the aims and objectives section. 
1.6 Microtubule Destabilisers 
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Compounds can interact with tubulin resulting in depolymerisation of 
microtubules (Figure 8) and are classified as microtubule destabilisers. This class of 
compounds are structurally diverse and have been reported to interact at the vinca or 
colchicine binding site preventing the assembly of α-β tubulin heterodimers.30 The 
most notable examples of this class of compounds are the vinca alkaloids vincristine 
(9) and vinblastine (10) (Figure 8). These compounds were isolated from the 
Madagascar periwinkle (Catharanthus roseus) and have been in clinical use for 
leukaemia and lymphoma since the 1950s.31 
 
Figure 8: Microtubule destabilisers. 
 
The emergence of drug resistance to the vinca alkaloids has inspired the 
search for novel alternatives which overcome this problem. The natural products 
maytansine (11), derived from the staff vine plant (Maytenus)32 and colchicine (12), 
derived from the meadow saffron plant (Colchicum autumnale)31 (Figure 8), display 
very potent microtubule destabilising properties. A major complication with 
colchicine (12) and maytansine (11) is severe toxicity limiting the clinical progression 
of these natural products.31  
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1.7 The Combretastatins 
 
Combretastatins are a group of phenolic stilbenes derived from the South African 
Willow tree (Combretum Caffrum) displaying lower toxicity than colchicine and 
maytansine, while still retaining excellent microtubule destabilising properties. 
Combretastatin A-4 (CA4, 13) shows the most promise by reversibly binding at the 
colchicine site on β tubulin preventing its association with α tubulin.33 The 
destabilising effect on microtubule dynamics results in potent antiproliferative 
activity across multiple cancer cell lines including multidrug resistant cell lines.  One of 
the most promising properties of CA4 is its ability to disrupt tumour vasculature 
without disrupting normal vasculature.34 CA4 is poorly water soluble therefore a 
range of analogues have been developed and evaluated in clinical trials with 
Zybrestat® currently being studied in a phase III trial for thyroid cancer (Figure 9 and 
table 1).35  
 
 
Figure 9: Various CA4 analogues are available. 
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1.8 Combretastatin SAR Study 
 
Combretastatin A-4 (CA4, 13) inspired extensive research into its SAR in attempts to 
develop second generation CA4 analogues with improved biological properties.  The 
3,4,5-trimethoxy aryl A ring is a major structural feature present in CA4 and in a 
number of natural products with microtubule disruption properties (Figure 10).36  
 




McGown et al. synthesised and screened 52 CA4 analogues to confirm the 
importance of this motif. Replacing the methoxy groups in CA4 for ethyloxy groups in 
analogue (16) or methyl groups in analogue (17) resulted in a twenty fold decrease in 
antiproliferative activity in the human leukaemia K562 cell line (Figure 11).37 
Interestingly while analogue (17) displayed a twenty fold loss of activity in K562 
compared to CA4, it was a more potent inhibitor of microtubule assembly (MA). 
Fluorine was also investigated in analogue (18) however it displayed a hundred fold 
loss in antiproliferative activity. This SAR study suggested that the 3,4,5-trimethoxy 
aryl was the preferential unit for antiproliferative activity. 
 
 
 Figure 11: CA4 SAR study highlighting the importance of the 3,4,5- trimethoxy aryl unit. 
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A recent study by Ley et al. challenged this SAR study by reporting a 3,5 
dibromo CA4 analogue (19) with comparable activity to CA4 in human epithelial 
cervical (HeLa) and ovarian (SK-OV-3) cancer cell lines but improved activity in a 
Taxol®-resistant ovarian cell line (SK-OV-3-3TR) (Figure 12).38  
 
 




Ley et al. suggest that a halogen bonding interaction may be operating 
between the tubulin protein and 3,5 dibromo analogue (19) resulting in this biological 
activity. This demonstrates that substituting the A ring of CA4 with bromine may 
confer additional useful properties such as activity in Taxol®-resistant cell lines.38 
McGown et al. reported that when the 4-OMe in the B ring in CA4 is replaced with 4-
H in analogue (20) there is a 100 fold loss in activity. Replacing the 3-OH in CA4 with 
3-F in analogue (21) resulted in a 10 fold loss of activity in K562, despite more potent 




 Figure 13: The B ring can be substituted however 3-OH, 4-OMe is the preferred configuration. 
 
 
   - 28 -   
Replacing the 3-OH in CA4 with a 3-Br in analogue (22) retained comparable 
activity as CA4 in K562 but with a higher MA IC50 demonstrating the ability to disrupt 
microtubule assembly does not always correlate with antiproliferative activity in vitro. 
The cis (Z) orientation of the double bond in CA4 is vital for biological activity however 
it can isomerise to the thermodynamically more stable trans (E) configuration (23) 
during storage and in vivo resulting in a loss in activity (Scheme 1).39 
 




Numerous studies have investigated replacing the double bond of CA4 with 
heterocycle isosteres which retain the Z figuration required for potent 
antiproliferative activity.40-45 This strategy enables the introduction of additional 
function groups to overcome the poor water solubility of CA4 previously reported.   A 
diverse range of different heterocyclic CA4 analogues have been reported including 
pyrrole40 (24), furan41 (25) and 1,2,3-triazole42 (26) which retain nanomolar 
antiproliferative activities (Figure 14). One particularly interesting example is 
thiazole43 (27) with an IC50 value of 0.03 nM in the HeLa cell line (human human 
cervical carcinoma) (Figure 14). In contrast CA4 displayed an IC50 value of 1.4 nM in 
HeLa. This 46 fold increase in antiproliferative activity in the HeLa cell line for thiazole 
(27) confirms that heterocyclic CA4 analogues are a valid method of overcoming the 
problems experienced with CA4.  
   - 29 -   
 
 Figure 14: Recent Z restricted combretastatin A-4 analogues.
40-45 
 
The design, synthesis and biological evaluation of novel combretastatin A-4 
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1.9 Chalcones as Tubulin Binding Agents 
 
Chalcones (1,3-diarylprop-2-en-1-ones) consist of two aromatic rings connected by an 
enone and are privileged structures present in an extensive range of biologically 
active molecules (Scheme 2). Chalcones exhibit various activities including anti-
inflammatory, anti-infective, anti-oxidative, anti-malarial and anti-cancer properties.46 
The versatility of the chalcone structure and the ease of its synthesis provide a 
valuable opportunity to develop novel molecules in the field of medicinal chemistry. 
 
 
Scheme 2: Chalcone synthesis. 
 
Chalcones have been reported to display a range of microtubule binding 
properties including nanomolar and picomolar IC50 values in various cancer cell lines 
(Figure 15).47-50 
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1.10 Chalcones as Starting Materials for Pyrazolines  
 
Chalcones, while interesting in themselves, can also serve as versatile starting 
materials for more complex molecules in medicinal chemistry. The vast range of 
commercially available substituted acetophenone and benzaldehydes in addition to 
the modular design and flexibility enables large compound libraries to be generated 
using simple and robust chemical synthesis. The pyrazoline motif is a particularly 
useful scaffold in medicinal chemistry enabling the arrangement of pharmacophores 
in a three dimensional arrangement and has been used to generate a variety of 
compounds that display antiproliferative activity in cancer cell lines (Figure 16).51-54  
 
 




The design, synthesis and investigation of novel pyrazolines are the subjects 
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1.11 National Cancer Institute (NCI) 60 Cell Line Panel  
 
The National Cancer Institute (NCI) developed the 60 cell line panel in the late 1980s 
as a rapid screening tool for academic and industrial laboratories to submit novel 
natural or synthetic compounds to assess anti-cancer activity across 60 different 
cancer cell lines from eight different cancer types without charge.55  To date, the NCI 
has screened over 50,000 novel compounds and has been involved in the 
development of many clinically used drugs including Taxol® and will continue to play a 
significant role in the future. A flow chart of the screening service available at the NCI 




Figure 17: Flow chart of the screening services available at the NCI. 
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To enter the NCI 60 cell panel suppliers provide the molecular structure of the 
compound including a short description of potential anti-cancer properties, typically 
including some initial IC50 values in cancer cell lines. The NCI assesses the novelty of 
the compound to ensure it or a related analogue has not been previously screened 
and if the compound satisfies these requirements then the NCI will accept the 
sample. The compound is initially screened in all 60 cell lines at a single high dose (10-
5M) and only compounds which meet NCI predetermined levels of growth inhibition 
are selected for further screening at 5 doses. Growth inhibition is reported as a GI50 
which is the concentration that inhibits cell growth by 50% with potent GI50 values in 
well characterised cell lines of particular interest. For example, NCI/ADR-RES is a 
multidrug resistant ovarian cell line and OVCAR-3 is an ovarian line which is 
particularly sensitive to tubulin binders.56 Compounds with promising activity are 
screened a second time to ensure reliability and consistency after which the 
compound is assessed by the biological evaluation committee to determine if it 
should progress to an in vivo hollow fibre assay. If the compound performs well in 
vivo the NCI will sponsor the clinical development of the compound. This is 
exemplified by the success of bortezomib which entered the single dose screen in July 
1995 and after 8 years of development at the NCI was FDA approved in 2003 for use 
in myeloma.55 
 
1.12 COMPARE Algorithm 
 
To fully capitalise on the vast database at the NCI, the COMPARE algorithm was 
developed in which the biological profile of a submitted compound is compared 
against the entire NCI library to identify compounds with similar activities across the 
60 cell lines.56 Generally compounds with similar activities across 60 cell lines have 
similar modes of action therefore COMPARE can be used to predict the mode of 
action of a novel compound.38 Halichondrin B, a natural product from the 
Halichondria okada marine sponge, was submitted to the NCI with an unknown mode 
of action. COMPARE analysis demonstrated a high correlation with microtubule 
binders, this was further investigated and Halichondrin B was experimentally 
confirmed to be a potent microtubule destabiliser.56 
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1.13 Identifying Novel Tubulin Binders 
 
Tubulin binders display characteristic hallmarks which can identify a compound as a 
tubulin binder and classify it as a microtubule stabiliser or destabiliser. These three 
hallmarks were used throughout our investigations and are discussed below. 
 
1.14 Cell Cycle Analysis 
 
Tubulin binding compounds typically cause cell cycle arrest in the G2/M phase of the 
cell cycle which can be easily determined using cell cycle analysis. This technique 
relies on measuring the DNA content of a cell using propidium iodide; a DNA 
intercalator which becomes fluorescent when bound to DNA. As the cell progresses 
through the cell cycle the DNA content increases therefore the extent of fluorescence 
is a direct indication of the amount of DNA within the cell and indicates progression 
within the cell cycle (Figure 18A). A healthy cell population without the presence of a 
tubulin binder will give a histogram as shown in figure 18B where the majority of cells 
as in the G1 phase. The presence of a tubulin binder, for example CA4 as shown in 




Figure 18: Cell cycle analysis to determine the location of cells in the cell cycle (A), histograms for SK-




G2/M cell cycle arrest is a characteristic feature of tubulin binders however it 
cannot classify a compound as a stabiliser or destabiliser. 
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1.15 In Vitro Tubulin Polymerisation Assay 
 
 This assay is based on the method reported by Shelanski et al.58 in which the 
polymerisation of tubulin into microtubules scatters light (measured as an optical 
density, OD) and provides an indication as to the extent of microtubule 
polymerisation. The presence of a tubulin stabiliser will promote microtubule 
polymerisation increasing the OD whereas the presence of a tubulin destabiliser will 
disrupt polymerisation lowering the OD compared to control (Figure 19). 
 
 
Figure 19: Idealised in vitro tubulin polymerisation curves for tubulin binders. 
 
1.16 Confocal Microscopy 
 
This technique involves fluorescently labelling microtubules, enabling direct 
visualisation of the effect a compound has on microtubule assembly (Figure 19). The 
presence of a microtubule stabiliser is typical of the results shown in figure 20B 
whereas figure 20C is typical of a microtubule destabiliser such as vincristine.59  
 
 
Figure 20: Typical confocal microscopy results of HeLa cells without drug (A), with Taxol® (B) and 
with vincristine (C), microtubules (green) and chromosomes (blue).
59
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Aims and Objectives in Cancer Research 
 
1.17 Urocanic-Chalcone Hybrids 
 
Design, synthesise and investigate the antiproliferative properties of structurally 
related urocanic-chalcone hybrids containing the urocanic pharmacophore of which 
hybrid (51) is predicted to be the most active (Figure 21).  
 
Figure 21: Proposed urocanic-chalcone hybrids. 
 
 A range of different substituted acetophenone and aldehydes will be used to 
produce structurally related analogues enabling a simple SAR study (Figure 22). 
  
Figure 22: Urocanic-chalcone library design. 
 
 Each hybrid will be screened for antiproliferative activity in three cancer cell 
lines and one non cancer cell line to determine selectivity. The most promising 
compounds will be submitted to the NCI for 60 cell line analysis, and COMPARE 
analysis to determine the mode of action which will be confirmed experimentally.  
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1.18 Pyrazoline Combretastatin A-4 Analogues   
 
Design, synthesis and investigation of the antiproliferative properties of CA4 
analogues, of which (68) is predicted to be the most active (Scheme 3). 
 
Scheme 3: Pyrazoline CA4 analogues. 
  
A range of analogues with different R1 and R2 groups will be used to produce 
structurally related compounds enabling a SAR study (Figure 23). 
 
 
Figure 23: Pyrazoline CA4 library design. 
 
 Each analogue along with its corresponding chalcone will be screened for 
antiproliferative activity and the most promising analogues screened in a non cancer 
cell line to determine selectivity towards cancer. Due to the presence of a stereogenic 
centre at position five of the pyrazoline ring (* in figure 23), the most promising 
analogues will be enantiomerically enriched to determine the effect of 
stereochemistry on biological activity. The most promising compounds will be 
submitted to the NCI for 60 cell line analysis, and COMPARE analysis to determine the 
mode of action which will be investigated experimentally. 
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Chapter 2: Urocanic-Chalcone Hybrids 
2.1 Overview 
 
The natural products eleutherobin (3)15,16 and sarcodictyin (4,5)17 are potent 
microtubule stabilisers displaying nanomolar antiproliferative activities in       Taxol®-
resistant cancer cell lines (Figure 24). 
 
Figure 24: Urocanic ester chain side in the natural products and simplified analogues.
15-17, 27-28 
 
 Nicolaou et al. reported the importance of the urocanic ester side chain for 
biological activity26 inspiring the design of simplified analogues containing this key 
pharmacophore. Gennari et al. reported two simplified analogues (6,7)27,28 containing 
the urocanic ester side chain which retained microtubule stabilising properties but 
only micromolar antiproliferative activities in cancer cell lines (Figure 24). Gennari et 
al. proposed that hydrolysis of the ester side chain was responsible for the loss in 
antiproliferative activity in vitro. The chalcone motif is a privileged structure present 
in a diverse range of range of biologically active molecules including microtubule 
binders. Herein we report the design and synthesis of fourteen urocanic-chalcones 
analogues and their antiproliferative activities in three cancer and one non cancerous 
cell line. Mechanistic studies are also reported to identify the mode of action of this 
class of compounds. 
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2.2 Chemical Synthesis 
 
Chalcones are commonly prepared using a Claisen-Schmidt condensation reaction 
between an acetophenone, benzylaldehyde and a base in a protic solvent with the 
general reaction mechanism outlined below (Scheme 4). 
 
 
Scheme 4: Claisen-Schmidt condensation mechanism. 
 
A solvent free method was adapted from a literature procedure of similar 
substrates,60 in which an acetophenone and ketone are ground together in a mortar 
and pestle in the presence of excess NaOH for five minutes to afford chalcones (43-
45) in high yield (Scheme 5). 
 
 
Scheme 5: Method A.
60 
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The method above was found to be only applicable for this carboxaldehyde as 
all other attempts at synthesising the remaining chalcones via this route gave 
complete recovery of starting materials. One possible explanation for this observation 
is that the carboxaldehyde is a liquid at room temperature whereas all other 
carboxaldehydes were solid. An alternative method using LiOH61 was optimised 
affording chalcones (40-42) in yields up to 74% (Scheme 6). 
 
 
Scheme 6: Method B to afford chalcones (40-42).
61 
 
The reaction conditions above were not effective with the imidazole 
analogues so a third method was investigated for chalcones (46-48) by adapting a 









Using one equivalent of BF3·OEt2 as reported
62 failed to afford the desired 
chalcone resulting in complete recovery of starting materials. Increasing the BF3·OEt2 
to two equivalents was required to afford the desired chalcone in yields up to 74%. It 
is believed that the first equivalent of BF3 coordinates to the basic nitrogen in the 
imidazole preventing enolate formation. A second equivalent is required to enable 
enolate formation allowing the reaction to proceed. It was found that BF3 remained 
   - 41 -   
coordinated to the chalcone product and required an additional step during 
purification to dissociate the BF3 from the final chalcone. The addition of 2M NaOH 
and gentle heating during the work up procedure successfully disrupted BF3 
coordination affording chalcones (46-48) in good yield (Scheme 7). 
 
To investigate the effect of the enone group, the saturated derivative (49) was 
synthesised using a standard hydrogenation procedure (Scheme 8).   
 
Scheme 8: Method D to afford chalcone (49). 
 
Methylation of the imidazole ring in chalcone (48) was attempted using 
caesium carbonate and methyl iodide to afford both isomers (50) and (51) in a single 
step (Scheme 9). 1H NMR indicated a 1:1 ratio of chalcones (50) and (51) however it 
was difficult to separate each isomer by column chromatography. 
 
Scheme 9: Method E to afford chalcones (50,51) in a 1:1 ratio. 
 
The distal methylated carboxaldehyde was not commercially available, 
therefore an existing literature procedure63 was adapted using NaH and MeI in DMF 
at 0oC resulting in selective distal methylation (Scheme 10). Crude 1H NMR revealed 
the presence of (51) and (50) in a ratio of 75:25 (51:50) which could be separated by 
column chromatography using a dichloromethane and isopropanol solvent system to 
afford (51) in >95% purity.  
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Scheme 10: Method F to afford chalcone (51) selectively.
63 
 
 Chalcone (50) was synthesised directly from the commercially available distal 
methylated carboxaldehyde using method C (Scheme 11) in 54% yield avoiding the 
purification difficulties experienced with methylation of chalcone (48) using method 
C. 
 
 Scheme 11: Method C to afford chalcone (50). 
 
 Chalcone (52) was synthesised from imidazole-2-carboxaldehyde using 
method C in 38% (Scheme 12). Chalcone (52) contains a symmetrical imidazole ring 
which upon methylation using method E afforded a single methylated product 
chalcone (53), due to symmetry in 54% yield (Scheme 12). 
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Scheme 12: Method C to give chalcone (52) which upon methylation afforded chalcone (53). 
The successful synthesis of this library of compounds via one or two step 
procedures enables the antiproliferative properties in various cancer and non cancer 
cell lines to be explored using the MTS cell proliferation assay. All chalcones were 
confirmed to be ≥95% pure by HPLC at two wavelengths prior to submission to 
biological evaluation. 
 
2.3 Biological Evaluation 
 
The antiproliferative activity of each analogue was investigated in three cancer 
cells, HT29 a human colon carcinoma, MDA-MB-231 a human breast carcinoma and 
LNCaP, an androgen-dependent human prostate cancer. The antiproliferative activity 
in a non cancerous human skin fibroblast cell line FEK-4 was also investigated to 
determine selectivity. All activities are reported as an average IC50 (concentration 
required to inhibit 50% cell proliferation) of at least three independent experiments ± 
standard deviation, except where indicated (Table 2).  
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40 H OMe H H 43 >500 >500 >500 >500 
41 OMe OMe H H 53 86.0 ± 2.6 102.4 ± 3.0 104.6 ± 7.9 135.1 ± 30.4 
42 OMe OMe OMe H 74 43.0 ± 6.5 49.9 ± 9.6 59.9 ± 7.5 156.1 ± 30.7 
43 H OMe H Me 63 61.8 ± 2.3 53.5 ± 4.6 75.5 ± 5.3 188.2 ± 74.9 
44 OMe OMe H Me 79 60.4 ± 10.7 42.8 ± 9.1 56.3 ± 10.1 161.7 ± 39.3 
45 OMe OMe OMe Me 83 12.5 ± 3.9 18.0 ± 6.3 69.5 ± 8.9 117.5 ± 20.1 
46 H OMe H H 53 23.6 ± 4.0 17.6 ± 3.8 33.5 ± 7.8 92.0 ± 11.2
a
 
47 OMe OMe H H 74 37.9 ± 8.6 18.2 ± 1.7 46.2 ± 5.5 84.2 ± 15.5 
48 OMe OMe OMe H 74 19.5 ± 0.4 22.9 ± 3.0 48.1 ± 6.2 53.2 ± 6.1 
49 OMe OMe OMe H 57 >500 223.4 ± 16.8 367.7 ± 111 >500
b
 
50 OMe OMe OMe Me 54 15.9 ± 1.5 16.9 ± 1.2  30.6 ± 6.8 49.9 ± 1.5 
51 OMe OMe OMe Me 36 2.9 ± 1.0 4.8 ± 1.8 48.4 ± 11.0 85.0 ± 21.1 
52 OMe OMe OMe H 38 5.0 ± 0.4 4.9 ± 0.8 17.1 ± 2.8 28.6 ± 8.7 
53 OMe OMe OMe Me 54 4.2 ± 0.5 4.9 ± 0.2 11.0 ± 2.9 17.5 ± 1.9 
(Dox) - - - - - 0.164 0.120 0.154 n.d 
 
Table 2: MTS Assays, IC50 is the concentration that inhibits 50% cell proliferation, values are the 
mean from three independent experiments ± standard deviation, except 
a
 two and 
b
 one experiment, 
(DOX) doxorubicin was used as a positive control compounds, ≥95% pure by HPLC. 
 
The addition of methoxy groups significantly increased the antiproliferative 
activity of the pyrrole series of hybrids across all cancer cell lines highlighting the 
importance of the 3,4,5 trimethoxy unit pharmacophore (Figure 26).  
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Figure 26: The importance of the 3,4,5 trimethoxy pharmacophore. 
 
Nitrogen methylation increased antiproliferative activity, however the site of 
methylation was important, with proximal methylation in chalcone (50) giving only a 




Figure 27: Distal methylation of chalcone (48) to afford chalcone (51) increased antiproliferative 
activity. 
 
Removal of the E double bond in chalcone (48) to afford chalcone (49) 
resulted in a dramatic loss in activity, highlighting the importance of the enone 
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(Figure 27). The 5-substituted imidazole analogue (48) displayed improved 
antiproliferative activities compared to the 2-pyrrole derivative (42) (Figure 28). The 
2-substituted imidazole analogue (52) displayed three fold higher antiproliferative 
activity than chalcone (48) (Figure 28).  
 
 
Figure 28: Chalcone (52) containing 2-imidazole ring more potent that chalcone (48) containing a 
4-imidazole ring. 
 
All chalcones were selective towards the cancer cells compared against the 
non cancerous FEK-4 human skin fibroblast cells. The extent of selectivity varied 
widely with the most active chalcone (53) being the least selective whereas the 
chalcone which closely resembles the natural products (51) displayed the most 
selectivity (Figure 29).  
 
 
Figure 29: Chalcone selectivity varied widely. 
 
 In summary chalcone (51) which most closely resembles the natural products 
eleutherobin and sarcodictyin displayed low micromolar activity in HT29 and MDA-
MB-231 and good selectivity towards cancer cell lines. 
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2.4 NCI 60 Cell Line Screen 
 
 Six of the most promising chalcones (45, 48, 50, 51, 52, 53) were accepted for 
screening at the NCI at the single (10-5) dose (see appendix A) of which only chalcone 
(51) was selected for further screening at the 5 dose level. Chalcone (51) displayed 
low micromolar GI50 values across multiple cancer cell lines including the multidrug 
resistant cell line NCI/ADR-RES (GI50 2.96 µM) (Table 3). Chalcone (51) also displayed 
the most promising results in the colon panel with GI50 values of 3.52-4.84 μM in six 
of the seven colon cell lines, however, it was not selected for further screening. 


























































































































Table 3: NCI 60 cell line screen, GI50 is the concentration required to inhibit growth by 50%. 
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2.5 COMPARE Analysis 
 
 A COMPARE analysis of chalcone (51) was performed to correlate the 
biological profile of this hybrid against all previously screened compounds in the NCI 








1 49 Rhizoxin Microtubule destabiliser 
2 46 Tetraplatin Alkylation of DNA 
3 41 Cyanomorpholino-ADR Alkylation of DNA 
4 40 Taxol® Microtubule stabiliser 
5 40 Methotrexate Antimetabolite 
 
Table 4: COMPARE analysis results. 
 
 The highest correlation was with the potent microtubule destabiliser rhizoxin 
which acts as a microtubule destabiliser binding to the vinca alkaloid binding site on β 
tubulin. The second and third highest correlations were with tetraplatin and 
cyanomorpholino-ADR two compounds which are known alkylators of DNA which do 
not interact with tubulin. The fourth highest correlation was the microtubule 
stabiliser Taxol® followed by the antimetabolite methotrexate. This analysis 
suggested that chalcone (51) may be a possible microtubule binder, although 
alternative mechanisms of action may be responsible for the activity observed. In 
order to investigate further, mechanistic studies including cell cycle analysis and in 
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2.6 Cell Cycle Analysis 
 
To confirm microtubule binding was responsible for the biological activity of chalcone 
(51), cell cycle analysis was performed on HT29 cells which were exposed to 5.0 µM 
and 25 µM of chalcone (51) over 24 hours. The histograms obtained were then 
compared to untreated cells and cells treated with 100 nM of the potent microtubule 
destabiliser colchicine (Figure 30). 
 
 
Figure 30: Cell cycle analysis, A) HT29 cells only, B) + 100 nM colchicine 
C) + 5.0 μM  chalcone (51), D) + 25 μM  chalcone (51). 
  
The untreated HT29 cells displayed a histogram in which the majority of the 
cell population (57%) resided in the G1 phase of the cell cycle (Figure 30A). In the 
presence of the positive control colchicine (B) the majority of the cell population 
(96%) resided in the G2/M phase of the cell cycle. The presence of 5.0 μM chalcone 
(51) (C) resulted in a histogram similar to the untreated cells (A) suggesting that 
chalcone (51) was not disrupting microtubules at this concentration. This is 
interesting as despite chalcone (51) having an IC50 value of 2.9 µM in HT29 the 
histogram is very similar to untreated cells (A). Increasing the concentration of 
chalcone (51) to 25 µM (D) resulted in the majority of the cell population (51%) now 
residing in the S phase of the cell cycle. The absence of the characteristic G2/M peak 
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for chalcone (51) at 5.0 and 25 μM, suggests that chalcone (51) is not a microtubule 
binder.   
 
2.7 In Vitro Tubulin Polymerisation Assay 
 
An in vitro tubulin polymerisation assay was also performed to investigate if chalcone 
(51) displayed microtubule binding properties and is shown in figure 31. The control 
curve is tubulin only, showing the steady increase in optical density over the first 40 
minutes as tubulin naturally polymerises into microtubules. The presence of 5.0 μM 
of the positive control Taxol® (orange dots) resulted in a rapid increase in tubulin 
polymerisation over the first 10 minutes after which the microtubules retain in their 
fully formed state. The presence of 20 µM chalcone (51) resulted in a curve almost 
identical to the control curve suggesting that chalcone (51) is neither stabilising nor 
destabilising tubulin polymerisation at this concentration. 
 
 
Figure 31: In vitro tubulin polymerisation assay, Taxol and chalcone (51) concentration 5.0 µM. 
 
 
In summary, further mechanistic studies including cell cycle analysis and in 
vitro tubulin polymerisation assay suggest that chalcone (51) is not a tubulin binder 
and is exerting its biological action through a currently unknown mechanism.  
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2.8 Conclusions 
 
Fourteen urocanic-chalcone analogues were synthesised using simple one or two step 
procedures and screened for antiproliferative activity in multiple cancer cell lines. A 
simple SAR study confirmed the importance of key structural units consistent with the 
proposed hypothesis (Figure 32) enabling the design of a second library with 
improved biological properties.  
 
 
Figure 32: Important structural requirements for antiproliferative activity. 
 
Chalcone (51) which most closely resembles the urocanic ester side chain in 
the natural products eleutherobin (3) and sarcodictyin (4,5) displayed low micromolar 
GI50 values across multiple cancer cell lines in the NCI 60 cell line panel including the 
multidrug resistant cell line NCI/ADR-RES (GI50: 2.96 µM). Of great interest is that this 
chalcone was also one of the most selective towards cancer cell lines.  
Further investigations into the mode of action of chalcone (51) suggest that it 
does not interact with tubulin. The importance of the enone for antiproliferative 
activity suggests this chalcone (51) may be acting at a Michael acceptor and 
interacting with intracellular nucleophiles during the S phase of the cell cycle (Scheme 
13). Further investigations are required to confirm this mode of action. 
 Scheme 13: Chalcone (51) may be acting as an intracellular Michael acceptor. 
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2.9 Future Work 
 
2.10 Determination of Mode of Action of Chalcone (51) 
 
One vital avenue for future work is to identify the mode of action of the lead chalcone 
(51). Cell cycle analysis suggested chalcone (51) was disrupting cellular proliferation in 
the synthesis phase of the cell cycle possibly via Michael addition.  Honda et al. 
recently reported using 1H NMR and UV/Vis spectroscopy to identify a series of 
monocyclic cyanoenones as potent Michael acceptors in the presence of the model 
nucleophile dithiothreitol.64 A similar study could be conducted with chalcone (51) in 
the presence of increasing concentrations of dithiothreitol. The gradual 
disappearance of protons Ha and Hb from chalcone (51) alongside the formation of 
new peaks for Hc and Hd upon dithiothreitol addition would suggest chalcone (51) was 
acting as a Michael acceptor (Scheme 14). 
 
Scheme 14: Proposed 
1
H NMR study with dithiothreitol. 
 
  Honda et al. also observed spectra changes upon addition of dithiothreitol to 
the monocyclic cyanoenones using UV/Vis spectroscopy.64 The disruption of the 
enone in chalcone (51) upon Michael addition of dithiothreitol would result in 
changes in the UV/Vis spectrum which could also be used to confirm that chalcone 
(51) is a Michael acceptor. Performing the above experiment with glutathione a 
nucleophile present in multiple cell lines would also be a valuable experiment to 
perform. 
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2.11 Prenylation of Chalcone (51) 
 
The prenyl group is present in a range of biologically active compounds including 
chalcone isobavachalcone (54) with an IC50 value of 6.2 µM in NB-39, a 
neuroblastoma cell line65 and chalcone xanthohumol (55) with an IC50 value of     3.5 
μM in MCF-7, a human breast carcinoma cell line66 (Figure 33). Prenylation is thought 
to increase the affinity between a compound and its target protein and has been 
reported to increase the growth inhibition profiles of bis-prenylated chalcone (57) 
compared with mono-prenylated chalcone (56)67 (Figure 33). 
 
Figure 33: The prenyl group in biologically active chalcones.
65-67 
 
Caggiano et al.68 reported a novel single step procedure involving Bi(OTf)3 and 
isoprene which could be applied to chalcone (51) to generate both the mono- and 
bis-prenylated chalcones (51A) and (51B) respectively (Scheme 15). Exploring the 
antiproliferative activity of chalcones (51A) and (51B) compared to chalcone (51) is 
of interest and worthy of investigation.  
 Scheme 15: Prenylation of chalcone (51) to generate chalcones (51A) and (51B). 
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Chapter 3: Pyrazoline Combretastatin A-4 Analogues 
3.1 Overview 
 
Combretastatin A-4 (CA4, 13)33 is a promising microtubule destabiliser with potent 
antiproliferative activity across multiple cancer cell lines including multidrug resistant 
cell lines (Figure 34). Combretastatin A-4 (CA4, 13) is poorly water soluble and 
susceptible to isomerisation to the less biologically active E configuration.39 As 
highlighted in chapter 1, numerous studies have reported heterocyclic combretastatin 
A-4 (CA4, 13) analogues with potent nanomolar antiproliferative activities without 
the limitations of combretastatin A-4 (CA4, 13).40-45 The pyrazoline motif is easily 
accessible from chalcone starting materials and provides an opportunity to develop 
novel heterocyclic CA4 analogues (Figure 34).  
 
Figure 34: Combretastatin (CA4)
33
 and proposed lead pyrazoline (68), Ar = C6H4. 
 
Herein we now report the design, synthesis and evaluation of pyrazoline CA4 
analogues derived from chalcones of which pyrazoline (68) is predicted to be the 
most potent due to structural similarity to CA4. All pyrazolines and their 
corresponding chalcone starting materials will be evaluated for antiproliferative 
activities and the most potent pyrazolines will be submitted to the NCI for screening 
in the 60 cell line panel. Mechanistic studies including cell cycle analysis, in vitro 
tubulin polymerisation assays and confocal microscopy will be performed to 
determine the mode of action of the lead pyrazoline.  
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3.2 Chemical Synthesis 
 
A simple and efficient synthesis of the pyrazoline scaffold was established in three 
steps from the commercially available starting materials in high yield (Scheme 16). 
The chalcone precursors were synthesized in good to excellent yield giving the E 
isomer exclusively as identified by characteristic 3J coupling of ca 15Hz. Chalcones 
have been reported to display a range of biological activities46-50 therefore all 
chalcone precursors were screened for antiproliferative activity in human colon 
carcinoma (HT29) and human breast carcinoma (MDA-MB-231) cell lines. 
 
 
Scheme 16: Chalcone synthesis. 
 
Table 5: MTS Assays, IC50 is the concentration that inhibits 50% cell proliferation, values are the 
mean from three independent experiments ± standard deviation, colchicine was used as a positive 
control, compounds ≥95% pure by HPLC and elemental analysis. 
 
The unsubstituted phenyl-derived chalcone (58) displayed the most promising 
antiproliferative activity, whilst the 4-OMe (59), 4-OBn (60) and 4-OH (61) substituted 
analogues retained similar activity in HT29. Surprisingly the 4-OBn substituted 
analogue (60) displayed poor activity (>100 μM) in MDA-MB-231 yet displayed good 
 IC50 (µM) 




58 C6H5 96 3.7 ± 0.5 5.3 ± 0.2 
59 4-OMe-C6H4 78 3.9 ± 0.7 10.1 ± 1.8 
60 4-OBn-C6H4 80 9.9 ± 1.0 >100 
61 4-OH-C6H4 44 4.2 ± 0.6 13.3 ± 1.6 
62 4-NO2 -C6H4 76 6.5 ± 1.3  12.4 ± 2.0 
63 4-NH2 -C6H4 59 14.9 ± 1.7 31.6 ± 6.6 
64 Pyridin-2-yl 85 9.6 ± 0.9 9.7 ± 4.3 
65 Furan-2-yl 80 9.6 ± 0.8 10.3 ± 1.0 
66 Thiophen-2-yl 93 4.9 ± 1.1 5.5 ± 1.0 
67 Naphthalen-2-yl 70 8.7 ± 1.2 10.6 ± 2.3 
Colchicine - - 0.007 ± 0.001 0.008 ± 0.001 
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antiproliferative activity (9.9 μM) in HT29. Analogues with an electron withdrawing 4-
NO2 group (62) and electron donating 4-NH2 group (63) were well tolerated at this 
position. Substitution of the phenyl ring in analogue (58) for a heterocycle such as 
pyridin-2-yl (64) or furan-2-yl (65) slightly reduced activity except for the thiophen-2-
yl analogue (66) which displayed comparable activity to the parent pyrazoline (58) in 
both cancer cell lines. 
 
3.3 Pyrazoline Formation 
 
2-Pyrazolines are commonly prepared by heating a chalcone and hydrazine in ethanol 
for between 1 -2 hours. The mechanism is believed to proceed through 1,2 addition 
of hydrazine affording a hydrazone which upon intramolecular conjugate addition 
results in cyclisation to the pyrazoline ring (Scheme 17).69,70  Tautomerisation affords 
the more stabilised 2-pyrazoline in which the double bond is localised on the benzylic 
position. 
 
Scheme 17: Pyrazoline synthesis.
69,70
  
Formation of the 2-pyrazoline ring is confirmed via the three non equivalent 
protons (HA, HB and HC) on the pyrazoline ring, resulting in three sets of doublet of 
doublet peaks in the 1H NMR spectrum.  
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3.4 Chemical Synthesis of Pyrazolines 
 
 
The chalcones (A series) shown in Scheme 16 were treated with hydrazine hydrate to 
afford the corresponding pyrazoline derivatives (B series). The B series were unstable 
and rapidly decomposed within a few days of isolation so were immediately treated 
with the desired acid chloride to afford the final pyrazoline derivatives (C series) 
(Scheme 18). The C series was found to be stable to decomposition and were purified, 
fully characterised and screened for antiproliferative activity in human colon 




Scheme 18: Pyrazoline synthesis and biological evaluation. 
 
To investigate the possibility of synthesising the C series of pyrazolines directly 
from the chalcone, chalcone (58) was treated with phenyl hydrazine to afford 
pyrazoline (75) directly in 60% yield. All compounds were determined to be ≥95% 
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3.5 Biological Evaluation 
 
All C series pyrazolines displayed similar or improved antiproliferative activities across 
both cancer cell lines compared to the corresponding A series chalcones 
demonstrating that chalcones are useful starting materials for more biologically active 
compounds (Table 6). 
 
 
Table 6: MTS Assays, IC50 is the concentration that inhibits 50% cell proliferation, values are the 
mean from three independent experiments ± standard deviation, except 
a
 two experiments, 
compounds ≥95% pure by HPLC and CHN analysis, 
b
 determined by chiral HPLC to be ≥95% ee. 
 
Pyrazoline (69) containing the 3-OH, 4-OMe arrangement present in CA4 
displayed modest antiproliferative activity in HT29 and good activity in MDA-MB-231 
(Table 6). Protection of the 3-OH to 3-OBn in pyrazoline (68) abolished activity 










68 C6H5 3-OBn,4-OMe-C6H3-CO 54 >100 >100 
69 C6H5 3-OH,4-OMe-C6H3CO 81 1.8 ± 0.1 0.51 ± 0.07 
70 C6H5 4-OMe-C6H3-CO 68 1.4 ± 0.1 0.82 ± 0.05 
71 C6H5 C6H5-CO 84 0.17 ± 0.04  0.17 ± 0.02  
71 (-)
b
 C6H5 C6H5-CO - 0.19 ± 0.03 0.10 ± 0.02 
71 (+)
b
 C6H5 C6H5-CO - 45.0 ± 7.8 99.6 ± 6.3 
72 C6H5 1-napthyl-CO 84 1.1 ± 0.1 0.9 ± 0.1 
73 C6H5 C6H5 58 40.5 ± 3.5 63.7 ± 13.7 





 4-OMe-C6H4 C6H5-CO - 0.84 ± 0.12 0.56 ± 0.12  
74(+)
b
 4-OMe-C6H4 C6H5-CO - 45.4 ± 7.8 56.5± 5.0
a
 
75 4-OH-C6H4 C6H5-CO 72 0.66 ± 0.06  0.25 ± 0.05 
76 4-NO2-C6H4 C6H5-CO 60 7.9 ± 0.6 19.6 ± 3.6 
77 4-NH2-C6H4 C6H5-CO 95 0.35 ± 0.03 0.36 ± 0.02  
78 Pyridin-2-yl C6H5-CO 72 1.3 ± 0.4 0.24 ± 0.04  
78 (-)
b
 Pyridin-2-yl C6H5-CO - 0.49 ± 0.07 0.33 ± 0.01 
78 (+)
b
 Pyridin-2-yl C6H5-CO - 13.0 ± 1.06 82.0 ± 18.9  
79 Furan-2-yl C6H5-CO 65 4.00 ± 0.27 2.18 ± 0.25 
80 Thiophen-2-yl C6H5-CO 61 1.19 ± 0.18 0.85 ± 0.02 
81 Naphthalen-2-yl C6H5-CO 58 10.1 ± 1.4 1.1 ± 0.2 
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whereas removal of the 3-OH in pyrazoline (70) retained similar activity as pyrazoline 
(69). Interestingly, the removal of the 4-OMe group in pyrazoline (71) significantly 
increased activity with low nanomolar activity in both HT29 and MDA-MB-231 cell 
lines (Figure 35). 
 
 Figure 35: Unsubstituted benzoyl ring preferred. 
 
Increasing the steric bulk of R1 and R2 was investigated in pyrazoline (72) and 
(81) respectively however both pyrazolines displayed reduced activity (Figure 44). 
Pyrazoline (73) without a carbonyl group displayed poor activity suggesting this is vital 
for antiproliferative activity (Figure 36). 
 
 Figure 36: Effect of steric bulk on antiproliferative activity. 
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 Substitution at the 4 position was investigated with pyrazolines (74), (75) and 
(77), all displaying good antiproliferative activities (Figure 37).  
 
 
 Figure 37: Substitution tolerated at 4 position. 
 
Replacing the phenyl ring for a pyridin-2-yl in pyrazoline (78) resulted in 
diminished activity in HT29 compared to pyrazoline (71), but surprisingly retained 
activity in MDA-MB-231. The furan-2-yl pyrazoline (79) and thiophen-2-yl pyrazoline 
(80) were investigated with both displaying micromolar activity with a slight 
preference for the thiophen-2-yl over furan-2-yl (Figure 38). 
 
 
Figure 38: Heterocycles detrimental to activity. 
 
Due to the presence of a stereogenic centre at position five of the pyrazoline 
ring, three of the most promising compounds (71, 74 and 78) were selected for 
semipreparatory chiral HPLC to separate the enantiomers and determine the effect of 
stereochemistry on antiproliferative activity.  
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3.6 Enantiomerically Pure Pyrazoline Combretastatin Analogues 
 
Pyrazolines (71), (74) and (78) were selected for semipreparatory chiral HPLC using a 
vancomycin based stationary phase, a mobile phase of 1:1 MeCN:H2O and a flow rate 
of 10 mL/min. The first eluting component was identified as the (+) enantiomer and 




Figure 39: Separation of pyrazoline (71+/-) enantiomers using semipreparatory chiral HPLC. 
 
 All enantiomers were confirmed to be ≥95 ee (enantiomeric excess) by chiral 
HPLC analysis prior to biological evaluation. The (-) enantiomer was found to be the 
most active component in all cases and displayed similar or better antiproliferative 
activity compared to the racemic mixture (Figure 40 and Table 6). 
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Figure 40: Enantiomerically pure pyrazoline combretastatin analogues. 
 
Selectivity was determined using the FEK-4 cell line with pyrazolines (71-) and 
(71+/-) displaying similar IC50 values in FEK-4 as in HT29 and MDA-MB-231. The poor 
selectively for HT29 and MDA-MB-231 cell lines is an interesting observation 
compared to chalcone (51) reported previously in chapter 2 (Figure 29). Chalcone (51) 
displayed low micromolar IC50 values in multiple cancer cell lines but good selectively 
with an IC50 of 85 μM in FEK-4. In constrast pyrazoline (71-) displayed low nanomolar 
IC50 values in both cancer cell lines and FEK-4. One potential solution to this problem 
to increase selectively for cancer cell lines over non cancer cell lines involves 
modifying the pyrazoline structure via prodrug strategies, potential options are 
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3.7 NCI 60 Cell Line Screen 
 
Pyrazolines (71+/-), (71-) and 71(+) were submitted to the NCI for 60 cell line analysis 
and were selected for both the single dose and five dose screens. A summary of the 
five dose data is below (Table 7) (see appendix A for full data sets). 
 
  GI50 (µM)   GI50 (µM) 
Panel Cell Line 71+/- 71- 71+ Panel Cell Line 71+/- 71- 71+ 



















































































































































































































































Table 7: NCI 60 cell line screen for pyrazolines (71+/-, 71- and 71+), GI50 is the concentration required 
to inhibit growth by 50%. 
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Pyrazoline (71-) displayed potent growth inhibition across the melanoma 
panel with GI50 values <80 nM in six of the eight cell lines, it also displayed GI50 values 
of 25 nM in a lung cancer cell line (NCI-H522) and an ovarian cell cancer line (OVCAR-
3) which is particularly sensitive to tubulin binding agents.56 Of great interest is that 
pyrazoline (71-) also displayed a GI50 value of 35 nM in the multidrug resistance 
NCI/ADR-RES cell line, suggesting that this compound may be useful in treating drug 
resistant cancers. Pyrazoline (71-) is currently under evaluation at the biological 
evaluation committee to determine if it should progress to in vivo screening.  The GI50 
value for pyrazoline (71+) show that this enantiomer is much less active. 
 
3.8 COMPARE Analysis 
 
A COMPARE analysis was performed using the NCI GI50 values to predict the likely 
mode of action of the lead compounds pyrazoline (71+/-) and (71-) (Table 8). 
Pyrazoline (71+/-) showed good correlation with maytansine and vinblastine. 
Pyrazoline (71-) displaying strong correlation with maytansine, vinblastine and 
vincristine suggesting that the disruption of tubulin polymerization was responsible 
for the biological activity of these compounds. Pyrazoline (71+) showed good 
correlation with non tubulin disrupting agents suggesting that it is not a tubulin 
disruptor.  
Pyrazoline Rank Correlation 
% 
Compound Target 
(71+/-)     
 1 49 maytansine Microtubule 
 2 46 trimetrexate dihydrofolate reductase 
 3 46 vinblastine sulphate Microtubule 
(71-)     
 1 62 maytansine Microtubule 
 2 58 vinblastine sulphate Microtubule 
 3 57 vincristine sulfate Microtubule 
(71+)     
 1 62 neocarzinostatin  
 2 62 CCNU DNA 
 3 60 didemnin B DNA 
 
 
Table 8: COMPARE analysis for pyrazoline (71+/-, 71- and 71+). 
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3.9 Cell Cycle Analysis 
 
Tubulin disruptors are known to cause arrest in the G2/M phase of the cell cycle 
therefore cell cycle analysis was performed. Using 100 nM pyrazoline (71-) resulted in 
65% of the cell population arresting in G2/M which  increased to 93%  at  a 
concentration of 500 nM providing further evidence that pyrazoline (71-) is a tubulin 




Figure 41: Cell cycle analysis, A) HT29 cells only, B) + 100 nM colchicine 




The promising cell cycle analysis results above, combined with the COMPARE 
analysis suggest that pyrazoline (71-) was exerting its biological mode of action via 
microtubule binding. To provide further evidence that tubulin binding was 
responsible for the activity of pyrazoline (71-) and to classify it as a microtubule 
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3.10 In Vitro Tubulin Polymerisation Assay 
 
The control experiment showed the steady increase in optical density (OD) observed 
over time as tubulin naturally polymerises into microtubules whereas the presence of 
5.0 μM of the tubulin stabiliser Taxol® resulted in rapid microtubule formation within 
the first 20 minutes (Figure 42). The addition of 5.0 μM pyrazoline (71-) reduced the 
OD reading compared to the control experiment. This suggests that the 
polymerization of tubulin to microtubules is being disrupted, similar to maytansine 
and vinblastine, and not acting as a tubulin stabiliser like Taxol®. 
 
 
Figure 42: In vitro tubulin polymerisation assay for 5.0 μM pyrazoline (71-) and 5.0 μM Taxol. 
 
This assay was repeated a second time giving results identical to the assay 
above confirming the cell cycle analysis results and enabling classification of 
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3.11 Confocal Microscopy 
 
Additional evidence of the microtubule disrupting properties of pyrazoline 
(71-) was obtained using the technique of confocal microscopy (Figure 43).  
 
Figure 43: Confocal microscopy A) HT29 cells only, B) + 100 nM colchicine,  
C) + 100 nM pyrazoline (71-), D) + 500 nM pyrazoline (71-). 
 
In Panel A (Figure 43A) the microtubule network (green) is clearly visible as a 
green cloud which encompasses the chromosomes (blue) within the dividing cells. In 
the presence of the positive control colchicine, the microtubule network is 
dramatically reduced providing visual evidence that colchicine is disrupting 
microtubule formation (B). The addition of 100 nM of pyrazoline (71-), the same 
concentration which resulted in 65% of the cell population residing in G2/M in the cell 
cycle analysis, the microtubule network is still present but reduced in volume (C). 
Increasing the concentration to 500 nM, a concentration resulting in 93% of the cell 
population residing in G2/M, severely reduced microtubule volume.  This study 
provides direct visual evidence that pyrazoline (71-) was disrupting microtubule 
formation providing further support with the results of the COMPARE and cell cycle 
analyses along with the in vitro tubulin polymerisation assays. 
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3.12 Determination of Absolute Stereochemistry 
 
A commonly used method for assigning the absolute stereochemistry of crystalline 
solids is to obtain an X-ray crystal structure and assign the absolute stereochemistry 
as R or S using the Cahn-Ingold-Prelog priory rules (Figure 44).71 
 
 Figure 44: Assignment of absolute stereochemistry. 
 
Pyrazoline (71-) was screened in a number of different solvents in order to 
produce crystals of sufficient size and quality for a X-ray structure determination 
(Table 9). Although crystals were obtained in many cases, they were not of suitable 
quality for x-ray crystallography. Compounds containing the nitro (NO2) group are 
often highly crystalline, therefore the nitro pyrazoline (76) was also submitted to this 
solvent screen but also failed to yield suitable crystals. 
 
Cpm EtOH MeOH MeCN THF EtOAc CHCl3 EtOH Toluene IPA CH2Cl2 
71(-) 
76 
X X X X X X X X X X 
 
Table 9: Solvent screen. 
 
A literature search revealed very few examples of enatiomerically pure 
pyrazolines with defined absolute stereochemistry (Figure 45).72,73 The examples 
found suggest that pyrazoline (71-) may have an S configuration based on the optical 
rotation, however further experiments are required in order to confirm this. 
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3.13 Pyrazole Combretastatin Analogue 
 
To overcome the problem with determining the absolute stereochemistry of 
pyrazoline (71-) and remove the issues arising from it, oxidation of pyrazoline (71) to 
pyrazole (85) lacking a stereogenic centre was attempted (Figure 19). 
 
 
Scheme 19: Removal of stereogenic centre by oxidation of pyrazoline (71) to pyrazole (85).
103 
 
Several attempts at this oxidation were attempted however none were 
successful despite similar compounds in the literature.103 It was predicted that the 
benzoyl ring was responsible for the difficulty therefore an alternative was 
investigated in which the NH pyrazoline was initially oxidised followed by addition of 
benzoyl chloride (Scheme 20).  
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Scheme 20: An alternative synthesis of pyrazole (85) and its regioisomer (85A). 
 
This reaction was successful however a mixture was obtained of the desired 
pyrazole (85) and the corresponding regioisomer (85A) in a ratio of 61:39 (85:85A) 




Scheme 21: Tautomersation of the NH pyrazole. 
 
Separation of regioisomers (85 and 85A) was attempted using silica gel 
column chromatography however without success. Molecular modelling with MOPAC 
indicated that the stereogenic centre present in pyrazoline (71-S) induces a curved 
conformation with a dihedral angle of 123o and bond distance of 4.9 Å between the A 
and B rings (Figure 55). A similar result was obtained with pyrazoline (71-R) (data not 
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shown). In contrast pyrazole (85) contains a flat aromatic pyrazole ring which forces 
the A and B rings to have a dihedral angle of 179o without significantly changing the 
bond length (Figure 46). In addition, the orientation of the C ring in pyrazole (85) is 
significantly altered which may influence activity. 
 
Figure 46: Molecular models of pyrazoline (71-S) and pyrazole (85).  
 
 To investigate how this structural change influenced antiproliferative activity, 
regioisomers (85 and 85A) were submitted for biological evaluation. Pyrazole mixture 
(85 and 85A) displayed over a hundred fold loss in antiproliferative activity compared 
to the parent pyrazoline confirming the importance of the curved shape in pyrazoline 
(71) for biological activity (Figure 47). 
 
 Figure 47: Pyrazoline (85) and its regioisomer (85A) display a hundred fold less antiproliferative 
activity compared to pyrazoline (71). 
(71-S) 
(85) 
Bond distance : 4.9 Å 
Dihedral angle : 123
o 
Bond distance : 4.8 Å 
Dihedral angle : 179
o 
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3.14 Prodrug Strategies 
 
Prodrugs are a useful technique of increasing the activity of a drug by incorporating a 
structural unit which can be biologically converted in vitro generating the active drug 
within the cell.75,76 The SAR study revealed substitution at the 4 position of the A ring 
with OH (75) and NH2 (77) displayed similar levels of activity to the unsubstituted 
pyrazoline (71) in HT29 and MDA-MB-231. This suggests these two analogues may be 
candidates for prodrug strategies (Scheme 22). In order to investigate further the 
ester (86) and amide pyrazoline (87) were generated in high yield and submitted to 
biological evaluation to determine if the parent OH  (75) and NH2 (77) analogues 
could be generated within the cell (Scheme 22). 
 
  
Scheme 22: Prodrug synthesis and biological evaluation. 
 
 The ester (86) displayed comparable antiproliferative activity as the parent OH 
pyrazoline (75), whereas the amide (87) displayed poor antiproliferative activity. To 
confirm that the antiproliferative activity of ester (86) was due to ester hydrolysis 
within the cell generating the parent OH pyrazoline intracellularly and not due to 
hydrolysis in the culture medium, a mass spectroscopy study was conducted. This 
study involved incubating the ester (86) and amide (87) pyrazolines in culture media 
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only (without cells) for 72 h, the time course of the MTS assay. Aliquots of the culture 
media were extracted at 0 h, 24 h, and 72 h time points and the presence and 
quantity of prodrug and corresponding parent pyrazoline calculated by comparing the 
relative signal intensities of the sodium adduct at each time point. The mass 
spectroscopy data obtained suggested that the activity observed for the ester 
pyrazoline (86) was due to hydrolysis in the culture media generating the active 
patent pyrazoline (75) which then elicited the antiproliferative activity observed 
(Table 10). 
  
 Incubation Time 
cpm 0 h 24 h 48 h 72 h 
Ester (86) 100% 47% 27% 20% 
Amide (87) 100% 100% 100% 100% 
 
Table 10: Prodrug stability studies. 
 
This suggests that simple ester groups may not be suitable for future prodrug 
strategies. In contrast, the amide pyrazoline (87) was fully stable over the 72 h time 
period without any detection of the parent NH2 pyrazoline (77) in the mass spectra. 
The poor biological activity of the amide suggests the amide unit was fully stable to 
intracellular amidases which were unable to hydrolyse the amide (87) to the active 
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3.15 Conclusions  
 
A library of fourteen pyrazoline combretastatin A-4 analogues, along with the ten 
chalcone precursors, were synthesised and screened for antiproliferative activity in 
two cancer line lines. Pyrazoline (69) was predicted to be the most active due to 
structural similarity to CA4 however analogue (71), lacking the 3-OH and 4-OMe 
substituted benzoyl ring, was the most active compound in the library (Figure 48). 
  
Figure 48: Predicted lead pyrazoline vs actual lead pyrazoline.  
 
 An SAR study revealed that a single aryl ring was preferred at A, with minor 
substitutions at the para position tolerated. A 3,4,5-trimethoxy aryl unit at B was 
critical for activity, a single aryl ring at position C was preferred and the ketone linking 
ring C to the pyrazoline ring was essential for antiproliferative activity (Figure 49).  
 
Figure 49: Pyrazoline SAR study. 
 
 Six enantiomerically pure pyrazolines were obtained using semipreparatory 
chiral HPLC and in all cases the (-) enantiomer was the active enantiomer and was the 
component responsible for the antiproliferative activity observed in the racemates. 
Pyrazoline (71-) displayed excellent nanomolar GI50 values across multiple cancer cell 
lines in the NCI 60 cell panel including the multidrug resistant  NCI/ADR-RES (GI50 35 
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nM) cell line (Figure 50). Pyrazoline (71-) displayed modest selectivity towards cancer 
cell lines and is currently under evaluation at the NCI biological evaluation committee 
to determine if it should progress to in vivo screening.  
 
 
Figure 50: Pyrazoline (71-) displayed excellent growth inhibition activity across multiple cancer cell 
lines and modest selectivity in FEK-4 human skin fibroblasts. 
 
 COMPARE analysis demonstrated a high correlation with microtubule binders 
suggesting pyrazoline (71-) had a similar mode of action. Cell cycle analysis, in vitro 
tubulin polymerisation and confocal microscopy analysis provided further evidence to 
suggest that pyrazoline (71-) is a microtubule destabiliser.  The simple molecular 
structure, combined with its simple three step synthesis from commercially available 
materials enables the design of a second library of pyrazoline (71-) analogues. 
Attempts to obtain suitable crystals for an X-ray crystal structure of pyrazoline 
(71-) to assign the absolute stereochemistry were unfortunately unsuccessful. 
Attempts to generate the corresponding pyrazole (85) resulted in a mixture of the 
desired product and its regioisomer (85A). Biological evaluation of this mixture 
indicated a hundred fold loss in antiproliferative activity confirming the importance of 
the stereogenic centre. 
To investigate the potential of applying prodrug strategies to this series of 
compounds, the para substituted OH pyrazoline (75) and NH2 pyrazoline (87) were 
aceylated to give ester (86) and amide pyrazolines (87) respectively. Biological 
evaluation indicated that amide (87) failed to confer the antiproliferative activity of 
the parent NH2 pyrazoline in vitro (Scheme 23). In contrast ester (86) conferred equal 
antiproliferative activity as the parent OH pyrazoline in vitro. To investigate if the 
activity observed was due to esterase hydrolysis intracellularly and not due to 
hydrolysis in the culture media, a mass spectroscopy (MS) study was performed. This 
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MS study indicated that ester (86) was rapidly hydrolysing in culture medium within 
24 hours to generating the active OH pyrazoline (75). After 72 hours only 20% of the 
original ester (86) remained suggesting that the ester is not suitable for future 
prodrug strategies (Scheme 23).  
 
  
Scheme 23: Prodrug summary.  
 
 A MS study was conducted with amide (87) which indicated that this 
compound was stable over the 72 hour period. Unfortunately, while the amide (87) 
was fully stable in culture medium after a 72 hour period, the poor antiproliferative 
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3.16 Future Work 
 
3.17 Enantioselective Synthesis of Pyrazoline (71-) 
 
One vital avenue for future work is the development of an enatioselective synthesis 
of pyrazoline (71-) enabling gram quantities of this potent nanomolar compound to 
be produced in high enantiomeric excess (ee). Fortunately Briere et al. reported a two 
step enatioselective synthesis of pyrazolines via the corresponding chalcone using 
quininium based catalysts.73 Briere et al. successfully synthesised unsubstituted 
pyrazoline (84-) in 99% yield with 99% ee (Figure 51). This procedure was also used to 
synthesise the (+) enantiomer in high ee by selecting a quininum based catalyst with 
inverted stereochemistry. This procedure should be applied to pyrazoline (71) 
enabling access to both enantiomers in high yield and high ee (Figure 51).  
Figure 51: Enantioselective synthesis of (84-).
73 
 
Synthesising (71-) on a gram scale in two steps would be a significant 
advancement from the time consuming and limited scale semipreparatory chiral HPLC 
currently in use. Access to larger quantities of (71-) would also greatly assist in the 
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3.18 Determination Pyrazoline (71-) Absolute Stereochemistry 
 
The ability to synthesise 71(-) on a larger scale enables a much wider range of 
recrystallisation solvents and conditions to be investigated to obtain crystals of 
sufficient size and quality for an X-ray structure determination enabling assignment of 
(71-) as R or S. A range of different chiral acids could also be investigated to 
determine if forming a diastereomeric mixture improves recrystalisation facilitating 
an X-ray structure determination. The use of Moshers acid74 and 1H NMR 
spectroscopy could also be use to assign absolute stereochemistry. 
 
3.19 Determination of Tubulin Binding Site of Pyrazoline (71-) 
 
Cell cycle analysis, in vitro tubulin polymerisation assays and confocal microscopy 
suggest that (71-) is a microtubule destabiliser, however a key question remaining is 
where is (71-) binding to tubulin. The majority of microtubule destabilisers containing 
a 3,4,5-trimethyloxyl unit bind to the colchicine binding site on β tubulin therefore it 
is predicted that (71-) is also binding at the colchicine binding site. This hypothesis can 
be investigated using a [3H]colchicine competition assay.75 In this assay tubulin is 
exposed to radioactive [3H]colchicine which binds to the colchicine binding site on β 
tubulin. Excess [3H]colchicine is then removed and (71-) added which if it binds at or 
near the colchicine binding site, will compete with [3H]colchicine resulting in an 
increase in radioactivity. The assignment of the tubulin binding site, alongside with an 
X-ray crystal structure of (71-) enables molecular modelling and in silico docking 
experiments facilitating the rational design of a second generation of analogues with 
improved tubulin binding properties. 
 
3.20 3,5 Dibromo Analogue of Pyrazoline (71-) 
 
Ley et al.38 demonstrated that CA4 analogue (19) retained nanomolar activity in 
cancer cell lines while also conferring activity in Taxol®-resistant cell lines (Figure 64). 
A similar approach could be applied to our lead pyrazoline (71) generating the 
dibromo analogue (71B) with potential improved biological properties (Figure 52). 
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Figure 52: 3,5 Dibromo analogue of (71B).  
 
3.21 Prodrug Analogues 
 
A second generation of pyrazoline prodrugs with improved water solubility via a 
range of salt derivatives could be developed (Scheme 24). Zybrestat® (14) the 
phosphate prodrug of CA4 currently in phase III clinical trials demonstrates that the 
phenolic group in pyrazoline (75) could be converted to the phosphate prodrug (75B).  
 
 
Scheme 24: Future prodrug approaches. 
 
Pyrazoline (71) demonstrated modest selectivity towards cancer cells 
therefore a further avenue worth exploring is increasing this selectivity by modifying 
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pyrazoline (71) to increase uptake in cancer cells. PEPT1, an oligopeptide transporter 
over expressed in the intestine is involved in conveying amino acids (AA) and di or tri 
peptides into the cell fuelling cell division.76 Numerous prodrugs have been reported 
which are designed to be taken up by PEPT1 including the anticancer drugs 
floxuridine77 and gemcitabine.78 Pyrazoline (71) displayed excellent nanomolar 
activity (GI50 277-371 nM) across all seven colon line lines in the NCI screen suggesting 
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Chapter 4: Introduction to Tissue Engineering 
4.1 Tissue Engineering 
 
Tissue engineering is a diverse interdisciplinary field that applies engineering 
principles to the biological sciences with the aim of maintaining, repairing or replacing 
tissue function.79,80 Three dimensional (3D) polymeric scaffolds are commonly used in 
tissue engineering to provide a framework for cells to attach and proliferate. A 
scaffold must meet strict criteria (Figure 53A) to be of clinical use with numerous 
natural and synthetic materials available (53B).81 
 
Figure 53: A) Cellular scaffold criteria
81




 Since its conception in the late 1980s, tissue engineering has grown into a 
multibillion dollar industry with the global tissue engineering industry estimated to 
have a value of 4.7 billion dollars in 2007.82 Current success stories include      tissue-
engineered bladders in 2006,83 a trachea in 200884 and urethras in 2011 (Figure 54).85 
The continued development of more sophisticated cellular scaffolds will enable more 
complex tissues to be produced in the near future.  
 




 and C) urethra.
85
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4.2 Metal Triggered Collagen Scaffolds 
 
A key challenge in current scaffold design involves controlling the architecture and 
porosity of a scaffold while enabling the scaffold to be removed when no longer 
required. Chmielewski et al. recently reported a method of modifying collagen with 
the well known metal chelator dipyridine (dipy). In the presence of various transition 
metals (Zn2+, Cu2+, Ni2+ and Ru2+) the modified collagen strands assembled into a 3D-
metal collagen network (Figure 55).86 
 
Figure 55: A) Bipyridine modified collagen, adapted from Chmielewski et al.
86 
 
 Chmielewski et al. successfully encapsulated HeLa cells, a human cervical 
carcinoma cell line, into the scaffold and confirmed the cells retained high viability 
and proliferated within the scaffold. Further studies demonstrated that the 
incorporation of two different metals during assembly resulted in scaffolds with 
different architectures and porosities (Figure 56). This is particularly interesting as it 




Figure 56: A) Scaffold architecture in the presence of Ru
2+
 and the above transition metals, adapted 
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 The addition of the potent metal chelator EDTA (ethylenediaminetetraacetic 
acid) disrupts the scaffold as the EDTA sequesters the transition metals from the bipy 
(Figure 57). This is a useful property as the scaffold can be easily removed once the 
encapsulated cells have achieved the desired population.  
 




 Chmielewski et al. recently modified this technique to produce metal triggered 
collagen particles which assemble in the presence of various transition metals (Figure 
58).87 
 
Figure 58: Metal triggered particle formation, A) +400 µM CuCl2 scale bar = 100 µm, B) +400 µM CuCl2 
scale bar 5 µm, C) +400 µM ZnCl2 scale bar = 5 µm, D) + 400 µM  CoCl2 scale bar 5 µm,  




 These recent developments validate metal chelation as a useful tool to 
assemble and control the architecture of tissue engineering scaffolds. The diverse 
range of metal chelators available, along with the range of transition metals and the 
potential to use combinations of transition metals, provide a valuable opportunity to 
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4.3 Modifying the Cell Surface 
 
Cell-cell contact is critically involved in a diverse range of applications including 
cellular communication and proliferation.88 The cell surface is a highly complex 
environment composed of lipids, proteins and carbohydrates which enable the cell to 
interact with surrounding cells and its environment. The ability to modify the cell 
surface to introduce additional functionality provides a valuable opportunity to 
increase cell-cell and cell-scaffold interactions. Bertozzi et al. reported a mild 
procedure for the introduction of non-native functional groups such as aldehydes on 
the cell surface.89 Treatment of cells with sodium periodate (NaIO4) oxidatively 
cleaves the vicinal diol on sialic acid residues in the cell surface to generate the 
corresponding aldehyde which remained on the cell surface for over 24 hours 
(Scheme 25).  
 
 




 Further studies confirmed that this process was non-toxic to the cells enabling 
the chemical ligation of compatible molecules onto the cell surface.  
 
4.4 Multicellular Aggregation 
 
Shakesheff et al. demonstrated that the non-native aldehydes were versatile 
functional groups for the attachment of biotin hydrazides via the formation of a 
hydrazone bond (Scheme 26).90,91  
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Shakesheff et al. proposed that upon addition of avidin, a tetrameric protein 
with four biotin binding sites, the biotinylated cells above would crosslink together 
forming a multicellular aggregate (Figure 59A).90,91 
 
Figure 59: A) Schematic representation of aggregation process, B) phase contrast images of 





After one hour of gentle agitation in the presence of 10 μg/mL avidin the 
biotin engineered cells formed multicellular aggregates in contrast to the untreated 
cells which retained in a single cell suspension (Figure 59B). Continued agitation for 
four hours increased the aggregate size compared to the untreated cells confirming 
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that modifying the cell surface was responsible for the aggregation observed. 
Shakesheff et al. proposed that as sialic acid residues are conserved across different 
cell lines, this process could be applied to heterocellular aggregates composed of two 
different cell types.91 This theory was confirmed for 3T3 fibroblasts (green) and L6 
myoblasts (red) which were aggregated together to form a randomly arranged 
heterocellular aggregate (Figure 60A). A layered aggregate with a 3T3 fibroblast 
(green) core and L6 myoblast (red) shell was also generated using this method (B).  
 
Figure 60: Heterocellular aggregates in A) random aggregate B) layered aggregate, 3T3 fibroblasts 




Sakai et al. expanded this approach by demonstrating that heterocellular 
aggregates formed via surface modification could under go self-organisation in vitro. 
They report that aggregates of biotinylated Hep G2 cells, (a human hepatoma cell line 
green) and avidin expressing MS1 cells (a mouse pancreatic cell line red) self-organise 
over the course of 18 hours, shown in Figure 61. 
 
 
Figure 61: Time-lapse images of heterocellular aggregates composed of Hep G2 (green) and MS1 




This result is particularly interesting as it demonstrates that MS1 cells (red) 
within the aggregate migrate towards other MS1 cells. Sakai et al. also investigated 
the formation of heterocellular aggregates composed of three different cell types Hep 
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G2 (green), MS1 (red) and NIH3T3 cells (a mouse fibroblast cell line magenta) and 
allowed them to self-organise over a 24 hour period (Figure 62). Interestingly the MS1 
cells (red) and NIH3T3 (magenta) cells organised around each other whereas the Hep 
G2 cells (green) preferred to aggregate with each other forming a central core (Figure 
62). 
 
Figure 62: Remodelling of heterocellular aggregate composed of Hep G2 (green), MS1 (red) and 






These pioneering experiments confirm the versatility of cell surface 
modification as a method of forming multicellular aggregates which can self-organise 
to form complex architectures in vitro. One significant disadvantage of this technique 
is the cost of the regents required, for example biotin hydrazide 10 mg = £60 and 
avidin 10 mg = £117. The high cost of the reagents limits this technique to small scale 
experiments and prevents its wider application on an industrial scale. The 
development of more cost effective reagents and methods should be investigated to 
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4.5 Pyrazolines as Novel Metal Chelators 
 
As discussed in chapters 2 and 3, chalcones have previously been shown to be 
interesting compounds themselves and as valuable starting materials for pyrazolines 
with potent antiproliferative activities reported (Figure 16 and 48). The pyrazoline 
structure also serves as a useful scaffold for the design of novel metal chelators with a 
variety of transition metals (Figure 63). 
 
 
Figure 63: Recent pyrazoline metal chelators.
93-96 
 
The modular design of the pyrazoline scaffold, combined with a variety of chalcone 
starting materials, enables a diverse range of pyrazolines to be designed to chelate 
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4.6 Maltol Derivatives as Metal Chelators 
 
Maltol (3-hydroxyl-2-methyl-4-pyrone, 92) is a FDA approved food additive present in 
a variety of products including beer, bread and tobacco due to its malty favour and 
low toxicity profiles.97,98 Maltol (92) is a well established Fe3+ chelator and its 
structurally related analogue deferiprone (93) is FDA approved for use in iron 
overload disease and beta thalassemia (Figure 65).99 Two further maltol analogues 
are malten (94), which has antiproliferative activities in cancer cell lines,100 and 
derivative (95) which displays antimalarial activity (Figure 64).101 
 
Figure 64: Maltol derivatives.
97-101 
 
Maltol (92) is available on an industrial scale and is cheap and readily available 
enabling its chemistry to be thoroughly investigated. The versatility of maltol is due to 
the ability to displace the oxygen atom in the pyrone ring for a variety of functional 
groups while retaining the Fe3+ chelation site (Figure 65). 
 
Figure 65: Insertion of various R
1
 groups onto the maltol motif. 
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Aims and Objectives in Tissue Engineering 
 
4.7 Pyrazoline Metal Chelators in Tissue Engineering 
 
One potential avenue for development of pyrazoline metal chelators is in tissue 
engineering by incorporating pyrazolines onto the cell surface (Figure 66). Pyrazolines 
could be attached onto the cell surface by incorporating a hydrazide on the R1 
functional group and attaching it to cells using the methods reported by Bertozzi et 
al.89 It is proposed that upon addition of transition metals to a solution of pyrazoline 
modified cells, multicellular aggregation would occur in a similar process observed by 
Shakesheff et al. (Figure 66A).90,91 
 
  
Figure 66: Proposed pyrazoline scaffold and pyrazoline modified cells, M
+
 = transition metals. 
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If successful, the cheap and commercial availability of chalcone starting 
materials, combined with the ability to fine tune metal chelation by altering the R2 
groups will provide a valuable alternative to the current biotin and avidin method. 
The pyrazoline motif could also be incorporated directly into tissue engineering 
scaffolds in a similar approach to Chmielewski et al.86 A suitable chemical handle, for 
example amine or carboxylic acid group, could be incorporated into the R1 group of 
the chalcone facilitating attachment of the pyrazoline to a polymer backbone (Figure 
66B). Upon addition of transition metals to a pyrazoline polymer solution metal 
chelation triggered cross-linking would occur generating a 3D network. The ability to 
alter the coordination site of the pyrazoline by altering the R2 group enables different 
metals to be chelated providing an opportunity to control scaffold porosity and 
architecture (Figure 66). 
 
4.8 Maltol Derivatives in Tissue Engineering 
 
The ability to functionalise the maltol (92) motif provides an opportunity to 
investigate the use of maltol derivatives in tissue engineering. The maltol motif could 
be attached to the cell surface via a hydrazide functional group enabling the 
generation of maltol modified cells that aggregate in the presence of Fe3+ cations 
(Figure 67A). The high specificity of maltol towards Fe3+ will ensure that additional 
biologically relevant metals (Na+, K+, Mg2+ and Ca2+) present in culture medium do not 
interfere with Fe3+ chelation. Furthermore, the low toxicity profile of maltol should 
ensure that the cells retain high viability and good proliferation.  The maltol motif 
could also be attached to a polymer backbone via the activated ester enabling the 
generation of a Fe3+ triggered tissue engineering scaffold (Figure 67B). 
 
 
   - 92 -   
 









   - 93 -   




Chapter 5: Pyrazoline Based Metal Chelators 
 
Design, synthesis and investigation of the metal chelation properties of a range of 
substituted pyrazolines derived from chalcones (Figure 68).  
 
Figure 68: Pyrazoline metal chelator library design. 
 
 Pyrazolines will be screened for the ability to chelate a range of metals using 
the techniques of UV/Vis and 1H NMR spectroscopy. Pyrazolines have previously been 
reported as fluorescence sensors93 for Zn2+ therefore fluorescence spectroscopy will 
be to investigate potential useful sensor applications. To be useful for tissue 
engineering purposes they must be non-toxic and able to chelate metals in the 
presence of competing biological metals including Na+, K+ and Ca2+ present in culture 
media. To confirm this MTS proliferation assays along with a range of competition 
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5.2 Chemical Synthesis 
 
A simple and robust procedure using cheap commercially available starting materials 
was developed. Chalcone (96) was synthesised in excellent yield using a previously 
reported procedure,102 in which 2-acetylpyridine and benzaldehyde were added to 
10% NaOH(aq) and left at 4 oC. After 24 hours the solid precipitate was collected, 
washed and dried to afford chalcone (96) in 97% without the need for further 
purification (Scheme 27).  
 
 
Scheme 27: Chemical synthesis of pyrazoline (97) and pyrazole (98) and MTS assays, values are the 
mean from three independent experiments except 
a
 from a single experiment. 
 
 Conversion of chalcone (96) to pyrazoline (97) was achieved in good yield by 
the addition of methylhydrazine at room temperature (Scheme 27). With pyrazoline 
(97) in hand a literature procedure103 was used to oxidise the pyrazoline to the 
pyrazole (98) in 80% yield. The MTS assay was used to confirm that both compounds 
displayed poor antiproliferative activities (ie not toxic) and therefore both were 
suitable for tissue engineering purposes (Scheme 27). 
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5.3 Reaction Mechanism 
 
The reaction of chalcone (96) with methylhydrazine is believed to proceed through a 
similar reaction mechanism as seen discussed previously with hydrazine (Scheme 
17).69,70 The non symmetrical arrangement in methylhydrazine could result in two 
possible products, pyrazoline (97) and the isomer pyrazoline (97A). In 
methylhydrazine the lone pair of electrons on nitrogen 2 are less sterically hindered 
by the methyl group than nitrogen 1 and therefore more available for 1,2 nucleophilic 
attack on the carbonyl group in chalcone (96) (Scheme 28).  1,2 nucleophilic attack by 
nitrogen 1 would generate pyrazoline (97A) which was not observed. 
Scheme 28: Proposed reaction mechanism for the synthesis of pyrazoline (97). 
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5.4 UV/Vis Spectroscopy 
 
UV/Vis spectroscopy is a rapid method of determining chelation properties by 
monitoring changes in the absorbance spectra in the absence and presence of metal 
cations. Pyrazoline (97) and pyrazole (98) were screened against a variety of metals, a 
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Table 11: Pyrazoline (97) and pyrazole (98) UV/Vis metal screen, cross indicates no change whereas 
tick indicates changes in absorbance spectra upon addition of cation. 
 
Pyrazoline (97) and pyrazole (98) produced negligible changes in absorbance 
spectra in the presence of Group 1 & 2 metals, however spectral changes were 
observed upon addition of a variety of transition metals. The addition of Zn2+ and Cd2+ 
to pyrazoline (97) is representative of the results obtained and shows the formation 
of a new absorbance band at 360 nm (ε = 8650 M-1 cm-1) and 350 nm (ε = 7650 M-1 
cm-1) upon addition of Zn2+ and Cd2+ respectively (Figure 69).  
 
Figure 69: Pyrazoline (97) absorbance spectra (MeCN, 500 μM) with the addition of 0–1.5 equiv. in 
0.1 increments of Zn
2+
 (A) and Cd
2+
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Interestingly these new bands increased linearly in absorbance up to 1.0 
equivalent of cation after which further addition produced negligible changes in 
absorbance suggesting a 1:1 stoichiometry between ligand and cation. Job plot 
analysis indicated a mole fraction of 0.5 of Zn2+ and Cd2+ achieved the highest 
absorbance, again suggesting that pyrazoline (97) and pyrazole (98) formed a 1:1 
complex with these cations. This result is consistent with similar pyrazolines found in 
the literature.104 An X-ray structure determination was sought to visually confirm that 
pyrazoline (97) was chelating Zn2+ in a 1:1 ratio and to provide information on bond 
lengths and angles. 
  
5.5 X-Ray Crystal Structure 
 
Attempts to obtain an X-ray structure of pyrazoline (97) chelated to Zn2+ using a 
previously reported method,104 actually resulted in crystals of pyrazole (98) chelated 
to Zn2+ (Scheme 29). It is presumed that under the reaction conditions or during the 
recrystallisation process an aerobic oxidation occurred oxidising the pyrazoline ring to 
the corresponding pyrazole. 
  
Scheme 29: Synthesis of Zn
2+
 complex. 
The crystal structure confirmed the pyrazole (98) was chelating Zn2+ with a 1:1 
stoichiometry (Figure 70) reinforcing the previous studies. 
 
Figure 70: An X-ray structure of the pyrazole Zn
2+
 complex, ellipsoids represented at 30% probability. 
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5.6 1H NMR Spectroscopy 
 
Cd2+ has a d10 electronic configuration and is therefore diamagnetic enabling 1H NMR 
studies to investigate how chelation influenced the 1H chemical shifts of the pyrazole 
(98) protons. In the absence of Cd2+ the pyrazole protons are distinct peaks in the 
aromatic region (i), however upon addition of Cd2+ the peaks begin to broaden and 





H NMR study of pyrazole (98) (DMSO-d6, 63 mM) with (i) 0.0, (ii) 0.9, (iii) 2.0 and 




A similar effect was observed with Zn2+ and for pyrazoline (97) in the presence 
of Zn2+ and Cd2+ (data not shown).  The broadening and increasing in chemical shift of 
aromatic protons is indicative of chelation and has been reported for a variety of 
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5.7 Fluorescence Spectroscopy 
 
We investigated the potential use of pyrazoline (97) and pyrazole (98) as Zn2+ 
fluorescence sensors as structurally similar pyrazolines have been reported in the 
literature.93,104,113 In the presence of various Group 1 and 2 metals no significant 
increase in fluorescence was observed as was expected from the UV/Vis spectroscopy 
studies (Figure 72A). 
 
 
Figure 72: Fluorescence spectra of pyrazoline (97) (A, λex = 320 nm) and pyrazole (98) (B, λex = 285 
nm, MeCN, 20 μM) upon addition of 5 equiv. of metal. 
  
 In the presence of a variety of transition metals there was little change in 
fluorescence intensity of pyrazoline (97), except in the presence of Zn2+ and Cd2+ (Figure 
72A). The addition of Zn2+ resulted in an eight fold increase in fluorescence at 460 nm, 
whereas the addition of Cd2+ resulted in a fourteen fold increase also at      460 nm 
suggesting that this pyrazoline may be a useful fluorescence sensor for Cd2+. This is of 
interest as the UV/Vis studies demonstrated that although pyrazoline (97) chelated a 
variety of transition metals, only Zn2+ and Cd2+ resulted in an increase in fluorescence. 
One major challenge in current Zn2+ sensor research is the ability to distinguish Zn2+ 
from Cd2+ due to the similar chemical properties of both cations108-109 and pyrazoline 
(97) suffers from this difficulty. Pyrazole (98) was also screened against a variety of 
cations with addition of Zn2+ resulting in a modest increase in fluorescence at 380 nm 
whereas the Cd2+ resulted in an increase at 350 nm (72B). This difference in wavelength 
of 30 nm, albeit small, enables pyrazole (85) to distinguish Zn2+ from Cd2+, fulfilling a 
major requirement of a Zn2+ sensor. This initial metal screen suggests that pyrazoline 
(97) may be a useful Cd2+ fluorescence sensor whereas oxidation to pyrazole (98) 
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generated a sensor more suitable for the detection of Zn2+. Titration studies were 
performed to further investigate the potential of pyrazoline (97) to act as fluorescence 
sensors for Cd2+ and Zn2+. Job plot analysis was in agreement with the previous UV/Vis 
studies confirming a 1:1 stoichiometry (Figure 73). The increased fluorescence intensity 




Figure 73: Fluorescence spectra of pyrazoline (97) (MeCN, 20 μM, λex = 320 nm) upon addition of 0–
20 equiv. Zn
2+
 (A) and Cd
2+
 (B), lower inset Job plot. 
 
 Titration studies were also performed on pyrazole (98) alongside Job plot 
analysis which was consistent with previous studies giving a 1:1 stoichiometry (Figure 
74). The increased fluorescence intensity observed with pyrazole (98) in the presence of 
Zn2+ suggests it is more suited as a Zn2+ fluorescence sensor. 
 
 
Figure 74: Fluorescence spectra of pyrazole (98) (MeCN, 20 μM, λex = 285 nm) upon addition of   0-20 
equiv. Zn
2+
 (A) and Cd
2+
 (B), lower inset Job plot. 
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 Detection limits were calculated using a literature method110 to determine the 
sensitivity of each compound towards Zn2+ and Cd2+ (Table 12). As expected from the 
fluorescence studies, pyrazoline (97) was more sensitive towards Cd2+ with a detection 
limit of 0.12 μM compared with a detection limit of 0.20 μM for Zn2+.  In contrast 
pyrazole (98) was more sensitive towards Zn2+ than Cd2+ with detection limits of 0.24 
and 0.34 μM respectively. 
 






Pyrazoline (97) 0.20 0.12 
Pyrazole (98) 0.24 0.34 
 
Table 12: Detection limits for pyrazoline (97) and pyrazole (98). 
 
5.8 Competition Assays 
 
In order for these ligands to be useful for tissue engineering purposes they must chelate 
Zn2+ in the presence of competing cations present in biological systems, for example 
culture media containing Na+, K+ , Mg2+ and Ca2+. Zn2+ was selected as the most suitable 
metal for chelation as Zn2+ is non toxic and is the second most abundant transition 
metal in the human body whereas Cd2+ is highly toxic and linked to a range of diseases 
including cancer. A competition assay106,111 involves measuring the fluorescence of the 
ligand with the competing cation (white bar), and in the presence of the competing 
cation and Zn2+ after a 3 minute equilibrium time (black bar) (Figure 75).  
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Figure 75: Competition assay, the white bar represents ligand (MeCN, 20 μM), and 5 equiv. of the 
cation, the black bar is the same plus 5 equiv. Zn
2+
 after equilibrating for 3 minutes. 
 
The competition assay for pyrazoline (97) indicated that paramagnetic Fe3+, Co2+ 
and Ni2+ cations resulted in fluorescence quenching as observed in previous studies 
(Figure 75A).105,112  The presence of Pb2+, Ru3+ and Na+ resulted in a minor decrease in 
fluorescence intensity (75A). Unfortunately in the presence of biologically relevant 
metals present in culture media resulted in major decreases in fluorescence intensity 
suggesting these cations are competing with Zn2+ chelation. This indicated that 
pyrazoline (97) would not be a suitable Zn2+ chelator for tissue engineering purposes. A 
similar assay was performed for pyrazole (98) (75B), fluorescence quenching with the 
paramagnetic metals was also observed along with competition from biologically 
relevant metals demonstrating that pyrazole (98) is also unsuitable for tissue 
engineering purposes. The presence of additional chelation sites via the R1 group may 
be a possible solution to overcome this problem by increasing Zn2+ chelation. R1 groups 
with larger steric bulk may also prevent competing cations from accessing the chelation 
site and prevent displacement of the bound Zn2+ (Scheme 30). This can be achieved 
using the chemistry previously reported in chapter 3 and will be investigated further 
with the B and C pyrazoline series. 
 
Scheme 30: Restricting the chelation site by increasing the R
1
 group.  
A B 
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5.9 B & C Pyrazoline Series Synthesis 
 
A range of additional R1 groups was investigated including thiocarbamide 
group in the B series and acetyl and benzoyl R1 substituents in the C series. All 
pyrazolines were synthesised from the corresponding chalcones using the procedures 
previously reported in chapter 4. The chalcone precursors were synthesized under 
Claisen-Schmidt conditions in excellent yield (85-97%) affording the 
thermodynamically stable E isomer as identified by characteristic 3J coupling of ca 15 
Hz (Scheme 31).  
 
 
Scheme 31: Synthesis of B and C pyrazolines series. 
 
Chalcone (96) was treated with thiosemicarbazide to synthesise the B series 
whereas treatment with hydrazine followed by the desired acid chloride gave the C 
series of pyrazolines. All pyrazolines were fully characterised and confirmed to be 
>95% pure by HPLC before analysis. 
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5.10 UV/Vis Spectroscopy and MTS antiproliferative Assays 
 
All pyrazolines were screened for Fe3+ chelation properties using UV/Vis spectroscopy 
however no changes in the absorbance spectra were observed. Pyrazoline (105) 
displayed excellent antiproliferative activities, therefore all pyrazolines were screened 
in HT29 and MDA-MB-231 (Table 13) to investigate potential therapeutic applications. 
 










100 C6H5 COMe 72 X 161.3 ± 21.9 294.1 ± 71.1 
101 C6H5 COCF3 65 X >500 >500 
102 C6H5 CSNH2 67 X 350.2 ± 42.0 140.5 ± 42.0 
103 C6H5 CSNHMe 89 X 25.6 ± 4.0 20.7 ± 0.79 
104 C6H5 C6H5-CO 76 X >500 >500
a
 
105 C6H5 3,4,5-OMe-C6H2-CO 75 X 2.5 ± 0.39 0.69 ± 0.11 
106 3,4,5-OMe-C6H2 3,4,5-OMe-C6H2-CO 84 X 22.5 ± 2.5 11.4 ± 0.75 
107 3,4,5-OMe-C6H2 COMe 80 X >500 52.5 ± 6.5 
108 3,4,5-OMe-C6H2 C6H5 34 X 26.2 ± 3.4 4.36 ± 0.8 
 
Table 13: MTS Assays, IC50 is the concentration that inhibits 50% cell proliferation, values are the 
mean from three independent experiments ± standard deviation, except a from a single experiment, 




5.11 SAR Study 
 
This library displayed a broad spectrum of activity from inactive unsubstituted 
pyrazoline (104) to active 3,4,5-trimethoxy aryl pyrazoline (105) demonstrating the 
importance of the 3,4,5-trimethoxy aryl pharmacophore (Figure 76). 
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Figure 76: The importance of the 3,4,5-trimethoxy aryl group. 
 
The addition of a second 3,4,5-trimethoxy aryl ring in pyrazoline (106) was 
detrimental to activity suggesting that only a single 3,4,5-trimethoxy aryl ring is 
preferred for antiproliferative activity. Suitable crystals of pyrazoline (105) for an x-
ray structure were obtained and the results are displayed in Figure 77.  
 
 
Figure 77: X-ray structure determination of pyrazoline (105), ellipsoids represented at 30% 
probability. 
 
An interesting SAR observation was the increase in activity observed when 
pyrazoline (102) was mono methylated to give pyrazoline (103) with low micromolar 
IC50 values in HT29 and MDA-MB-231 (Figure 78). 
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Figure 78: Methylation of pyrazoline (102) significantly increased antiproliferative activity.  
 
An X-ray structure of pyrazoline (102) was obtained which indicated the formation of 
an intramolecular hydrogen bond between the thiosemicarbazide amino group and 




Figure 79: X-ray structure determination of pyrazoline (102), ellipsoids represented at 30% 
probability. 
 
Mono methylation of pyrazoline (102) to generate pyrazoline (103) could be 
easily achieved under mild conditions (Scheme 32) resulting in an increase in biological 
activity. Interestingly, under these reaction conditions the only product obtained was the 
mono methylated product (103) with no sign of the dimethylated product (109). 
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Scheme 32: Mild methylation conditions gives single methylated product (103) only. 
 
Pyrazoline (103) retained an amino hydrogen suitable for forming 
intramolecular hydrogen bonds resisting rotation around the thiosemicarbazide unit. In 
order to overcome this problem more vigorous reaction conditions were attempted 
(Scheme 33) using the stronger base NaH however without success. 
 
  
Scheme 33: Harsh methylation conditions.  
 
An alternative method of generating dimethylated pyrazoline (109) was to 
synthesise it directly from chalcone (96) using dimethyl-3-thiosemicarbazide. Surprisingly 
submitting this dimethylated thiocarbazide to identical reaction conditions used to 
generate pyrazoline (102) failed to give the desired product (Scheme 34). 
 
Scheme 34: Dimethyl-3-thiosemicarbazide reaction. 
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5.12 NCI 60 Cell Line Screen 
 
Pyrazoline (105) was the most active compound in the C series of compounds and 
was submitted for screening at the NCI at the single (10-5) dose (see appendix A) and 
was selected for screening at the five dose level. Pyrazoline (105) displayed promising 
GI50 values across the NCI 60 cell line screen including nanomolar activity (0.277-0.848 
μM) in six of the seven colon cancer cell lines including the multidrug resistant 
ovarian cell line NCI/ADR-RES 0.519 μM (Table 14). Of the five ovarian cell lines, the 
greatest activity was observed with OVCAR-3, a cell line sensitive to tubulin disruptors 
suggesting that pyrazoline (105) may also be a tubulin binder. 
 

























































































































Table 14: NCI screen for pyrazoline (105). 
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5.13 Cell Cycle Analysis 
 
To investigate the mode of action of pyrazoline (105) as a microtubule binding agent, 
cell cycle analysis was performed on HT29 cells (Figure 80). Panel A contained the 
typical histogram for untreated HT29 cells with the majority of the cell population 
(60.2%) resided in the G1 phase of the cell cycle, whereas the presence of 100 nM 
colchicine resulted in the majority of the cells (88.8%) residing in the G2/M phase. 
The presence of 100 nM pyrazoline (105) resulted in the formation of the distinct 
G2/M peak of over half of the cell population in this phase of the cell cycle. Increasing 
the concentration of pyrazoline (105) to 500 nM resulted in over 94% of the cells 




Figure 80: Cell cycle analysis, A) Untreated HT29 cells, B) + 100 nM colchicine, C) + 1.0 µM pyrazoline 
(105), D) + 5.0 μM pyrazoline (105), results are representative of three independent experiments. 
 
 In order to investigate further into the mode of action of pyrazoline (105) and 
to classify it as a microtubule stabiliser or destabiliser an in vitro tubulin 
polymerisation assay was performed. 
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5.14 In Vitro Tubulin Polymerisation Assay 
 
The control shows the increase in optical density (OD) as tubulin naturally 
polymerises over the course of 60 minutes whereas in the presence of the 5.0 µM of 
the microtubule stabiliser Taxol® polymerisation is rapidly achieved within the first 10 
minutes (Figure 80). The curve for pyrazoline (105) indicated that at a concentration 
of 20.0 μM this compound was disrupting microtubule formation compared to 
control, suggesting that this is responsible for the mode of action of pyrazoline (105) 
(Figure 81). 
 
Figure 81: In vitro tubulin polymerisation assay for 20.0 μM pyrazoline (105). 
 
In order to provide further evidence that pyrazoline (105) was disrupting 
microtubule formation, a confocal microscopy study was performed to visually 
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5.15 Confocal Microscopy 
 
The microtubule network in untreated HT29 cells is shown in panel A (Figure 82A) the 
microtubule network is visible as a green cloud surrounding the cells with the 
chromosomes (blue) in the middle. The addition of 100 nM of colchicine as a positive 
control resulted in an irregular and reduced microtubule network (panel B).  
 
 
Figure 82: Confocal microscopy A) HT29 cells only, B) + 100 nM Colchicine, C) + 1.0 µM pyrazoline 
(105), D) + 5.0 µM pyrazoline (105). 
 
Upon addition of 100 nM of pyrazoline (105), the same concentration that 
resulted in 50% of the cell population residing in the G2/M phase, the microtubule 
network is reduced slightly in size. Increasing the concentration of pyrazoline (105) to 
500 nM, the concentration that resulted in 95% of the cell population residing in 
G2/M resulted in an irregular and reduced microtubule network (Panel D). This study 
confirmed that pyrazoline (105) was disrupting microtubule formation reinforcing the 
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5.16 Conclusions 
 
A collection of ten pyrazolines was synthesised and screened for metal chelation 
properties and antiproliferative activities in HT29 and MDA-MB-231 cancer cell lines. 
Pyrazoline (97) chelated a variety of transition metals and was a “turn on” 
fluorescence sensor with emission of fluorescence at 460 nm in the presence of Zn2+ 
and Cd2+ (Figure 83). 
 
Figure 83: Pyrazoline (97) and pyrazole (98) were “turn on” fluorescence sensors, pyrazoline (105) 
was a microtubule destabiliser. 
 
Oxidation of pyrazoline (97) could be achieved in high yield to afford pyrazole 
(98) which was also a “turn on” fluorescence sensor for Zn2+ and Cd2+ and could 
distinguished between Zn2+ and Cd2+ with fluorescence emission at different 
wavelengths. Further studies including Job plots and an X-ray crystal structure 
demonstrated that both pyrazoline (97) and pyrazole (98) chelated Zn2+ and Cd2+ with 
a 1:1 stoichiometry. Competition assays indicated that the presence of additional 
metal cations including Group 1 & 2 metals disrupted fluorescence restricting the 
potential use of these sensors in biological environments. In order to overcome this, a 
range of more sterically crowded chelation sites were investigated including acetyl, 
benzoyl and thiosemicarbazide units. The presence of large substituents prevented 
chelation, however pyrazoline (105) was discovered to display promising 
antiproliferative activity. Pyrazoline (105) was submitted to the NCI and displayed 
nanomolar GI50 values in six of the seven colon cancer cell lines. Further investigations 
revealed that pyrazoline (105) was a microtubule destabiliser in a similar manner as 
pyrazoline (71) discussed previously in chapter 3.       
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5.17 Future Work 
 
5.17 Aqueous Zn2+ Fluorescent Sensors  
 
Zhao et al.113 recently reported a novel pyrazoline based turn on fluorescent sensor 
which could detect Zn2+ in aqueous solutions and in the presence of a range of 
competing cations including the biological metals Na+, K+, Ca2+ and Mg2+ present in 
culture media (Figure 84). Further studies by Zhao et al.113 indicated that pyrazoline 
(110) chelated Zn2+ with a 1:1 stoichiometry and with a detection limit of 0.12 μM 
which is comparable with pyrazoline (97) reported previously.  
 





Miao et al.114 recently reported the structurally similar pyrazoline (111) with 
thiosemicarbazide substitution which is also a “turn on” fluorescence sensor for Zn2+ 
in aqueous solutions (Figure 84). Pyrazoline (111) was confirmed to chelate Zn2+ with 
a 1:1 stoichiometry and retained Zn2+ in the present of the biologically relevant 
metals Na+, K+, Ca2+ and Mg2+. The common feature present in these two sensors is 
the A ring with a single hydroxyl substituent at the ortho position. This may be a key 
feature required to prevent competition from competing cations while conferring 
good water solubility. The attachment of a suitable chemical handle onto the B ring 
would able pyrazoline (110) to be investigated as a suitable Zn2+ chelator in culture 
media and could be used as proposed in the aims and objectives (Figure 85). 
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 Figure 85: Proposed modification of the aqueous fluorescence Zn
2+
 sensors for attachment to the 
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Design, synthesis and investigation of maltol derivatives, compounds of interest 
include a maltol dimer (111), a maltol trimer (112) and a maltol hydrazide (113) 
shown in Figure 86. 
 
 
Figure 86: Synthesis of maltol dimer (111), trimer (112) and hydrazide (113) from the 
industrial produced feedstock maltol (92). 
 
Maltol hydrazide (113) was used to form multicellular aggregates in the 
presence of Fe3+ and the dimer and trimer derivatives were used as model systems for 
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6.2 Maltol Dimer and Trimer Synthesis 
 
To investigate the potential of developing a maltol based polymer which assembles in 
the presence of Fe3+ a maltol dimer and trimer were synthesised to act as model 
systems for more complex polymers (Scheme 35). Maltol (92) is highly water soluble 
therefore it was benzylated using a literature procedure115 to afford benzylated 
maltol (114) which was soluble in organic solvents enabling further functionalisation 
(Scheme 35). Treatment with excess β-alanine gave the maltol carboxylic acid (115) in 
78% yield following a literature procedure.115 With maltol carboxylic acid (115) in 
hand, a literature procedure115 was adapted to afford the maltol activated ester (116) 
in 70% which was a versatile intermediate for further amide coupling reactions.  
Scheme 35: Synthesis of maltol activated ester (116) from maltol (92). 
 
An excess of maltol activated ester (116) with 0.4 equiv. ethylenediamine gave 
the benzylated maltol dimer (117) in 65% yield (Scheme 36). 
 
Scheme 36: Synthesis of benzylated maltol dimer (117) from maltol activated ester (116). 
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The removal of the benzyl group was achieved under standard hydrogenation 
conditions to give the desired deprotected maltol dimer (111) in 75% yield (Scheme 
36). The benzylated maltol trimer (118) was synthesised from tris(2-
aminoethyl)amine in 62% yield.  
 
Scheme 37: Synthesis of benzylated maltol trimer (118) from maltol activated ester (116). 
 
An identical procedure was applied to the benzylated maltol trimer (118) in an 
attempt to generate the deprotected maltol trimer (112), however, after 24 h          1H 
NMR indicated only partial removal of the benzyl groups (Scheme 37). The reaction 
was resubmitted and the reaction continued for a further 48 h, however full removal 
of all three benzyl groups was still not achieved. One possible explanation for the 
failure to fully remove the benzyl protection groups was due to the large steric bulk of 
the benzylated maltol trimer (118) preventing adsorption onto the Pd/C catalyst. The 
difficulty experienced with the removal of the benzyl protection group in the 
benzylated maltol trimer (118) poses a significant challenge when expanding from a 
trimer to polymer with several benzyl protection groups. Unfortunately due to time 
constraints and the success of alternative strategies, further optimisation of reaction 
conditions was not pursued.  
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6.3 Maltol Hydrazide (121) Synthesis 
 
A synthetic procedure for the maltol hydrazide (121) was developed by conversion of 
the maltol carboxylic acid (115) synthesised previously (Scheme 35) to the maltol 
methyl ester (119) in 99% yield (Scheme 38). Reaction of the maltol methyl ester 
(119) with hydrazine afforded the benzylated maltol hydrazide (120) in 62% yield 
which was deprotected under standard conditions to give the desired maltol 
hydrazide product (121) in 84% yield (Scheme 38). 
 
Scheme 38: Maltol hydrazide (121) synthesis. 
 
The MTS assays confirmed that maltol hydrazide (121) was non-toxic in the 
cell lines examined, with a high IC50 value of >200 µM in HT29 and MDA-MB-231 
cancer cells suggesting it was suitable for further cell based studies at a concentration 
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6.4 Fe3+ Triggered Homocellular Aggregation 
 
Following the procedure reported by Bertozzi et al.89 HT29 cells were exposed to mild 
oxidation conditions (1 mM NaIO4, 10 minutes, 4 
oC) to generate non-native 
aldehydes on the cell surface (Figure 87). The HT29 cells were exposed to maltol 
hydrazide (121) (200 µM, 60 mins, 20 oC) resulting in hydrazone bond formation 
chemically attaching the maltol unit to the cell surface. The maltol modified HT29 
cells were then treated with FeCl3 in PBS (phosphate buffered saline) (50 μM, 20 
oC) 
and with gentle rocking agitation, pleasingly resulted in multicellular aggregation 
within 10 minutes (Figure 87). 
 
 
Figure 87: A) Generation of non-native aldehydes on the cell surface followed by attachment of the 
maltol unit which upon Fe
3+ 
chelation form multicellular aggregates, B) representative phase 
contrast images of the aggregation process in serum free medium, scale bars = 400 μm, results are 
representative of three independent experiments.  
 
 After 20 minutes agitation large cellular aggregates had formed which were 
visible to the naked eye. Similar results were obtained in PBS medium, however 
performing the experiment in complete culture medium (containing 10% serum) 
resulted in no cellular aggregation. It is believed that the proteins in the serum was 
sequestering the Fe3+ and preventing aggregation. As a result of this all further 
experiments were performed in serum free culture medium. After 1 hour of agitation, 
   - 120 -   
the aggregates were treated with EDTA (1 mM) and further agitated for one hour at 
room temperature in an attempt to reverse the aggregation process to generate a 
single cell suspension. Unfortunately, the presence of EDTA failed to dissociate the 
aggregates suggesting that native cell-cell interactions were now present and cells 
retained in their aggregated state.  
 
6.5 Optimisation of Aggregation Conditions 
 
A variety of Fe3+ concentrations were examined in order to optimise the aggregation 
process (Figure 88). An Fe3+ concentration between 5.0 and 20.0 µM failed to 
aggregate the cells, increasing the concentration to 50 µM resulted in large aggregate 
sizes compared to untreated HT29 cells (Figure 88A). Further increases in Fe3+ 
concentration resulted in smaller aggregate sizes, possibly due to Fe3+ saturation on 
the cell surface. The effect on agitation time was also investigated with 20 minutes 
giving good sized aggregates, extending agitation beyond this gave larger sized 
aggregates due to the association of different aggregates (Figure 88B). 
 
Figure 88: A) The effect of Fe
3+
 concentration on mean apparent area for untreated HT29 and treated 
cells after 20 min agitation, B) the effect of agitation time on mean apparent area for untreated and 
maltol engineered HT29 cells after addition of 50 μM Fe
3+
. Data are shown as mean ± standard 
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6.6 MTS Antiproliferative Assays 
 
To confirm that modifying the cell surface with the maltol motif was not detrimental 
to cellular proliferation, MTS antiproliferative assays were performed after 24 h, 48 h 
and 72 h (Figure 87). After 24 h incubation the O.D reading for the untreated cells (1), 
oxidised cells (2) and maltol cells (3) were all comparable both in the absence and 
presence of 50 µM Fe3+ (Figure 89). After 48 h slightly higher O.D readings were 
observed indicating that all cell types were actively proliferating. After 72 h the O.D 
reading remained above 0.7, demonstrating that this process is not having a 
detrimental effect cellular proliferation. Interestingly after 72 h the maltol cells in the 
presence of Fe3+ had a higher O.D than maltol cells without Fe3+, suggesting that 
aggregate formation was actually increasing the rate of cellular proliferation. This 
may be the result of increased cell to cell contact and intracellular signalling. 
 
Figure 89: MTS assays on 1) untreated cells, 2) oxidised cells and 3) maltol engineered HT29 cells in 
the absence (black bar) and presence of 50 μM Fe
3+
 (white bar) after 24 h, 48 h and 72 h incubation. 
Each bar is the average of three independent experiments ± standard deviation. 
 
6.7 Selectivity for Fe3+ 
 
Maltol (92) displays excellent selectivity for Fe3+ but has been reported to chelate a 
variety of other transition metals including Ru3+, Cu2+ and Zn2+.97,98 To investigate the 
influence of different transition metals on the aggregation process a range of 
specificity assays were performed (Figure 90). In the presence of 50 μM Fe3+ the 
multicellular aggregates formed whereas in the presence of 50 µM Ru3+, Cu2+ and Zn2+ 
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no aggregation was observed (Figure 90), confirming that aggregation occurs 
selectively in the presence of Fe3+.  
 
Figure 90: Phase contrast images of untreated and maltol engineered HT29 cells in the presence of 
50 μM of transition metals after 20 mins agitation time, scale bars = 400 μm, results are 
representative of three independent experiments. 
 
6.8 Fe3+ Triggered Heterocellular Aggregation 
 
To demonstrate this can be applied to aggregate two different cell types together, 
HT29 and MDA-MB-231 cells were fluorescently labelled green and red respectively 
using CellTracker™ and modified to have maltol on the surface. Upon addition of  50 
μM Fe3+ the two different cell types began to aggregate together resulting in the 
formation of heterocellular aggregates (Figure 91). 
 
Figure 91: Fluorescence images of HT29 cells (Green) and MDA-MB-231 cells (Red) in the presence of 
50 µM Fe
3+
, scale bars = 400 μm, results are representative of three independent experiments. 
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Three aggregates are displayed at X 10 magnification clearly showing that the 
HT29 (green) and MDA-MB-231 (red) cells are randomly arranged within the 
aggregate giving areas of yellow (ie combination of red and green) (Figure 92). 
 
Figure 92: Fluorescence images of three aggregates at X 10 magnification, HT29 cells (Green) and 
MDA-MB-231 cells (Red) in the presence of 50 µM Fe
3+
, scale bars = 200 μm. 
 
This result is particularly pleasing as it demonstrates that modifying the cell 
surface and attachment of the maltol unit is not just limited to HT29 cells and can be 
applied to other cell types. This process can be applied to replicate the heteroceullar 
aggregates reported from Shakesheff et al.91 and Sakai et al.92 but using a Fe3+ 
chelation system instead of a biotin and avidin system. To investigate possible self-
organisation as reported by Sakai et al.92 the heterocellular aggregates were 
incubated for several days, however no self-organisation was observed.  
 In summary, maltol hydrazide (121) can be attached to HT29 and MDA-MB-
231 cells which have been treated to express non-native aldehydes on the cell 
surface. Addition of Fe3+ to the cell medium resulted in rapid multicellular aggregation 
within 20 minutes of gentle agitation but only in PBS and serum free culture medium, 
the presence of serum in the culture medium prevented aggregation. MTS assays 
confirmed that this process was non-toxic and even slightly increased the 
proliferation of the aggregated cells compared to untreated cells. The process is Fe3+ 
specific with no sign of aggregation in the presence of Ru3+, Cu2+ or Zn2+ after 20 
minutes agitation. This process can also be applied to generate heterocellular 
aggregates in which two different cell types are assembled together within 20 
minutes. The ability to synthesise the maltol hydrazide (121) in high yield in five steps 
from cheap commercially available starting materials suggests that it could be useful 
alternative to previously reported reagents. 
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6.9 Conclusions 
 
Conversion of maltol (92) into the maltol activated ester (116) enabled synthesis of 
the benzylated maltol dimer (117) and trimer (118) in 65% and 62% yield respectively. 
Removal of both benzyl groups in the maltol dimer (111) was achieved within 24 h 
however complete removal of the benzyl groups in the trimer was not observed, 
limiting the potential to develop a maltol based polymer via this route. 
 
Maltol hydrazide (121) was synthesised in five steps from the industrially 
available feedstock maltol (92) and was confirmed to be non-toxic with an IC50 value 
>200 µM in HT29 and MDA-MB-231 cells. Maltol hydrazide (121) was chemically 
attached to HT29 cells via the procedure reported by Bertozzi et al.89 and upon 
addition of 50 μM Fe3+ these cells aggregated together within 20 minutes with gentle 
agitation. Further studies demonstrated that this process was specific for Fe3+ and 
could be applied to generate heterocellular aggregates composed of HT29 and MDA-
MB-231 cells (Figure 93). 
 
 









   - 125 -   
6.10 Future work 
 
6.11 In Vitro 3D MTS Assay 
 
Solid tumours in vivo are disorganised 3D collections of multiple cancer cells forming 
cell-cell contacts and intracellular signalling driving cell differentiation and 
proliferation.1,2 Solid tumours suffer from poor drug uptake, drug concentration 
gradients and with up to 60% of solid tumours containing hypoxic regions, all of these 
features can impact upon a drug response in vivo.116 Current 2D cell culture systems, 
for example the MTS assay while rapid and efficient, fail to fully replicate this complex 
interplay in vitro. 3D cell culture screening could be the solution by providing a critical 
bridge between initial 2D cell culture screening and in vivo animal models (Figure 
94).116,117 This additional screening step would ensure only drug candidates which 
retain predetermined levels of activity against 3D cell cultures enter in vivo animal 
models. This would reduce the number of animals required for a drug discovery 
programme saving time, money and reducing the ethical implications of using large 
numbers of animal models.  
 
Figure 94: Bridging the gap between 2D cell culture drug screening and animal models.  
 
  Numerous methods to generate 3D cell culture systems have been 
reported,118,119 however the maltol hydrazide (121) aggregation method has the 
added potential of forming heterocellular aggregates of specific sizes depending on 
aggregation conditions within twenty minutes. This method is more rapid and   cost-
effective that the biotin and avidin methods reported by Shakesheff et al.86 and Sakai 
et al.92 allowing its application on a larger more industrial scale. 
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6.12 Thiomaltol Hydrazide (123) 
 
One problem encountered with the maltol hydrazide (121) cellular aggregation 
method was sequestration of Fe3+ in complete culture media (containing 10% serum) 
preventing cellular aggregation. This problem was resolved when serum free culture 
media was used, however for long term cell culture complete culture media is the 
preferred option. An alternative to overcome this is thiomaltol (122)  (Scheme 39) 
which has been reported to chelate a variety of metals120-122 including Zn2+, Cu2+, 
Mo6+, Ni2+ and Co2+ which may be less susceptible to sequestration by the serum in 
complete culture media. Cohen et al. reported a one-pot procedure to synthesis 
thiomaltol (122) from maltol (92) in 70% using phosphorus pentasulfide (P4S10) and 
hexamethyldisiloxane (HMDO).123 This approach could be applied to synthesis 
thiomaltol hydrazide (123) directly from maltol hydrazide (121) in a single step 
(Method 1, scheme 39) or via thiomaltol (122) (Method 2). 
 
Scheme 39: Thiomaltol (122) and thiomaltol hydrazide (123). 
 
 Thiomaltol hydrazide (123) could be attached to the cell surface using the 
methods of Bertozzi et al.89 and then screened against a variety of metals to 
determine if aggregation occurs in complete culture media. A combination of 
different metals could also be investigated to determine if cellular aggregates with 
different morphologies could be formed in a similar manner reported by Chmielewski 
et al.86   
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7.0 Final Conclusions 
 
The chalcone motif is present in an extensive range of biologically active molecules 
with various activities reported.46-50 We reported fourteen novel urocanic-chalcone 
hybrids combining the urocanic side chain pharmacophore in eleutherobin (3) and 
sarcodictyin (4,5) and the 3,4,5-trimethoxy aryl pharmacophore present in 
combretastatin (CA4) (Chapter 2). Combining pharmacophores from natural products 
via the chalcone motif enabled access to novel compounds with promising 
antiproliferative activities, published in 2011 (Med. Chem. Comm., 2011, 2, 1011-
1015).124 
 While interesting in themselves, chalcones also serve as valuable starting 
materials for more complex molecules in medicinal chemistry.51-54 Twenty pyrazoline 
based (CA4) analogues were synthesised in two steps in good to excellent yield from 
chalcones (Chapter 3). Pyrazoline (71-) displayed nanomolar antiproliferative 
activities and was classified as a microtubule destabiliser confirming that chalcones 
are useful intermediates for more potent molecules (Med. Chem. 
Comm., 2013, submitted).   
 The pyrazoline motif was modified to generate non-toxic pyridine based 
pyrazolines as potential metal chelators for use in tissue engineering. Pyrazoline (97) 
was a potential "Turn on" fluorescent sensor for Cd2+ which upon oxidation to the 
corresponding pyrazole (98), could distinguish Cd2+ from Zn2+ (Chapter 5). This 
observation provides valuable insight for future pyrazoline sensors and was published 
in 2012 (Org. Biomol. Chem., 2012, 10, 8753-8757).125 Further studies suggested that 
they were not suitable for tissue engineering purposes therefore an alternative 
strategy using the well established Fe3+ chelator maltol was developed.  
Maltol hydrazide (121) was synthesised and attached to the cell surface of 
HT29 cells which upon addition of Fe3+ ions resulted in cellular aggregation due to 
metal chelation (Chapter 6). This process was applied to generate heterocellular 
aggregates composed of different cell types with valuable applications for cancer 
research and tissue engineering (Chem. Commun., 2013, Manuscript in preparation). 
 
   - 128 -   
Chapter 8: References 
 
 
1. J. Ferlay, H.R. Shin, F. Bray, D. Forman, C. Mathers and D.M. Parkin, Int. J. 
Cancer, 2010, 137, 2893-2917. 
2. D. Hanahan and R.A. Weinberg, Cell, 2000, 100, 57-70. 
3. D. Hanahan and R.A. Weinberg, Cell, 2011, 144, 646-674. 
4. B.A. Chabner and T.G. Roberts, Nat. Rev. Cancer, 2005, 5, 65-72. 
5. A.D. Huitema, K.D. Smits, R.A. Mathot, J.H. Schellens, S. Rodenhuis and J.H. 
Beijnen, Anticancer Drugs, 2000, 11, 515-533. 
6. G.J. Peters, C.L. Van der Wilt, C.J. Van Moorsel, J.R. Kroep, A.M. Bergman and 
S.P. Ackland, Pharmacol. Ther., 2000, 87, 227-253. 
7. M.A. Jordan and L. Wilson, Nat. Rev. Cancer, 2004, 4, 253-65. 
8. M. Kavallaris, Nat. Rev. Cancer, 2010, 10, 194-204. 
9. T. Fojo, The Role of Microtubules in Cell Biology, Neurobiology and Oncology, 
Humana Press, 2008, p. 359. 
10. S. Nobili, D. Lippi, E. Witort, M. Donnini, L. Bausi, E. Mini and S. Capaccioli, 
Pharmacol. Res., 2009, 59, 365-378. 
11. Y. Zhao, W.S. Fang and K. Pors, Expert Opin. Ther. Pat., 2009, 19, 607-622 and 
A. E. Prota, K. Bargsten, D. Zurwerra, J. J. Field, J. Fernado Diaz, K-H. Altmann 
and M. O. Steinmetz, Science, 2013, 339, 587-590. 
12. C. Ferlini, D. Gallo and G. Scambia, Expert Opin. Investig. Drugs, 2008, 17, 335-
347. 
13. G.A. Orr, P. Verdier-Pinard, H. McDaid and S.B. Horwitz, Oncogene, 2003, 20, 
7280-7295. 
14. R.H. Alvarez, V. Valero and G.N. Hortobagyi, Ann. Med., 2011, 43, 477-486. 
15. W. H. Fenical, P. R. Jensen and T. Lindel, 1995, US Patent 5473057. 
16. T. Lindel, P.R. Jensen, W. Fenical, B.H. Long, A.M. Casazza, J. Carboni and C.R. 
Fairchild, J. Am. Chem. Soc., 1997, 119, 8744-8745. 
17. M. D’Ambrosio, A. Guerriero and F. Pietra, Helv. Chim. Acta, 1987, 70, 2019-
2027. 
   - 129 -   
18. B.H. Long, J.M. Carboni, A.J. Wasserman, L.A. Cornell, A.M. Casazza, P.R. 
Jensen, T. Lindel, W. Fenical and C.R. Fairchild, Cancer Res., 1998, 58, 1111-
1115. 
19. E. Hamel, D.L. Sackett, D. Vourloumis and K.C. Nicolaou, Biochemistry, 1999, 
38, 5490-5498. 
20. K.C. Nicolaou, F. van Delft, T. Ohshima, D. Vourloumis, J. Xu, S. Hosokawa, J. 
Pfefferkorn, S. Kim and T.Li, Angew. Chem., Int. Ed. Engl., 1997, 36, 2520-2524. 
21. K.C. Nicolaou, T. Ohshima, S. Hosokawa, F.L. van Delft, D. Vourloumis, J.Y. Xu, 
J. Pfefferkorn and S. Kim, J. Am. Chem. Soc., 1998, 120, 8674-8680. 
22. X.T. Chen, C.E. Gutteridge, S.K. Bhattacharya, B. Zhou, T.R.R. Pettus, T. Hascall 
and S.J. Danishefsky, Angew. Chem., Int. Ed., 1998, 37, 185-187. 
23. X.T. Chen, B. Zhou, S.K. Bhattacharya, C.E. Gutteridge, T.R.R. Pettus and S.J. 
Danishefsky, Angew. Chem., Int. Ed., 1998, 37, 789-792. 
24. D. Castoldi, L. Caggiano, L. Panigada, O. Sharon, A.M. Costa and C. Gennari, 
Angew. Chem., Int. Ed., 2005, 44, 588-591 
25. D. Castoldi, L. Caggiano, L. Panigada, O. Sharon, A.M. Costa and C. Gennari, 
Chem. Eur. J., 2006, 12, 51-62. 
26. K.C. Nicolaou, J. Pfefferkorn, J. Xu, N. Winssinger, T. Ohshima, S. Kim, S. 
Hosokawa, D. Vourloumis, F. van Delft and T. Li, Chem. Pharm. Bull., 1999, 47, 
1199-1213. 
27. R. Beumer, P. Bayon, P. Bugada, S. Ducki, N. Mongelli, F.R. Sirtori, J. Telser and 
C. Gennari, Tetrahedron, 2003, 59, 8803-8820. 
28. D. Castoldi, L. Caggiano, P. Bayon, A.M. Costa, P. Cappella, O. Sharon and C. 
Gennari, Tetrahedron, 2005, 61, 2123-2139. 
29. G.C.H. Chiang, A.D. Bond, A. Ayscough, G. Pain, S. Ducki and A.B. Holmes, 
Chem. Commun., 2005, 1860-1862. 
30. S.M. Chen, L.H. Meng and J. Ding, Expert Opin. Investig. Drugs, 2010, 19,    
329-343. 
31. A.L. Risinger, F.J. Giles and S.L. Mooberry, Cancer Treat. Rev., 2009, 35, 255-
261. 
32. E. Hamel, Pharmacol. Ther., 1992, 55, 31-51. 
   - 130 -   
33. G.R. Pettit, S.B. Singh, E. Hamel, C.M. Lin, D.S. Alberts and D. Garcia-Kendall, 
Experientia., 1989, 15, 209-211. 
34. G.M. Tozer, C. Kanthou and B.C. Baguley, Nat. Rev. Cancer, 2005, 5, 423-425. 
35. D.W. Siemann, D.J. Chaplin and P.A. Walicke, Expert Opin. Investig. Drugs, 
2009, 18, 189-197. 
36. R.O. Carlson, Expert Opin. Investig. Drugs, 2008, 17, 707-722. 
37. K. Gaukroger, J.A. Hadfield, N.J. Lawrence, S. Nolan and A.T. McGown, Org. 
Biomol. Chem., 2003, 7, 3033-3037. 
38. T.M. Beale, R.M. Myers, J.W. Shearman, D.S. Charnock-Jones, J.D. Brenton, 
F.V. Gergely and S.V. Ley, Med. Chem. Commun., 2010, 1, 202-208. 
39. G.R. Pettit, N. Melody, A. Thornhill, J.C. Knight, T.L. Groy and C.L. Herald, J. 
Nat. Prod., 2009, 72, 1637-1642. 
40. M.G. Banwell, E. Hamel, D.C. Hockless, P. Verdier-Pinard, A.C. Willis and D.J. 
Wong, Bioorg. Med. Chem., 2006, 1, 4627-4638. 
41. T. Pirali, S. Busacca, L. Beltrami, D. Imovilli, F. Pagliai, G. Miglio, A. Massarotti, 
L. Vertotta, G.C. Tron, G. Sorba and A.A. Genazzani, J. Med. Chem., 2006, 49, 
5372-5376. 
42. L. Cafici, T. Pirali, F. Condorelli, E.D. Grosso, A. Massarotti, G. Sorba, P.L. 
Canonico, G.C. Tron and A.A. Genazzani, J. Comb. Chem., 2008, 10, 732-740. 
43.  R. Romagnoli, P.G. Baraldi, A. Brancale, A. Ricci, E. Hamel, R. Bortolozzi, G. 
Basso and G. Viola, J. Med. Chem., 2011, 54, 5144-5153. 
44. D. Simoni, G. Grisolia, G. Giannini, M. Roberi, R. Rondanin, L. Paccagli, R. 
Barcuchello, M. Rossi, R. Romagnoli, R.P. Invidiata, S. Grimaudo, M.K. Jung, E. 
Hamel, N. Gebbia, L. Crosta, V. Abbadessa, A. Di Cristina, L. Dusonchet, M. 
Meli and M. Tolomeo, J. Med. Chem., 2005, 48, 723-736. 
45. C. Congiu, V. Onnis, L. Vesci, M. Castonia and C. Pisano, Bioorg. Med. Chem., 
2010, 18, 6238-6248. 
46. D. I. Batovska and I. T. Todorova, Curr. Clin. Pharmacol., 2010, 5, 1-29. 
47. S. Ducki, D. Rennison, M. Woo, A. Kendall, J.M.D. Chabert, A.T. McGown and 
N.J. Lawrence, Bioorg. Med. Chem, 2009, 17, 7698-7710. 
48. T. Caulfield, M.P. Cherrier, C. Combeau and P. Mailliet, Patent EP1253141A1. 
   - 131 -   
49. D.J. Kerr, E. Hamel, M.K. Jung and B.L. Flynn, Bioorg. Med. Chem., 2007, 15, 
3290-3298. 
50. S. Ducki, G. Mackenzie, N.J. Lawrence and J.P. Snyder, J. Med. Chem., 2005, 48, 
457-465. 
51. C. Congiu, V. Onnis, L. Vesci, M. Castorina and C. Pisano, Bioorg. Med. Chem., 
2010, 18, 6238-6248. 
52. P.C. Lv, H.Q. Li, J. Sun, Y. Zhou and H.L. Zhu, Bioorg. Med. Chem., 2010, 18, 
4606-4614. 
53. S.A.F. Rostom, M.H. Badr, H.A. Abd El Razik, H.M.A. Ashour and A.E. Wahag, 
Arch. Pharm. Chem. Life. Sci., 2011, 344, 572-587. 
54. P.C. Lv, D.D. Li, Q.S. Li, X. Lu, Z.P. Xiao and H.L. Zhu, Bioorg. Med. Chem. Lett., 
2011, 21, 5374-5377. 
55. G. Caponigro and W.R. Sellers, Nat. Rev. Drug Discov., 2011, 10, 179-187. 
56. R.H. Shoemaker, Nat. Rev. Cancer., 2006, 6, 813-823. 
57. W.S. Yang, K. Shimada, D. Delva, M. Patel, E. Ode, R. Skouta and B.R. 
Stockwell, ACS. Med. Chem. Lett., 2012, 12, 35-38. 
58. M.L. Shelanski, F. Gaskin and C.R Cantor, Proc. Nat. Acad. Sci. USA., 1973, 70, 
765-768. 
59. M.V.R. Reddy, B. Akula, S.C. Cosenza, C.M. Lee, M.R. Mallireddigari, V.R. 
Pallela, C.V. Subbaiah, A. Udofa and E.P. Reddy, J. Med. Chem., 2012, 55, 5174-
5187. 
60. N.M. Rateb and H.F. Zohdi, Synth. Commun., 2009, 39, 2789-2794. 
61. S. Bhagat, R. Sharma, D.M. Sawant, L. Sharma and A. K. Chakraborti, J. Mol. 
Catal. A: Chem., 2006, 244, 20-24. 
62. T. Narender and K. Papi Reddy, Tetrahedron Lett., 2007, 48, 3177-3180. 
63. N. Lauth-de Viguerie, N. Sergueeva, M. Damiot, H. Mawlawi, M. Riviere and A. 
Lattes, Heterocycles, 1994, 37, 1561-1576. 
64. S. Zheng, Y.R. Laxmi, E. David, A.T. Dinkova-Kostova, K.H. Shiavoni, T. Ren, T. 
Zheng, I. Trevino, R. Bumeister, I. Ojima, W.C. Wigley, J.B. Bliska, D.F. Mierke 
and T. Honda, J. Med. Chem., 2012, 55, 4837-4846. 
65. R. Nishimura, K. Tabata, M. Arakawa, Y. Ito, Y. Kimura, T. Akihisa, H. Nagai, A. 
Sakuma, H. Kohno and T. Suzuki, Bio. Pharm. Bull., 2007, 30, 1878-1883. 
   - 132 -   
66. C.L. Miranda, J.F. Stevens, A. Helmrich, M.C. Henderson, R.J. Rodriguez, Y.H. 
Yang, M.L. Deinzer, D. W. Barnes and D.R. Buhler, Food. Chem. Toxicol., 1999, 
37, 271-285. 
67. N.P. Reddy, P. Aparoy, T.C.M. Reddy, C. Achari, P.R. Sridhar and P. Reddanna, 
Bioorg. Med. Chem., 2010, 18, 5807-5815. 
68. K.E. Judd and L. Caggiano, Org. Biomol. Chem., 2011, 9, 5201-5210. 
69. A. Leavai, J. Heterocyclic Chem., 2002, 39, 1-13. 
70. Z.-L. Gong, L.-W. Zheng, B.-X. Zhao, D.-Z. Yang, H.-S. Lv, W.-Y. Liu and S. Lian, J. 
Photochem. Photobiol., A, 2010, 209, 49–55. 
71. R.S. Cahn, C. Ingold and V. Prelog, Angew. Chem. Int. Ed. Engl., 1966, 5, 385-
415. 
72. N. Vanthuyne, C. Roussel, J.V. Naubron, N. Jagerovic, P.M. Lazaro, I. Alkorta 
and J. Elguero, Tetrahedron Asymm., 2011, 22, 1120-1124. 
73. O. Mahe, I. Dez, V. Levacher and J.F. Briere, Angew. Chem. Int. Ed., 2010, 49, 
7072-7075. 
74. J.A. Dale, D.L. Dull and H.S. Mosher, J. Org. Chem., 1969, 34, 2543-2549. 
75. S.K. Tahir, P. Kovar, S.H. Rosenberg and S.C. Ng, Biotechniques, 2000, 29, 156-
160.  
76. A. Dahan, M. Khamis, R. Agbaria and R. Karaman, Expert Opin. Drug Deliv., 
2012, 9, 1001-1013. 
77. C.P. Landowski, B.S. Vig, X. Song and G.L. Amidon, Mol. Cancer. Ther., 2005, 4, 
659-667. 
78. X. Song, P.L. Lorenzi, C.P. Landowski, B.S. Vig, J.M. Hilfinger and G.L. Amidon, 
Mol. Pharm., 2005, 2, 157-167. 
79. R. Langer and J.P. Vacanti, Science, 1993, 260, 920-926 
80. H. Naderi, M.M. Matin and A.R. Bahrami, J. Biomater. Appl., 2011, 26, 383-
417. 
81. T. Garg, O. Singh, S. Arora and R. Murthy, Crit. Rev. Ther. Carrier Sys., 2012, 29, 
1-63. 
82. M.J. Lysaght, A. Jaklenec and E. Deweerd, Tiss. Eng. Part. A., 2008, 14, 305-
315. 
   - 133 -   
83. A. Atala, S.B. Bauer, S. Soker, J.J. Yoo and A.B. Retik, Lancet, 2006, 15, 1241-
1246. 
84. P. Macchiarini, P. Jungebluth, T. Go, M.A. Asnaghi, L.E. Rees, T.A. Cogan, A. 
Dodson, J. Martorell, S. Bellini, P.P. Parnigotta, S.C. Dickinson, A.P. Hollander, 
S. Mantero, M.T. Conconi and M.A. Birchall, Lancet, 2008, 13, 2023-2030. 
85. A. Raya-Rivera, D.R. Esquiliano, J.J. Yoo, E. Lopez-Bayghen, S. Soker and A. 
Atala, Lancet, 2011, 2, 1175-1185. 
86. M.M. Pires, D.E. Przbyla and J. Chmielewski, Angew. Chem. Int. Ed. 2009, 48, 
7813-7817. 
87. M.M Pires and Chmielewski, J. Am. Chem. Soc., 2009, 25, 2706-2712. 
88. M.P. Lutolf and J.A. Hubbell, Nat. Biotechnol., 2005, 23, 47-55. 
89. G.A. Lemieux and C.R. Bertozzi, Trends. Biotechnol., 1998, 16, 506-513 and K. 
E. Norgard, H. H. Powell, M. Kriegler, A. Varki and N. M. Varki, Proc. Natl. 
Acad. Sci. U.S.A., 1993, 90, 1068-1072. 
90. P.A. De Bank, B. Kellam, D.A. Kendall and K.M. Shakesheff, Biotechnol. Bioeng., 
2003, 30, 800-808. 
91. P.A. De Bank, Q. Hou, R.M. Warner, I.V. Wood, B.E. Ali, S. Macneil, D.A. 
Kendall, B. Kellam, K.M. Shakesheff and L.D. Buttery, Biotechnol. Bioeng., 
2007, 15, 1617-1625. 
92. N. Kojima, S. Takeuchi and Y. Sakai, Biomaterials, 2011, 32, 6059-6067. 
93. P. Wang, N. Onozawa-Komatsuzaki, Y. Himeda, H. Sugihara, H. Arakawa and K. 
Kasuga, Tetrahedron Lett., 2001, 42, 9199-9201. 
94. S. Hu, S. Zhang, Y. Hu, Q. Tao and A. Wu, Dyes Pigment, 2013, 96, 509-515. 
95. I. Ali, W.A. Wani, A. Khan, A. Hague, A. Ahmad, K. Saleem and N. Manzoor, 
Microb. Pathog., 2012, 53, 66-73. 
96. S. Wang, W. Shao, H. Li, C. Liu, K. Wang and J. Zhang, Eur. J. Med. Chem., 2011, 
46, 1914-1918. 
97. L.E. Scott and C. Orvig, Chem. Rev., 2009, 109, 4885-4910. 
98. K.H. Thompson, C.A. Berta and C. Orvig, Chem. Soc. Rev., 2006, 35, 545-556. 
99. T. Zhou, Y. Ma, X. Kong and R.C. Hider, Dalton Trans., 2012, 41, 6371-6389.  
100. S. Amatori, I. Bagaloni, E. Macedi, M. Formica, L. Giorgi, V. Fusi and M.                     
Fanelli, Br. J. Cancer, 2010, 13, 239-248. 
   - 134 -   
101. L.S. Dehkordi, Z.D. Liu and R.C. Hider, Eur. J. Med. Chem., 2008, 43, 
 1035-1047. 
102. E.B. Mubofu and J.B.F.N. Engberts, J. Phys. Org. Chem.,2004, 17, 180-186. 
103. J. McNulty and I.W.J. Still, J. Chem. Soc., Perkin Trans. 1, 1994, 1329- 1337. 
104. M. Barceló-Oliver, A. Terrón, A. García-Raso, I. Turel and M. Morell, Acta 
Crystallogr., Sect. E: Struct. Rep. Online, 2010, 66, m899–m900. 
105. Z. Li, L. Zhang, L. Wang, Y. Guo, L. Cai, M. Yu and L. Wei, Chem. Commun., 
2011, 47, 5798–5800. 
106. Z. Xu, K.-H. Baek, H. N. Kim, J. Cui, X. Qian, D.R. Spring, I. Shin and J. Yoon, J. 
Am. Chem. Soc., 2010, 132, 601–610. 
107. Z. Xu, X. Liu, J. Pan and D.R. Spring, Chem. Commun., 2012, 48, 4764–4766. 
108. Z. Xu, J. Yoon and D.R. Spring, Chem. Soc. Rev., 2010, 39, 1996–2006. 
109. M.D. Pluth, E. Tomat and S.J. Lippard, Annu. Rev. Biochem, 2011, 80, 333–
355. 
110. B.P. Joshi, J. Park, W.I. Lee and K.-H. Lee, Talanta, 2009, 78, 903–909. 
111. L. Xue, C. Liu and H. Jiang, Org. Lett., 2009, 11, 1655–1658. 
112. H. Chen, W. Gao, M. Zhu, H. Gao, J. Xue and Y. Li, Chem. Commun., 2010, 46, 
8389–8391. 
113. Z.L. Gong and B.X. Zhao, Sens. Actuators, B, 2011, 159, 148-153. 
114. Z. Zheng, F-W. Wang, S-W. Wang, S-Q. Wang, F. Ge, B-X. Zhao and J-Y. Ming, 
Org. Biomol. Chem., 2012, 10, 8640-8644. 
115. P.S. Dobbin, R.C. Hider, A.D. Hall, P.D. Taylor, P. Sarpong, J.B. Porter, G. Xiao 
and D.V.D. Helm, J. Med. Chem., 1993, 36, 2448-2458. 
116. S. Breslin and L. O’Driscoll, Drug Discov. Today, 2013, 18, 240-249. 
117. G. Mehta, A.Y. Hsiao, M. Ingram, G.D. Luker and S. Takayama, J. Controlled 
Release, 2012, 164, 192-204. 
118. F. Hirschhaeuser, H. Menne, C. Dittfeld, J. West, W. Mueller-Klieser and L.A. 
Kunz-Schughart, Biotechnol. J., 2010, 148, 3-15. 
119. R.Z. Lin and H.Y. Chang, Biotechnol. J., 2008, 3, 1172-1184. 
120. S. Chaves, R. Jelic, C. Mendoca, M. Carrasco, Y. Yoshikawa, H. Sakurai and 
M.A. Santos, Metallomics, 2010, 2, 220-227. 
   - 135 -   
121. J.A. Lewis, B.L. Tran, D.T. Puerta, E.M. Rumberger, D.N. Hendrickson and S.M. 
Cohen, Dalton Trans., 2005, 2588-2596. 
122. S. Chaves, M. Gil, S. Canario, R. Jelic, M. Joao Romao, J. Trincao, E. 
Herdtweck, J. Sousa, C. Diniz, P. Fresco and M.A. Santos, Dalton Trans., 2008, 
1773-1782. 
123. J.A. Lewis, D.T. Puerta and S.M. Cohen, Inorg. Chem., 2003, 42, 7455-7459. 
124. A. Ciupa, N.J. Griffiths, S.K. Light, P.J. Wood and L. Caggiano, Med. Chem.    
Comm, 2011, 2, 1011-1015. 
125. A. Ciupa, M.F. Mahon, P.A. De Bank and L. Caggiano, Org. Biomol. Chem., 























   - 136 -   
9. Experimental and MTS Assays 
General Experimental 
 
Chemicals, solvents and reagents used are commercially available and were used 
without further purification. PE refers to petroleum ether, bp 40-60 °C. TLCs were 
carried out on Merck Aluminium backed TLC plates Silica Gel 60 F254 and viewed 
using UV light of wavelength 254 nm and then stained with potassium permanganate. 
Merck Silica Gel (0.040-0.063 mm) was used for column chromatography. Compounds 
were loaded as an oil, CH2Cl2 solution or dry loaded by adsorption onto silica. Melting 
points were obtained using a Reichert-Jung heated-stage microscope. Infrared 
spectra were recorded on a Perkin-Elmer Spectrum RXI FT-IR system and all values are 
recorded in cm−1. 
NMR spectra were obtained on Varian Mercury VX (400 MHz) or Bruker 
Avance III (500 or 400 MHz) spectrometers. The chemical shifts are recorded in parts 
per million (ppm) with reference to tetramethylsilane. The coupling constants J are 
quoted to the nearest 0.5 Hz and are not corrected. The multiplicities are assigned as 
a singlet (s), doublet (d), triplet (t), doublet of doublets (dd), quartet (q) and multiplet 
(m). Mass spectra and high resolution mass spectra were obtained on a micrOTOFTM 
from Bruker Daltonics (Bremen, Germany) coupled with an electrospray source (ESI-
TOF) using an autosampler in an Agilent 1100 LC system. Data was processed using 
external calibration with the Bruker Daltonics software, DataAnalysisTM as part of the 
overall hardware control software, Compass 1.1TM.  
X-ray Crystallography: Single crystals were analysed at 150(2) K using graphite 
monochromated Mo(Kα) radiation and a Nonius Kappa CCD diffractometer. The 
structures were solved using SHELXS-97 and refined using SHELXL-97. UV/Vis 
spectroscopy studies were performed on a BMG labtech Fluostar plate reader with 
NUNC 96 well flat bottom plates at room temperature. Fluorescence studies were 
performed on a Hitachi F-2000 fluorescence spectrophotometer with a 150 W xenon 
lamp using a cuvette with 1 cm path length. Polarimeter was performed on an AA-10 
series Optical Activity Ltd polarimeter with a 1 mL flow cell with a path length of 10 
cm3. Data processing and analysis was using performed using SigmaPlot 8. 
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MTS Cell Proliferation Assay 
 
Human cancer cell lines HT29, MDA-MB-231 and LNCaP were supplied by Cancer 
Research UK. They were maintained in DMEM with high glucose (4.5 g/L) and L-
glutamine, supplemented with penicillin 100 U/mL, streptomycin 100 μg/mL and 
foetal bovine serum at 10% for HT29 and MDA-MB-231, and 20% for LNCaP. FEK-4 
primary human skin fibroblasts were a gift from Prof. Rex M. Tyrrell (University of 
Bath) and were maintained in MEM supplemented with L-glutamine, supplemented 
with penicillin 100 U/mL, streptomycin 100 μg/mL and 15% foetal bovine serum. All 
reagents supplied by Invitrogen. 
 
1. Cells were maintained in 75 cm2 tissue culture flasks (Nunc) with a weekly 1:10 
split. 
 
2: For the MTS assay, seed densities of 500, 1000, 1500 and 2000 cells per well in 50 
μL were used for HT29, MDA-MB-231, FEK-4 and LNCaP cell lines respectively. The 
seed densities had been determined previously to give an acceptable optical density 
value after 3 days incubation. 
 
3: Plates were incubated at 37 oC, in humidified 5% CO2 in air for 2-4 h. 
 
4: Test agents were prepared at 100 × final concentration in DMSO (Sigma), diluted 1 
in 50 in culture medium and 50 μL added to the appropriate wells, to give a final 
volume of 100 μL. 
 
5: Quadruplicate samples were run as follows: 
Culture medium only (background) 
Cells only 
Cells + 1% DMSO 
Cells + test compound 
 
6: Plates were incubated at 37 oC, in humidified 5% CO2 in air. 
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This exposure time appears to be adequate to demonstrate anti-proliferative activity, 
and is routinely used by other workers.  
 
7: The MTS reagent was added, 20 μL per well. This is Promega Cell Titer® Aqueous 
One Solution Cell Proliferation Assay. 
 
8: Plates were incubated at 37 oC, in humidified 5% CO2 in air, for colour 
development. 
 
9: Optical density readings at 490 nm were taken at 1-4 h, because the culture 
medium gives a high OD490nm this was subtracted from all other OD490nm. 
 
10: Means and standard deviations were calculated from background corrected 
OD490nm values. 
 
11: IC50 values were calculated using the pharmacology function in SigmaPlot 8 (SPSS 
Inc). Each assay was repeated on three separate occasions.  
 
Note: This assay is based upon the development of a coloured metabolite from viable 
cells. Therefore the inhibition of colour development by an active agent does not 
distinguish between inhibition of cell metabolism ie cytostasis and reduction in cell 
number ie cytotoxicity. Nevertheless, this assay provides a very quick and easy first 
approach for screening test compounds. 
 
Cell Cycle Analysis 
 
Following the procedure reported,38 except using HT29 cells: 
 
1. Cells were subcultured into a T25 flask (5 × 105 cells, 3 mL media) and grown for 24 
h. 
 
   - 139 -   
2. Fresh media containing required concentration of drug/control was added (3 mL) 
and the cells were incubated with drug for a further 24 h.  
 
3. The supernatant media was collected, and combined with a PBS wash (5 mL). 
Trypsin (1 mL) was added and cells incubated for 5 min.  
 
4. The trypsin was neutralised with media (2 mL) and this was combined with the 
supernatant and a further PBS wash (5 mL). The cell suspension was centrifuged 
(1000 rpm, 6 min), the supernatant was removed, and the cell pellet was 
resuspended in PBS (5 mL). 
 
 5. This was centrifuged (1000 rpm, 6 min), and the supernatant was removed. The 
cell pellet was resuspended in PBS (0.5 mL), and this suspension was carefully added 
to ice cold 70% ethanol solution (4.5 mL).The cells were fixed for a minimum of 2 h, 
before centrifuging (1000 rpm, 5 min). 
 
6. The supernatant was removed and the cells resuspended in PBS (5 mL). The cells 
were washed via two centrifuging and resuspension cycles, and were finally 
resuspended in 1 mL of a solution of DNase-free RNase A (20 μg/mL) and propidium 
iodide (20 μg/mL) in 0.1% (v/v) Triton X-100 in PBS.  
 
7. Cells were incubated at rt for 30 min in the dark. Cell fluorescence was determined 
using a FACSCalibur (BDBiosciences), gating for mononuclear cells. 
 
Cytoskeleton BK004P In Vitro Tubulin Polymerisation Assay Kit 
 
Following the manufacturer instructions (Cat # BK004P)58: 
 
1. One 4 mg tube of tubulin (HTS03) was resuspended with 1 ml of cold G-PEM buffer 
(990 µl general tubulin buffer with 10 µl GTP stock) to give a final protein 
concentration of 4 mg/mL. The tube was placed on ice for 3 min until complete 
resuspension of the protein was observed. 
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2. A 96 well half area plate was prewarmed to 37 oC by placing in an incubator for 30 
mins prior. 
 
3. Pipette 10 µL of compound of interest at 10x strength in G-PEM buffer into two 
wells of the prewarmed 96 well half area plate and 10 µL of general tubulin buffer 
only into two of the control wells and incubate the plate for 2 min at 37 oC. 
 
4. Remove the 96 well half area plate and pipette 100 µL of tubulin into the required 
wells and immediately place the plate into the spectrophotometer prewarmed to 37 
oC and start recording using optical density reading at     340 nm at one reading per 
minute for one hour. 
 
5. The optical density of each compound was plotted against time to obtain the 





Following the procedure reported,38 except using HT29 cells: 
 
1. HT29 cells were subcultured in each well of a six well plate containing a glass 
coverslip and incubated at 37 oC for 24 h.  
 
2. When the cells were approximately 50% confluent, the coverslips were removed 
and placed into a well of a new 6 well plate containing 450 μL medium. Drug solution 
in medium (50 μL, 10× concentrations to give appropriate 1× final concentrations) 
was then added along with a blank (50 μL of medium) and plates incubated for 24 h. 
 
3. After 24 h the media was aspirated, the coverslips washed with PBS (500 μL per 
well) followed by fixation in freshly diluted 3% formaldehyde solution in PBS (500 μL) 
followed by incubation at 37 °C for 10 min.  
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4. After aspiration cells were permeabilised with PBS-T (0.1% Triton in PBS, 500 μL) 
for 5 min, and then incubated at 37 °C with blocking solution (10% bovine serum 
albumin (BSA) in PBS (500 μL)) for 5 min.  
 
5. This was removed and DM1A primary mouse antibody (1 in 200 in blocking 
solution, 500 μL) was added and incubated at 37 °C for 2 h.  
 
6. The primary antibody solution was removed and the cells were washed 3 times (5 
min at 37 °C) with PBS-T (500 μL). The appropriate Alexa Fluor® 546-coupled 
secondary antibody was then added as a solution in BSA in PBS (1 in 200 in blocking 
solution, 500 μL) and the plate returned to the incubator for a further 2 h ensuring 
minimal light exposure. 
  
7. Cells washed 3 times (5 min at 37 °C) with PBS-T (500 μL), with a final wash in water 
(500 μL). The coverslips inverted onto microscope slides with mounting medium 
containing DAPPI stain (30 μL) and allowed to dry at rt overnight and then stored at 4 
°C until they were viewed using a confocal microscope. 
 
HPLC – System 1 
 
Analytical RP-HPLC was performed on a Dionex HPLC system equipped with a 
Dionex Acclaim 3 µm C-18 (150 × 4.6 mm) column with a flow rate of 1 mL/min. 
with detection at 214 nm and 254 nm shown. Mobile phase A was 0.1% TFA in H 2O 
and mobile phase B was 0.1% TFA in MeCN. The gradient was T = 0 min., B = 5%; T 
= 10 min., B = 95%; T = 15 min., B = 95%; T = 15.1 min., B = 5%; T = 18.1 min., B = 
5%. 
 
HPLC – System 2 
 
Analytical RP-HPLC was performed on a JASCO HPLC system equipped with a 
phenomenex Max-RP 80A 4 µm C-18 (150 × 4.6 mm) column with a flow rate of 
1.0 mL/min. with detection at 274 nm and 254 nm shown. Mobile phase A was 
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50% H2O and mobile phase B was 50% MeCN.  
 
HPLC – System 3 
 
Semipreparative HPLC was performed on a JASCO HPLC system equipped with a 
Astec semipreparative Chirobiotic V2 column with a flow rate of 10 mL/min. with 
detection at 254 nm shown. Mobile phase A was 50% H2O and mobile phase B was 
50% MeCN.  
 
HPLC – System 4 
 
Enantiomeric excess determined using a JASCO HPLC system equipped with a 
Astec analytical Chirobiotic V2 column with a flow rate of 1.0 mL/min. with 
detection at 254 nm shown. Mobile phase A was 50% H2O and mobile phase B was 
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1.1 Method A 
Following the procedure previously reported,61
 
except using 1.0 equivalent LiOH·H2O, 
LiOH·H2O (2.5 mmol) was added to rapidly stirred solution of acetophenone (2.5 mmol) in 
EtOH (2.0 mL) at 30 oC open to the atmosphere for 10 min resulting in a rapid colour 
change from colourless to yellow. The aldehyde (2.5 mmol) was then added and stirring 
continued for 6 h resulting in a gradual colour change from yellow to orange. After 6 h the 
solvent was removed under reduced pressure and distilled water (5 mL) added followed by 
1.5M HCl(aq) (5 mL) to the remaining residue. The product was extracted with EtOAc (3 × 
20 mL), the organic layers were combined and washed with saturated brine solution (20 
mL). The organic fraction was dried (Na2SO4), filtered and solvent removed under reduced 
pressure to give a yellow solid. The solid was purified by column chromatography with 
silica gel using PE:EtOAc 6:4 to afford the desired chalcone. 
 
(E)-1-(4-methoxyphenyl)-3-(1H-pyrrol-2-yl)prop-2-en-1-one (40)  
 
 
Following Method A on a 5.0 mmol scale, chalcone (40) was obtained as a yellow solid 
(0.49 g, 43%).  
Rf [PE-EtOAc 4:6] 0.85; Mp 170-172 
oC (EtOAc/heptane); IR νmax(film)/cm
-1 3050, 1649 
and 1594; 1H NMR δH (400 MHz; CDCl3) 3.87 (3 H, s, OCH3), 6.31-6.33 (1 H, m, pyrrole 
CH), 6.65-6.70 (1 H, m, pyrrole CH), 6.95 (2 H, d, J 9.0 Hz, Ar CH), 6.94-6.96 (1 H, m, 
pyrrole CH), 7.16 (1 H, d, J 15.0 Hz, COCH=CH), 7.73 (1 H, d, J 15.0 Hz, COCH=CH), 7.99 
(2 H, d, J 8.5 Hz, Ar CH) and 8.95 (1 H, br s, pyrrole NH); 13C NMR δC (100 MHz; CDCl3) 
55.46 (OCH3), 111.4 (pyrrole CH), 113.8 (pyrrole CH), 114.7 (Ar CH), 115.7 (pyrrole 
CH), 122.3 (Ar CH), 129.5 (Cq), 130.5 (HC=CH), 131.6 (Cq), 133.8 (HC=CH), 163.2 (Cq) 
and 188.7 (C=O); MS m/z (ES+) Found 228.1025 (MH+) and 250.0846 (MNa+), 
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C14H14NO2 (MH
+) requires 228.1025 and C14H13NO2Na (MNa
+) requires 250.0844;     
HPLC (analytical, system 1) tR = 9.1 min. 
 
(E)-1-(3,4-dimethoxyphenyl)-3-(1H-pyrrol-2-yl)prop-2-en-1-one (41)  
 
 
Following Method A, chalcone (41) was obtained as a yellow solid (0.34 g, 53%).  
 
Rf [PE-EtOAc 4:6] 0.63; Mp 80-81 
oC (EtOAc/heptane); IR νmax(film)/cm
-1 3458, 1651 
and 1584; 1H NMR δH (400 MHz; CDCl3) 3.91 (3 H, s, OCH3), 3.92 (3 H, s, OCH3), 6.31-
6.33 (1 H, m, pyrrole CH), 6.69-6.71 (1 H, m, pyrrole CH), 6.85 (1 H, d, J 8.0, Ar CH), 
6.95-6.98 (1 H, m, pyrrole CH), 7.21 (1 H, d, J 15.5 Hz, COCH=CH), 7.59 (1 H, d, J 1.5 Hz, 
Ar CH), 7.61 (1 H, dd, J 8.5 and 1.5 Hz, Ar CH), 7.75 (1 H, d, J 15.5 Hz, COCH=CH) and 
9.25 (1 H, br s, pyrrole NH); 13C NMR δC (100 MHz; CDCl3) 56.0 (OCH3), 110.1 (pyrrole 
CH), 111.0 (pyrrole CH), 111.4 (pyrrole CH), 115.0 (Ar CH), 115.4 (Ar CH), 122.6 (Ar 
CH), 122.9 (HC=CH), 129.5 (Cq), 131.8 (Cq), 134.0 (HC=CH), 149.2 (Cq), 153.0 (Cq) and 
188.7 (C=O); MS m/z (ES+) Found 258.1135 (MH+) and 280.0949 (MNa+), C15H16NO3 
(MH+) requires 258.1130 and C15H15NO3Na (MNa
+) requires 280.0950; HPLC 
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Following Method A, chalcone (42) was obtained as a yellow solid (0.53 g, 74%).  
 
Rf [PE-EtOAc 4:6] 0.73; Mp 104-106 
oC (EtOAc/heptane); IR νmax(film)/cm
-1 3457, 1654 
and 1575; 1H NMR δH (400 MHz; DMSO) 3.76 (3 H, s, OCH3), 3.90 (6 H, s, OCH3), 6.22-
6.24 (1 H, m, pyrrole CH), 6.74-6.75 (1 H, m, pyrrole CH), 7.15-7.16 (1 H, m, pyrrole 
CH), 7.35 (2 H, s, Ar CH), 7.54 (1 H, d, J 15.0 Hz, COCH=CH), 7.62 (1 H, d, J 15.0 Hz, 
COCH=CH) and 11.71 (1 H, br s, pyrrole NH); 13C NMR δC (100 MHz; DMSO) 56.1 
(OCH3), 60.2 (OCH3), 105.7 (Ar CH), 110.6 (pyrrole CH), 114.4 (pyrrole CH), 116.4 
(pyrrole CH), 124.1 (HC=CH) 129.2 (Cq), 133.7 (Cq), 134.1 (HC=CH), 141.5 (Cq), 152.9 
(Cq) and 187.1 (C=O); MS m/z (ES+) Found 288.1241 (MH+) and 310.1061 (MNa+), 
C16H18NO4 (MH
+) requires 288.1236 and C16H17NO4Na (MNa
+) requires 310.1055;        

















Following the procedure previously reported,60
 
acetophenone (5.0 mmol), the 
aldehyde (5.0 mmol) and NaOH (7.0 mmol) was added to a porcelain mortar and 
ground using a porcelain pestle at rt (20 oC) for 5 mins resulting in the formation of a 
viscous yellow paste. The paste was then purified by column chromatography with 
silica gel using PE:EtOAc 6:4 solvent system to afford the desired chalcone. 
 






Following Method B, chalcone (43) was obtained as a yellow solid (0.76 g, 63%).  
 
Rf [PE-EtOAc 4:6] 0.64; Mp 101-103 
oC (EtOAc/heptane); IR νmax(film)/cm
-1 1654 and 
1575; 1H NMR δH (400 MHz; CDCl3) 3.74 (3 H, s, pyrrole CH3), 3.87 (3 H, s, OCH3), 6.20-
6.22 (1 H, m, pyrrole CH), 6.79-6.80 (1 H, m, pyrrole CH), 6.82-6.83 (1 H, m, pyrrole 
CH), 6.96 (2 H, d, J 9.0 Hz, Ar CH), 7.31 (1 H, d, J 15.0 Hz, COCH=CH), 7.79 (1 H, d, J 
15.0 Hz, COCH=CH) and 8.02 (2 H, d, J 9.0 Hz, Ar CH); 13C NMR δC (100 MHz; CDCl3) 
34.3 (pyrrole CH3), 55.4 (OCH3), 109.5 (pyrrole CH), 111.9 (pyrrole CH), 113.7 (Ar CH), 
116.5 (pyrrole CH), 127.4 (HC=CH), 130.3 (Cq), 130.4 (Ar CH), 131.4 (HC=CH), 131.5 
(Cq), 163.0 (Cq) and 188.2 (C=O); MS m/z (ES+) Found 242.1191 (MH+) and 264.1007 
(MNa+), C15H16NO2 (MH
+) requires 242.1181 and C15H15NO2Na (MNa
+) requires 
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(E)-1-(3,4-dimethoxyphenyl)-3-(1-methyl-1H-pyrrol-2-yl)prop-2-en-1-one (44)  
 
 
Following Method B, chalcone (44) was obtained as a yellow solid (1.07 g, 79%).  
 
Rf [PE-EtOAc 4:6] 0.59; Mp 126-126 
oC (EtOAc/heptane); IR νmax(film)/cm
-1 1647, 1597 
and 1573; 1H NMR δH (400 MHz; CDCl3) 3.75 (3 H, s, pyrrole CH3), 3.94 (3 H, s, OCH3), 
3.95 (3 H, s, OCH3), 6.19-6.21 (1 H, m, pyrrole CH), 6.78-6.79 (1 H, m, pyrrole CH), 
6.82-6.83 (1 H, m, pyrrole CH), 6.90 (1 H, d, J 8.5 Hz, Ar CH), 7.30 (1 H, d, J 15.5 Hz, 
COCH=CH), 7.61 (1 H, d, J 2.0 Hz, Ar CH), 7.64 (1 H, dd, J 8.0 and 2.0 Hz, Ar CH) and 
7.79 (1 H, d, J 15.0 Hz, COCH=CH); 13C NMR δC (100 MHz; CDCl3) 34.3 (pyrrole CH3), 
55.9 (OCH3), 56.0 (OCH3), 109.6 (pyrrole CH), 109.9 (pyrrole CH), 110.6 (pyrrole CH), 
111.9 (Ar CH), 116.3 (Ar CH), 122.4 (HC=CH), 127.5 (Ar CH) 130.3 (HC=CH), 131.4 (Cq), 
131.7 (Cq), 149.0 (Cq), 152.8 (Cq) and 188.0 (C=O); MS m/z (ES+) Found 272.1273 
(MH+) and 294.1094 (MNa+), C16H18NO3 (MH
+) requires 272.1287 and C16H17NO3Na 
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Following Method B, chalcone (45) was obtained as an orange oil (1.25 g, 83%).  
 
Rf [PE-EtOAc 4:6] 0.67; IR νmax(film)/cm
-1 1647 and 1568; 1H NMR δH (400 MHz; CDCl3) 
3.77 (3 H, s, pyrrole CH3), 3.92 (3 H, s, OCH3), 3.94 (6 H, s, OCH3), 6.21-6.24 (1 H, m, 
pyrrole CH), 6.81-6.83 (1 H, m, pyrrole CH), 6.85-6.87 (1 H, m, pyrrole CH), 7.21 (1 H, 
d, J 15.0 Hz, COCH=CH), 7.26 (2 H, s, Ar CH) and 7.80 (1 H, d, J 15.0 Hz, COCH=CH); 13C 
NMR δC (100 MHz; CDCl3) 34.3 (pyrrole CH3), 56.3 (OCH3), 56.3 (OCH3), 105.7 (Ar CH), 
109.7 (pyrrole CH), 112.2 (pyrrole CH), 116.4 (pyrrole CH), 127.8 (HC=CH), 130.2 (Cq), 
132.1 (HC=CH), 134.1 (Cq), 153.0 (Cq), 153.0 (Cq) and 188.7 (C=O); MS m/z (ES+) 
Found 302.1371 (MH+) and 324.1192 (MNa+), C17H20NO4 (MH
+) requires 302.1392 and 
C17H19NO4Na (MNa
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Method C 
 
Following the procedure previously reported,62
 
except using 2.0 equivalents of 
BF3·OEt2, BF3·OEt2 (5.0 mmol) was added dropwise under dry conditions to a rapidly 
stirred solution of acetophenone (2.5 mmol) and aldehyde (2.5 mmol) in dry dioxane 
(2.0 mL) under N2 at 25 
oC. The solution was heated to 75 oC for 6 h and the reaction 
followed by TLC. The reaction was cooled and quenched by addition of EtOAc (100 
mL) and distilled water (100 mL) and the aqueous fractions extracted with EtOAc (3 × 
50 mL). 2M NaOH (50 mL) was added to the aqueous layer and gently heated at 50 oC 
with magnetic stirring for 30 min, resulting in a slight colour change and formation of 
a black precipitate. The aqueous layer was extracted with EtOAc (3 × 50 mL) and the 
organic layers were combined and washed with saturated brine solution (50 mL) and 
dried using Na2SO4. The solvent was filtered and removed under reduced pressure to 
produce a yellow/orange solid/oil which was purified by column chromatography 
with silica gel using CH2Cl2:MeOH 9:1 solvent system to afford the desired chalcone. 
 
(E)-3-(1H-imidazol-4-yl)-1-(4-methoxyphenyl)prop-2-en-1-one (46)  
 
 
Following Method C, chalcone (46) was obtained as an orange solid (0.30 g, 53%).  
 
Rf [CH2Cl2:MeOH 9:1] 0.19; Mp 173-175 
oC (EtOAc/heptane); IR νmax(film)/cm
-1 3458, 
1660 and 1604; 1H NMR δH (400 MHz; DMSO) 3.85 (3 H, s, OCH3), 7.08 (2 H, d, J 9.0 
Hz, Ar CH), 7.63 (1 H, d, J 15.0 Hz, COCH=CH), 7.67 (1 H, d, J 15.5 Hz, COCH=CH), 7.64 
(1 H, s, Im CH), 7.85 (1 H, s, Im CH), 8.03 (2 H, d, J 9.0 Hz, Ar CH) and 12.56 (1 H, br s, 
Im NH); 13C NMR δC (100 MHz; DMSO) 55.5 (OCH3), 114.0, 117.8, 130.4 (Ar CH, Im CH 
and HC=CH), 130.8 (Cq), 162.8 (Cq), 162.9 (Cq) and 187.2 (C=O); MS m/z (ES+) Found 
229.0978 (MH+), C13H13N2O2 (MH
+) requires 229.0977; HPLC (analytical, system 1) tR = 
6.0 min. 
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(E)-1-(3,4-dimethoxyphenyl)-3-(1H-imidazol-4-yl)prop-2-en-1-one (47)  
 
 
Following Method C, chalcone (47) was obtained as a pale yellow solid (0.48 g, 74%).  
 
Rf [CH2Cl2:MeOH 9:1] 0.17; Mp 170-171 
oC (THF/heptane); IR νmax(film)/cm
-1 3457, 
1659 and 1605; 1H NMR δH (400 MHz; DMSO) 3.85 (3 H, s, OCH3), 3.86 (3 H, s, OCH3), 
7.10 (1 H, d, J 8.5 Hz, Ar CH), 7.54 (1 H, d, J 2.0 Hz, Ar CH), 7.64 (1 H, d, J 15.0 Hz, 
COCH=CH), 7.64 (1 H, s, Im CH), 7.68 (1 H, d, J 15.5 Hz, COCH=CH), 7.73 (1 H, dd, J 8.5 
and 2.0 Hz, Ar CH), 7.86 (1 H, s, Im CH) and 12.30 (1 H, br s, Im NH); 13C NMR δC (100 
MHz; DMSO) 55.5 (OCH3), 55.7 (OCH3), 110.5 (Ar CH), 110.9 (Ar CH), 117.7 (Im CH), 
122.6 (Ar CH), 130.9 (Cq), 135.0 (HC=CH) 135.6 (HC=CH). 138.0 (Im CH) 148.8 (Cq), 
152.9 (Cq) and 187.2 (C=O); MS m/z (ES+) Found 259.1082 (MH+) and 281.0897 
(MNa+), C14H15N2O3 (MH
+) requires 259.1083 and C14H14N2O3Na (MNa
+) requires 
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Following Method C, chalcone (48) was obtained as an orange solid (0.53 g, 74%).  
 
Rf [CH2Cl2:MeOH 9:1] 0.19; Mp 174-176 
oC (EtOAc/heptane); IR νmax(film)/ cm
-1 3456, 
1661 and 1581; 1H NMR δH (400 MHz; CDCl3) 3.85 (6 H, s, OCH3), 3.89 (3 H, s, OCH3), 
7.26 (2 H, Ar CH), 7.38 (1 H, s, Im CH), 7.69 (1 H, d, J 15.5 Hz, COCH=CH), 7.77 (1 H, s, 
Im CH), 7.77 (1 H, d, J 15.0 Hz, COCH=CH) and 8.17 (1 H, br s, Im NH); 13C NMR δC (100 
MHz; CDCl3) 56.2 (OCH3), 60.9 (OCH3), 105.9 (Ar CH), 119.3 (Im CH), 123.4 (Im CH), 
133.4 (Cq), 134.6 (HC=CH), 135.9 (Cq), 137.2 (HC=CH), 142.3 (Cq), 153.0 (Cq) and 
189.1 (C=O); MS m/z (ES+) Found 289.1183 (MH+), C15H17N2O4 (MH
+) requires 
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Method D 
 
Chalcone (48) (100 mg, 0.347 mmol) was added to a stirred solution of 10wt% Pd/C 
(20 mg) in MeOH (4 mL) under 1.0 atm of H2 and stirring continued at 25 
oC for 19 h. 
The reaction was then quenched with EtOAc     (50 mL) and washed through celite 
with distilled water, the organic layer was extracted with EtOAc (3 × 50 mL) and the 
organic layers were combined and washed with saturated brine solution (50 mL). The 
organic fraction was dried (Na2SO4), filtered and solvent removed under reduced 
pressure to give the product (49) as a pale yellow oil (57 mg, 57%) without the need 
for further purification.  
 
 
3-(1H-imidazol-5-yl)-1-(3,4,5-trimethoxyphenyl)propan-1-one (49)  
 
 
Rf [CH2Cl2:MeOH 9:1] 0.41; IR νmax(film)/cm
-1 3454, 1678, 1586 and 1505; 1H NMR δH 
(400 MHz; CDCl3) 3.05 (2 H, t, J 7.0 Hz, CH2), 3.35 (2 H, t, J 7.0 Hz, CH2), 3.89 (6 H, s, 
OCH3), 3.90 (3 H, s, OCH3), 6.85 (1 H, s, Im CH), 7.21 (2 H, s, Ar CH), 7.45 (1 H, br s, Im 
NH) and 7.65 (1 H, s, Im CH); 13C NMR δC (100 MHz; CDCl3) 20.5 (CH2), 38.2 (CH2), 56.3 
(OCH3), 60.9 (OCH3), 105.5 (Ar CH), 118.2 (Im CH), 131.9 (Cq), 134.2 (Im CH), 135.1 
(Cq), 142.7 (Cq), 153.0 (Cq) and 198.7 (C=O); MS m/z (ES+) Found 291.1350 (MH+) and 
313.1162 (MNa+), C15H19N2O4 (MH
+) requires 291.1345 and (MNa+) C15H18N2O4Na 
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Method E 
 
(E)-3-(1-methyl-1H-imidazol-4-yl)-1-(3,4,5-trimethoxyphenyl)prop-2-en-1-one (51)  
 
Following the procedure reported,63
 
except cooled to 0 oC, NaH (60% dispersion in 
mineral oil, 1.5 mmol) was added to a stirred solution of chalcone (1.0 mmol) in DMF 
(5.0 mL) at 0 oC followed by dropwise addition of MeI (1.5 mmol) and the reaction 
was kept at 0 oC and followed by TLC until the disappearance of the chalcone starting 
material. The reaction was quenched with the addition of EtOAc (50 mL) and H2O (50 
mL), the organic layer separated and the aqueous fraction extracted with EtOAc (2 × 
50 mL). The organic fractions were combined and washed with saturated brine 
solution (20 mL). The organic fraction was dried (Na2SO4), filtered and solvent 
removed under reduced pressure. Crude 1H NMR revealed the presence of chalcone 
(50), in addition to the product chalcone (51) in a ratio of 25:75 (50:51). The mixture 
was purified by column chromatography with silica gel using CH2Cl2:IPA solvent 
system increasing from 0% to 12% IPA in 1% increments of 200 mL to afford the 
desired chalcone (51)  as an orange oil (0.11g, 36%).  
 
(E)-3-(1-methyl-1H-imidazol-4-yl)-1-(3,4,5-trimethoxyphenyl)prop-2-en-1-one (51)  
 
 
Rf [CH2Cl2:MeOH 9:1] 0.38; IR νmax(film)/cm
-1 1659, 1603 and 1580; 1H NMR δH (400 
MHz; CDCl3) 3.71 (3 H, s, Im CH3), 3.90 (3 H, s, OCH3), 3.92 (6 H, s, OCH3), 7.15 (1 H, s, 
Im CH), 7.33 (2 H, s, Ar CH), 7.49 (1 H, s, Im CH) and 7.70 (2 H, s, COCH=CH); The peak 
at δH 7.70 ppm can vary depending on the concentarion of the sample and can appear 
as two doublets;
 1H NMR – Diluted δH (400 MHz; CDCl3) 3.73 (3 H, s, Im CH3), 3.92 (3 
H, s, OCH3), 3.94 (6 H, s, OCH3), 7.17 (1 H, s, Im CH), 7.34 (2 H, s, Ar CH), 7.50 (1 H, s, 
Im CH), 7.69 (1 H, d, J 15.0 Hz, COCH=CH) and 7.74 (1 H, d, J 15.0 Hz, COCH=CH);
 13C 
NMR δC (100 MHz; CDCl3) 33.8 (Im CH3), 56.4 (OCH3), 60.9 (OCH3), 106.0 (Ar CH), 
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119.6 (Im CH) 124.1 (Im CH), 133.6 (Cq), 135.1 (HC=CH), 138.0 (Cq), 139.1 (HC=CH), 
142.3 (Cq), 153.1 (Cq) and 188.9 (C=O); MS m/z (ES+) Found 303.1354 (MH+) and 
325.1166 (MNa+), C16H19N2O4 (MH
+) requires 303.1345 and C16H18N2O4Na (MNa
+ ) 
requires 325.1164; HPLC (analytical, system 1) tR = 5.9 min. 
 




Following Method E, chalcone (50) was obtained as an orange oil (0.41 g, 54%).  
 
Rf [CH2Cl2:MeOH 9:1] 0.38; IR νmax(film)/cm
-1 1657, 1591 and 1579; 1H NMR δH (400 
MHz; CDCl3) 3.78 (3 H, s, Im CH3), 3.94 (3 H, s, OCH3), 3.95 (6 H, s, OCH3), 7.25 (2 H, s, 
Ar CH), 7.37 (1 H, d, J 15.5 Hz, COCH=CH), 7.57 (1 H, s, Im CH), 7.65 (1 H, s, Im CH) and 
7.69 (1 H, d, J 15.0 Hz, COCH=CH); 13C NMR δC (100 MHz; CDCl3) 32.1 (Im CH3), 56.4 
(OCH3), 61.0 (OCH3), 105.9 (Ar CH), 119.6 (Im CH), 129.1 (Im CH), 129.6 (Cq), 132.3 
(HC=CH), 133.3 (Cq), 141.1 (HC=CH), 142.6 (Cq), 153.1 (Cq) and 188.2 (C=O); MS m/z 
(ES+) Found 303.1337 (MH+) and 325.1150 (MNa+), C16H19N2O4 (MH
+) requires 
303.1345 and C16H18N2O4Na (MNa
+) requires 325.1164; HPLC (analytical, system 1) tR 






Following Method C, except on a 5.0 mmol scale, chalcone (52) was obtained as an 
yellow solid (0.55 g, 38%).  
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Rf [CH2Cl2:MeOH 9:1] 0.46; Mp 198-201 
oC (EtOAc/heptane); IR νmax(film)/cm
-1 3439, 
1661, 1607 and 1582; 1H NMR δH (400 MHz; CDCl3) 3.89 (6 H, s, OCH3), 3.93 (3 H, s, 
OCH3), 7.26-7.30 (4 H, m, Ar CH and Im CH), 7.75 (1 H, d, J 15.0 Hz, COCH=CH) and 
7.86 (1 H, d, J 15.0 Hz, COCH=CH); 13C NMR δc (100MHz; CDCl3) 56.3 (OCH3), 61.0 
(OCH3), 106.1 (Ar CH and Im CH), 122.4 (HC=CH), 131.0 (HC=CH), 132.8 (Cq), 142.8 
(Cq), 143.8 (Cq), 153.2 (Cq) and 188.7 (C=O); MS m/z (ES+) Found 289.1184 (MH+) and 
311.0998 (MNa+), C15H17N2O4 (MH
+) requires 289.1188 and C15H16N2O4Na (MNa
+) 
requires 311.1008; HPLC (analytical, system 1) tR = 6.0 min. 
 
Method F  
 
Chalcone (52) (1.4 mmol) was added to a rapidly stirred solution of 3.0 equivalents of 
Cs2CO3 (4.2 mmol) in THF (30 mL) at 30 
oC open to the atmosphere for 15 min. 
followed by dropwise addition of 3.0 equivalents of MeI (4.2 mmol) and stirring 
continued for 6 h. The reaction was then cooled and quenched by addition of CH2Cl2 
(50 mL) and distilled water (50 mL) and the organic layer extracted with CH2Cl2 (3 × 50 
mL), the organic layers were combined and washed with saturated brine solution (50 
mL). The organic fraction was dried (Na2SO4), filtered and solvent removed under 
reduced pressure to give a pale yellow oil. The oil was purified by column 
chromatography with silica using CH2Cl2:MeOH 9:1 solvent system to afford the 





Rf [CH2Cl2:MeOH 9:1] 0.47; Mp 100-102 
oC (EtOAc/heptane); IR νmax(film)/cm
-1 1658, 
1605 and 1580; 1H NMR δH (400 MHz; CDCl3) 3.81 (3 H, s, Im CH3), 3.93 (3 H, s, OCH3), 
3.94 (6 H, s, OCH3), 7.03 (1 H, s, Im CH), 7.21 (1 H, s, Im CH), 7.36 (2 H, s, Ar CH), 7.68 
(1 H, d, J 15.0 Hz, COCH=CH) and 8.06 (1 H, d, J 15.0 Hz, COCH=CH); 13C NMR δC (100 
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MHz; CDCl3) 33.0 (Im CH3), 56.4 (OCH3), 60.9 (OCH3), 106.0 (Ar CH), 123.9 (HC=CH), 
127.2 (Im CH), 130.3 (HC=CH), 131.4 (Im CH), 133.0 (Cq), 142.7 (Cq), 143.7 (Cq), 153.2 
(Cq) and 188.1 (C=O); MS m/z (ES+) Found 303.1360 (MH+) and 325.1172 (MNa+), 
C16H19N2O4 (MH
+) requires 303.1345 and C16H18N2O4Na (MNa
+) requires 325.1164; 
HPLC (analytical, system 1) tR = 5.9 min. 
Method G 
 
0.5 equivalent KOH was added to a rapidly stirred solution of the required 
acetophenone (5.0 mmol) and 3,4,5-trimethoxybenzaldehyde (6.0 mmol) in 20 mL 
EtOH and allowed to stir at rt (20 oC). After 24 h the solvent was removed under 
reduced pressure and the resulting solid purified by column chromatography with 






Following Method G, chalcone (58) was obtained as a yellow solid (1.43 g, 96%). 
 
Rf [PE-EtOAc 4:6] 0.65; Mp 137-138 
oC (MeOH); IR νmax(film)/cm
-1 1662, 1609, 1580, 1508 and 
1132; 1H NMR δH (500 MHz; CDCl3) 3.91 (3 H, s, OCH3), 3.94 (6 H, s, OCH3), 6.87 (2 H, s, Ar CH), 
7.41 (1 H, d, J 16.0 Hz, COCH=CH), 7.50-7.58 (2 H, m, Ph CH), 7.59-7.61 (1 H, m, Ph CH), 7.72 
(1H, d, J 15.5 Hz, Ph COCH=CH) and 8.02 (2 H, d, J 7.0 Hz, Ph CH); 13C NMR δC (125 MHz; CDCl3) 
56.2 (OCH3), 61.0 (OCH3), 105.7 (CH), 121.5 (CH), 128.5 (CH), 128.6 (CH), 130.4 (Cq), 132.7 
(CH), 138.3 (Cq), 140.5 (Cq), 145.0 (CH), 153.5 (Cq) and 190.6 (Cq); MS m/z (ES+) Found 
299.1253 (MH+) and 321.1113 (MNa+), C18H19O4 (MH
+) requires 299.1283 and C18H18O4Na 
(MNa+) requires 321.1103; Elemental Analysis Found C (72.49%) H (6.11%) N (0.00%) requires 
C (72.47%) H (6.08%) N (0.00%); HPLC (analytical, system 2) tR = 9.0 min. 
(E)-1-(4-methoxyphenyl)-3-(3,4,5-trimethoxyphenyl)prop-2-en-1-one (59) 
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Following Method G, chalcone (59) was obtained as a yellow solid (1.28 g, 78%). 
 
Rf [PE-EtOAc 4:6] 0.44; Mp 135-138 
oC (EtOAc); IR νmax(film)/cm
-1 1605, 1505, 1327 
and 1128; 1H NMR δH (500 MHz; CDCl3) 3.89 (3 H, s, OCH3), 3.90 (3 H, s, OCH3), 3.92 (6 
H, s, OCH3), 6.86 (2 H, s, Ar CH), 6.99 (2 H, d, J 9.0 Hz, Ar CH), 7.42 (1 H, d, J 15.5 Hz, 
COCH=CH), 7.71 (1 H, d, J 15.5 Hz, COCH=CH) and 8.04 (2 H, d, J 9.0 Hz, Ar CH); 13C 
NMR δC (125 MHz; CDCl3) 55.5 (OCH3), 56.2 (OCH3), 60.9 (OCH3), 105.6 (CH), 113.8 
(CH), 121.2 (CH), 130.6 (CH), 130.8 (CH), 131.1 (Cq), 140.3 (Cq), 144.1 (Cq), 153.5 (Cq), 
163.4 (Cq) and 188.7 (Cq); MS m/z (ES+) Found 329.1400 (MH+) and 351.1209 (MNa+),  
C19H21O5 (MH
+) requires 329.1389 and C19H20O5Na (MH
+) requires 351.1208; 
Elemental Analysis Found C (69.58%) H (6.22%) N (0.00%) requires C (69.50%) H 





Following Method G, chalcone (60) was obtained as a pale yellow solid (1.61 g, 80%). 
 
Rf [PE-EtOAc 4:6] 0.53; Mp 139-140 
oC; IR νmax(film)/cm
-1 1603, 1419, 1243 and 702; 
1H NMR δH (500 MHz; CDCl3) 3.85 (3 H, s, OCH3), 3.90 (6 H, s, OCH3), 5.14 (2 H, s, CH2), 
6.86 (2 H, s, Ar CH), 7.05 (2 H, d, J 8.5 Hz, Ar CH), 7.34-7.44 (6 H, m, Ph CH and 
COCH=CH), 7.71 (1 H, d, J 15.5 Hz, COCH=CH) and 8.03 (2 H, d, J 8.5 Hz, Ar CH); 13C 
NMR δc (125 MHz; CDCl3) 56.2 (OCH3), 60.9 (OCH3), 70.1 (CH2), 105.5 (CH), 114.6 (CH), 
121.1 (CH), 127.4 (CH), 128.2 (CH), 128.6 (CH), 130.5 (Cq), 130.7 (CH), 131.3 (Cq), 
136.1 (Cq), 140.2 (Cq), 144.1 (CH), 153.4 (Cq), 162.5 (Cq) and 188.6 (Cq); MS m/z (ES+) 
Found 427.1572 (MNa+), C25H24O5Na (MNa
+) requires 427.1521; Elemental Analysis 
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Found C (74.13%) H (6.09%) N (0.00%) requires C (74.24%) H (5.98%) N (0.00%); HPLC 







Following Method G, except using 2 equivalents of KOH and a reaction time of 72 h, 
chalcone (61) was obtained as a yellow solid (0.685 g, 44%). 
 
Rf [CH2Cl2-MeOH 9:1] 0.45; Mp 240-244 
oC (MeOH); IR νmax(film)/cm
-1 3650, 1431, 
1240 and 1037; 1H NMR δH (500 MHz; DMSO) 3.71 (3 H, s, OCH3), 3.86 (6 H, s, OCH3), 
6.90 (2 H, d, J 8.5 Hz, Ar CH), 7.20 (2 H, s, Ar CH), 7.63 (1 H, d, J 15.5 Hz, COCH=CH), 
7.86 (1 H, d, J 15.5 Hz, COCH=CH), 8.08 (2 H, d, J 9.0 Hz, Ar CH) and 10.26-10.60 (1H, 
br s, OH); 13C NMR δC (125 MHz; DMSO) 56.1 (OCH3), 60.1 (OCH3), 106.3 (CH), 115.4 
(CH), 121.3 (CH), 129.1 (Cq), 130.5 (Cq), 131.2 (CH), 139.5 (Cq), 143.2 (CH), 153.1 (Cq), 
162.3 (Cq) and 187.0 (Cq); MS m/z (ES+) Found 315.1249 (MH+) and 337.1057 (MNa+), 
C18H19O5 (MH
+) requires 315.1232 and C18H18O5Na (MNa
+) requires 337.1052; 
Elemental Analysis Found C (68.64%) H (5.84%) N (0.00%) requires C (68.78%) H 
(5.37%) N (0.00%). 
Method H 
 
1-(4-nitrophenyl)ethanone (5.0 mmol) and 3,4,5-trimethoxybenzaldehyde (5.0 mmol) 
in EtOH (20 mL) were stirred on ice for 10 min, followed by the slow addition of 0.2 
equivalent NaOH in 10 mL H2O. Stirring was continued on ice for 2 h after which the 
solution was poured onto ice and the solid filtered and dried to give a yellow solid. 
The solid was purified by column chromatography with silica gel using PE:EtOAc 6:4 to 
afford the desired chalcone as a yellow solid (1.31g, 76%). 





Rf [CH2Cl2-MeOH 9:1] 0.93; Mp 172-174 
oC (MeOH); IR νmax(film)/cm
-1 1605, 1505, 
1327 and 1128; 1H NMR δH (500 MHz; CDCl3) 3.92 (3 H, s, OCH3), 3.93 (6 H, s, OCH3), 
6.87 (2 H, s, Ar CH), 7.35 (1 H, d, J 16.0 Hz, COCH=CH), 7.75 (1 H, d, J 15.5 Hz, 
COCH=CH), 8.14 (2 H, d, J 8.5 Hz, Ar CH) and 8.36 (2 H, d, J 9.0 Hz, Ar CH); 13C NMR δC 
(125 MHz; CDCl3) 56.3 (OCH3), 61.0 (OCH3), 106.0 (CH), 120.6 (CH), 123.9 (CH), 129.4 
(CH), 129.7 (Cq), 141.1 (Cq), 143.2 (CH), 147.0 (Cq), 150.0 (Cq), 153.6 (Cq) and 189.1 
(Cq); MS m/z (ES+) Found 366.0965 (MNa+), C18H17NO6Na (MNa
+) requires 366.0953; 
Elemental Analysis Found C (62.91%) H (4.93%) N (4.16%) requires C (62.97%) H 









2.0 equivalents of KOH was added to a rapidly stirred solution of 1-(4-
aminophenyl)ethanone (5.0 mmol) and 3,4,5-trimethoxybenzaldehyde (5.0 mmol) in 
EtOH (20 mL) at rt (20 oC). After 18 h the reaction mixuture was poured onto ice and 
the solid collected and purified by column chromatography with silica gel using 









Rf [CH2Cl2-MeOH 9:1] 0.73; Mp 159-160 
oC; IR νmax(film)/cm
-1 3694, 3513, 1621 and 
1282; 1H NMR δH (500 MHz; CDCl3) 3.89 (3 H, s, OCH3), 3.92 (6 H, s, OCH3), 4.16 (2 H, s, 
NH2), 6.71 (2 H, d, J 8.5 Hz, Ar CH), 6.86 (2 H, s, Ar CH), 7.41 (1 H, d, J 15.5 Hz, 
COCH=CH), 7.69 (1 H, d, J 16.0 Hz, COCH=CH) and 7.93 (2 H, d, J 8.5 Hz, Ar CH); 13C 
NMR δC (125 MHz; CDCl3) 56.2 (OCH3), 61.0 (OCH3), 105.5 (CH), 113.9 (CH), 121.4 
(CH), 128.6 (Cq), 130.8 (Cq), 131.1 CH), 140.0 (Cq), 143.3 (CH), 151.0 (Cq), 153.4 (Cq) 
and 188.0 (Cq); MS m/z (ES+) Found 314.1394 (MH+) and 336.1227 (MNa+), 
C18H20N1O4 (MH
+) requires 314.1392 and C18H19N1O4Na (MNa
+) requires 336.1212; 
Elemental Analysis Found C (68.83%) H (6.14%) N (4.47%) requires C (68.99%) H 






Following Method G, except using 10.0 mmol 1-(pyridin-2-yl)ethanone and 12.0 mmol 
3,4,5-trimethoxybenzaldehyde, chalcone (64) was obtained as a yellow solid (2.54 g, 
85%). 
 
Rf [PE-EtOAc 4:6] 0.77; Mp 155-156 
oC (MeOH); IR νmax(film)/cm
-1 1605, 1217 and 791; 
1H NMR δH (500 MHz; CDCl3) 3.89 (3 H, s, OCH3), 3.92 (6 H, s, OCH3), 6.94 (2 H, s, Ar 
CH), 7.45 (1 H, dd, J 8.0, 5.0 and 1.0 Hz, py CH), 7.86 (1 H, d, J 16.0 Hz, COCH=CH), 8.16 
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(1 H, d, J 16.0 Hz, COCH=CH), 8.18-8.19 (1 H, m, py CH) and 8.73-8.74 (1 H, m, py CH); 
13C NMR δC (125 MHz; CDCl3) 56.2 (OCH3), 60.9 (OCH3), 106.0 (CH), 119.9 (CH), 122.9 
(CH), 126.8 (CH), 130.6 (Cq), 137.0 (CH), 140.5 (Cq), 145.0 (CH), 148.7 (CH), 153.4 (Cq), 
154.2 (Cq) and 189.2 (Cq); MS m/z (ES+) Found 322.1074 (MNa+), C17H17NO4Na (MNa
+) 
requires 322.1055; Elemental Analysis Found C (68.35%) H (5.79%) N (4.72%) 






Following Method G, chalcone (65) was obtained as a dark orange solid (1.18 g, 80%). 
 
Rf [PE-EtOAc 4:6] 0.74; Mp 150-152 
oC (EtOAc); IR νmax(film)/cm
-1 1655, 1579, 1508, 
1461 and 1130; 1H NMR δH (500 MHz; CDCl3) 3.90 (3 H, s, OCH3), 3.92 (6 H, s, OCH3), 
6.60 (1 H, dd, J 3.5 and 1.5 Hz, furan CH), 6.88 (2 H, s, Ar CH), 7.34 (1 H, d, J 15.5 Hz, 
COCH=CH), 7.34 (1 H, dd, J 3.5 and 0.5 Hz, furan CH) 7.66 (1 H, dd, J 1.5 and 0.5 Hz, 
furan CH) and 7.80 (1 H, d, J 16.0 Hz, COCH=CH); 13C NMR δC (125 MHz; CDCl3) 56.2 
(OCH3), 61.0 (OCH3), 105.8 (CH), 112.6 (CH), 117.4 (CH), 120.4 (CH), 130.2 (Cq), 140.5 
(Cq),144.1 (CH) 146.4 (CH), 153.5 (Cq), 153.7 (Cq) and 177.9 (Cq); MS m/z (ES+) Found 
289.1139 (MH+) and 311.0938 (MNa+), C16H17O5 (MH
+) requires 289.1076 and 
C16H16O5Na (MNa
+) requires 311.0895; Elemental Analysis Found C (66.78%) H 
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Following Method G, chalcone (66) was obtained as a dark orange solid (1.41 g, 93%). 
 
Rf [PE-EtOAc 4:6] 0.86; Mp 153-156 
oC (EtOAc); IR νmax(film)/cm
-1 1655, 1584, 1504 
and 1130; 1H NMR δH (500 MHz; CDCl3) 3.90 (3 H, s, OCH3), 3.93 (6 H, s, OCH3), 6.87 
(2H, s, Ar CH), 7.19 (1 H, dd, J 5.0 and 3.5 Hz, thiophene CH), 7.30 (1 H, d, J 15.5 Hz, 
COCH=CH), 7.69 (1 H, dd, J 5.0 and 1.0 Hz, thiophene CH), 7.77 (1 H, d, J 15.5 Hz, 
COCH=CH) and 7.88 (1 H, dd, J 3.5 and 1.0 Hz, thiophene CH); 13C NMR δC (125 MHz; 
CDCl3) 56.2 (OCH3), 61.0 (OCH3), 105.7 (CH), 120.9 (CH), 128.2 (CH), 130.2 (Cq), 131.7 
(CH), 133.8 (CH), 140.5 (Cq), 144.2 (CH), 145.5 (Cq), 153.5 (Cq) and 181.9 (Cq); MS m/z 
(ES+) Found 305.0935 (MH+) and 327.0763 (MNa+), C16H17O4S (MH
+) requires 305.0848 
and C17H18N4SNa (MNa
+) requires 327.0667; Elemental Analysis Found C (63.03%) H 





Following Method G, chalcone (67) was obtained as a dark orange solid (1.22 g, 70%). 
 
Rf [PE-EtOAc 4:6] 0.89; Mp 115-116 
oC (MeOH); IR νmax(film)/cm
-1 1655, 1579, 1508 
and 1125; 1H NMR δH (500 MHz; CDCl3) 3.92 (3 H, s, OCH3), 3.95 (6 H, s, OCH3), 6.91 (2 
H, s, CH), 7.55 (1 H, d, J 16.0 Hz, COCH=CH), 7.56-7.62 (3 H, m, CH), 7.79 (1 H, d, J 16.0 
Hz, COCH=CH), 7.91 (1 H, d, J 8.0 Hz, Ar CH), 7.95 (1 H, d, J 8.5 Hz, Ar CH), 8.01 (1 H, d, 
J 7.5 Hz, Ar CH) and 8.53 (1 H, s, Ar CH); 13C NMR δC (125 MHz; CDCl3) 56.3 (OCH3), 
61.0 (OCH3), 105.8 (CH), 121.6 (CH), 124.5 (CH), 126.8 (CH), 127.8 (CH), 128.3 (CH), 
128.6 (CH), 129.5 (CH), 129.8 (CH), 130.4 (Cq), 132.6  (Cq), 135.4 (Cq), 135.6 (Cq), 
140.5 (Cq), 145.0 (CH), 153.5 (Cq) and 190.4 (Cq); MS m/z (ES+) Found 371.1259 
(MNa+), C22H20O4Na (MNa
+) requires 371.1300; Elemental Analysis Found C (75.93%) 
H (5.83%) N (0.00%) requires C (75.84%) H (5.79%) N (0.00%); HPLC (analytical, 
system 2) tR = 14.3 min. 




Hydrazine monohydrate (8.0 mmol) was added to a rapidly stirred solution of 
chalcone (58) (2.0 mmol) in EtOH (20 mL) and heated to 80 oC for 2 h. The solvent was 
removed under reduced pressure and the resulting brown oil was dissolved in CH2Cl2 
(20 mL) and 3-(benzyloxy)-4-methoxybenzoyl chloride (4.0 mmol) added dropwise 
followed by NEt3 (6.0 mmol) and the solution stirred at rt for 3 h. The solvent was 
then removed under reduced pressure and the solid was purified by column 
chromatography with silica gel using PE:EtOAc 6:4 to afford the desired pyrazoline 







Rf [PE-EtOAc 4:6] 0.53; Mp 75-78 
oC; IR νmax(film)/cm
-1 1627, 1598, 1437 and 1125; 1H 
NMR δH (500 MHz; CDCl3) 3.17 (1 H, dd, J 17.5 and 5.5 Hz, pyrazoline CH), 3.75 (1 H, 
dd, J 17.5 and 12.0 Hz, pyrazoline CH), 3.79 (3 H, s, OCH3), 3.80 (6 H, s, OCH3), 3.96 (3 
H, s, OCH3), 5.20 (2 H, s, Bn CH2), 5.72 (1 H, dd, J 11.5 and 5.0 Hz, pyrazoline CH), 6.49 
(2 H, s, Ar CH), 6.97 (1 H, d, J 8.5 Hz, Ar CH), 7.26-7.35 (4 H, m, Ar CH), 7.40-7.45 (5 H, 
m, Ar CH), 7.72-7.77 (3 H, m, Ar CH) and 7.87 (1 H, d, J 8.5 Hz, Ar CH); 13C NMR δC (125 
MHz; CDCl3) 41.5 (CH2), 56.0 (OCH3), 56.0 (OCH3), 60.7 (OCH3), 61.8 (CH), 70.9 (CH2), 
102.1 (CH), 110.2 (CH), 115.8 (CH), 124.8 (CH), 126.1 (CH), 126.7 (CH), 127.3 (CH), 
127.9 (CH), 128.5 (CH), 128.8 (CH), 130.4 (CH), 131.3 (Cq), 136.8 (Cq), 137.1 (Cq), 
137.8 (Cq), 147.3 (Cq), 152.1 (Cq), 153.6 (Cq), 154.6 (Cq) and 165.5 (Cq); 
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MS m/z (ES+) Found 553.2318 (MH+) and 575.2170 (MNa+), C33H33N2O6 (MH
+) requires 
553.2339 and C33H32N2O6Na (MNa
+) requires 575.2158; Elemental Analysis Found C 
(71.65%) H (5.76%) N (5.05%) requires C (71.72%) H (5.84%) N (5.07%); HPLC 




Pyrazoline (68) (0.4 mmol) was added to a stirred solution of 10wt% Pd/C  (22 mg) in 
EtOAc (5 mL) under 1 atm of H2 and stirring continued at rt for     18 h. The solution 
was filtered through filter paper and the solvent removed under reduced pressure to 
a solid which was recrystallised from EtOAc to give pyrazoline (69) as a grey solid 







Rf [PE-EtOAc 4:6] 0.29; Mp 218-220 
oC (EtOAc); IR νmax(film)/cm
-1 3546, 1631, 1589, 
1423 and 1130; 1H NMR δH (500 MHz; CDCl3) 3.17 (1 H, dd, J 17.5 and 5.0 Hz, 
pyrazoline CH), 3.75 (1 H, dd, J 18.0 and 12.0 Hz, pyrazoline CH), 3.79 (3 H, s, OCH3), 
3.81 (6 H, s, OCH3), 3.95 (3 H, s, OCH3), 5.74 (1 H, dd, J 12.0 and 5.0 Hz, pyrazoline CH), 
5.79 (1 H, s, OH), 6.51 (2 H, s, Ar CH), 6.91 (2 H, d, J 8.5 Hz, Ar CH), 7.40-7.43 (3 H, m, 
Ar CH) and 7.67-7.76 (4 H, m, Ar CH); 13C NMR δC (125 MHz; CDCl3) 41.5 (CH2), 56.0 
(OCH3), 61.0 (OCH3), 61.6 (OCH3), 102.1 (CH),  109.5 (CH), 116.8 (CH), 123.3 (CH), 
126.6 (CH), 126.7 (CH), 127.0 (CH), 127.3 (CH), 130.4 (Cq), 131.2 (Cq), 137.1 (Cq), 
137.8 (Cq), 144.6 (Cq), 149.0 (Cq), 153.6 (Cq), 154.5 (Cq) and 165.6 (Cq); MS m/z (ES+) 
Found 463.1847 (MH+) and 485.1696 (MNa+), C26H27N2O6 (MH
+) requires 463.1869 
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and C26H26N2O6Na (MNa
+) requires 485.1689; Elemental Analysis Found C (67.55%) H 
(5.56%) N (5.94%) requires C (67.52%) H (5.67%) N (6.06%); HPLC (analytical, system 






Following Method J, except using 5.0 mmol chalcone (58) and 10.0 mmol                      
4-methoxybenzoyl chloride, pyrazoline (70) was obtained as a white solid (1.51 g, 
68%). 
 
Rf [PE-EtOAc 4:6] 0.62; Mp 141-143 
oC (Et2O); IR νmax(film)/cm
-1 1627, 1593, 1428 and 
1130; 1H NMR δH (500 MHz; CDCl3) 3.19 (1 H, dd, J 17.5 and 5.0 Hz, pyrazoline CH), 
3.77 (1 H, dd, J 18.0 and 12.0 Hz, pyrazoline CH), 3.80 (3 H, s, OCH3), 3.82 (6 H, s, 
OCH3), 3.88 (3 H, s, OCH3), 5.75 (1 H, dd, J 12.0 and 5.0 Hz, pyrazoline CH), 6.52 (2 H, s, 
Ar CH2), 6.97 (2 H, d, J 9.0 Hz, Ar CH), 7.41-7.43 (3 H, m, Ar CH), 7.72-7.74 (2 H, m, Ar 
CH) and 8.11 (2 H, d, J 9.0 Hz, Ar CH); 13C NMR δC (125 MHz; CDCl3) 41.6 (CH2), 55.3 
(OCH3), 56.0 (OCH3), 60.7 (OCH3), 61.6 (CH), 102.2 (CH), 113.0 (CH), 126.3 (Cq), 126.7 
(CH), 128.7 (CH), 130.4 (CH), 131.3 (Cq), 132.3 (CH), 137.2 (Cq), 137.8 (Cq), 153.6 (Cq), 
154.4 (Cq), 161.8 (Cq) and 165.8 (Cq); MS m/z (ES+) Found 447.1944 (MH+) and 
469.1746 (MNa+), C26H27N2O5 (MH
+) requires 447.1919 and C26H26N2O5Na (MNa
+) 
requires 469.1739; Elemental Analysis Found C (70.03%) H (5.76%) N (6.18%) 










Following Method J, except using 1.0 mmol chalcone (58) and 2.0 mmol benzoyl 
chloride, pyrazoline (71) was obtained as a white solid (0.35 g, 84%). 
 
Rf [PE-EtOAc 4:6] 0.73; Mp 124-126 
oC (Et2O); IR νmax(film)/cm
-1 1630, 1591, 1424, 
1231 and 1132; 1H NMR δH (500 MHz; CDCl3) 3.21 (1 H, dd, J 17.5 and 5.0 Hz, 
pyrazoline CH), 3.78 (1 H, dd, J 17.5 and 11.5 Hz, pyrazoline CH), 3.81 (3 H, s, OCH3), 
3.82 (6 H, s, OCH3), 5.76 (1 H, dd, J 11.5 and 5.0 Hz, pyrazoline CH), 6.53 (2 H, s, Ar 
CH), 7.39-7.52 (6 H, m, Ar CH), 7.71 (2 H, d, J 8.0 Hz,       Ar CH) and 8.03 (2 H, d, J 7.5 
Hz, Ar CH); 13C NMR δC (125 MHz; CDCl3) 41.8 (CH2), 56.1 (OCH3), 60.7 (OCH3), 61.4 
(CH), 102.3 (CH), 126.8 (CH), 127.7 (CH), 128.7 (CH), 130.0 (CH), 130.5 (CH), 131.0 
(CH), 131.3 (Cq), 133.8 (Cq), 137.4 (Cq), 137.6 (Cq), 153.7 (Cq), 154.8 (Cq) and 166.6 
(Cq); MS m/z (ES+) Found 417.1873 (MH+) and 439.1663 (MNa+), C25H25N2O4 (MH
+) 
requires 417.1814 and C25H24N2O4Na (MNa
+) requires 439.1633; Elemental Analysis 
Found C (71.96%) H (5.71%) N (6.62%) requires C (72.1%) H (5.81%) N (6.73%); HPLC 
(analytical, system 2) tR = 9.3 min. 
 
(71+) HPLC (semipreparative, system 3); NMR data consistent with above;                
αD
20
 +70 (0.001, EtOAc); HPLC (analytical, system 4) tR = 12.3 min, 97% ee. 
 
(71-) HPLC (semipreparative, system 3); NMR data consistent with above;                 
αD
20
 -70 (0.001, EtOAc); HPLC (analytical, system 4) tR = 22.0 min, 98% ee. 
  
 






Following Method J, except using 1.0 mmol chalcone (58) and 2.0 mmol       1-
naphthoyl chloride, pyrazoline (72) was obtained as a white solid (0.39 g, 84%). 
 
Rf [PE-EtOAc 4:6] 0.63; Mp 138-141 
oC (Et2O); IR νmax(film)/cm
-1 1641, 1598, 1428 and 
1130; 1H NMR δH (500 MHz; CDCl3) 3.26 (1 H, dd, J 17.5 and 4.5 Hz, pyrazoline CH), 
3.83-3.94 (10 H, m, OCH3 and pyrazoline CH), 5.88 (1 H, dd, J 11.5 and 4.5 Hz, 
pyrazoline CH), 6.63 (2 H, s, Ar CH), 7.29-7.37 (3 H, m,          Ar CH), 7.44-7.56 (5 H, m, 
Ar CH), 7.69 (1 H, d, J 7.0 Hz, Ar CH), 7.90 (1 H, d, J 8.0 Hz, Ar CH), 7.95 (1 H, J 8.0 Hz, 
Ar CH) and 8.03 (1 H, J 8.0 Hz, Ar CH);         13C NMR δC (125 MHz; CDCl3) 42.3 (CH2), 
56.1 (OCH3), 60.8 (OCH3), 60.8 (CH), 102.1 (CH), 124.5 (CH), 125.5 (CH), 126.0 (CH), 
126.3 (CH), 126.5 (CH), 126.7 (CH), 128.3 (CH), 128.6 (CH), 129.9 (CH), 130.4 (CH), 
130.5 (Cq), 131.0 (Cq), 133.3 (Cq), 133.4 (Cq), 137.3 (Cq), 137.5 (Cq), 153.8 (Cq), 154.8 
(Cq) and 167.4 (Cq); MS m/z (ES+) Found 467.2001 (MH+) and 489.1818 (MNa+), 
C29H27N2O4 (MH
+) requires 467.1970 and C29H26N2O4Na (MNa
+) requires 489.1790; 
Elemental Analysis Found C (74.70%) H (5.64%) N (5.84%) requires C (74.66%) H 
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Phenyl hydrazine (6.0 mmol) was added to a rapidly stirred solution of chalcone (58) 
(3.0 mmol) in EtOH (20 mL) and heated to 80 oC for 3 h. The solvent was then 
removed under reduced pressure and the solid was purified by column 
chromatography with silica gel using PE:EtOAc 6:4 to afford the desired pyrazoline 






Rf [PE-EtOAc 4:6] 0.87; Mp 173-174 
oC; IR νmax(film)/cm
-1 1593, 1504 and 1125; 1H 
NMR δH (500 MHz; DMSO) 3.15 (1 H, dd, J 17.5 and 7.0 Hz, pyrazoline CH), 3.63 (3 H, 
s, OCH3), 3.70 (6 H, s, OCH3), 3.90 (1 H, dd, J 17.5 and 12.0 Hz, pyrazoline CH), 5.34 (1 
H, dd, J 12.0 and 7.5 Hz, pyrazoline CH), 6.63 (2 H, s, Ar CH), 6.75 (1 H, t, J 7.0 Hz, Ar 
CH), 7.05 (2 H, d, J 8.0 Hz, Ar CH), 7.18 (2 H, t, J 7.5 Hz, Ar CH), 7.37-7.44 (3 H, m, Ar 
CH) and 7.75 (2 H, d, J 8.0 Hz, Ar CH); 13C NMR δC (125 MHz; DMSO) 43.1 (CH2), 55.8 
(OCH3), 59.9 (OCH3), 63.9 (CH), 102.9 (CH), 113.1 (CH), 118.8 (CH), 125.7 (CH), 128.6 
(CH), 128.7 (CH), 128.8 (CH), 132.2 (Cq), 136.5 (Cq), 138.4 (Cq), 144.8 (Cq), 147.5 (Cq) 
and 153.3 (Cq); MS m/z (ES+) Found 411.1747 (MNa+), C24H24N2O3Na  (MNa
+) requires 
411.1685; Elemental Analysis Found C (74.29%) H (6.21%) N (7.16%) requires C 
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Following Method J, except using 1.0 mmol chalcone (59), pyrazoline (74) was 
obtained as a white solid (0.27 g, 61%). 
 
Rf [PE-EtOAc 4:6] 0.55; Mp 126-128
oC (EtOAc); IR νmax(film)/cm
-1 1630, 1598, 1452 and 
1420; 1H NMR δH (500 MHz; CDCl3) 3.18 (1 H, dd, J 17.5 and 5.0 Hz, pyrazoline CH), 
3.75 (1 H, dd, J 17.5 and 11.5 Hz, pyrazoline CH), 3.81 (3 H, s, OCH3), 3.82 (3 H, s, 
OCH3), 3.84 (3 H, s, OCH3), 5.74 (1 H, dd, J 11.5 and 4.5 Hz, pyrazoline CH), 6.53 (2 H, s, 
Ar CH), 6.92 (2 H, d, J 7.0 Hz, Ar CH), 7.44-7.51 (3 H, m, Ar CH), 7.65 (2 H, d, J 8.5 Hz, 
Ar CH) and 8.03 (2 H, d, J 7.0 Hz, Ar CH); 13C NMR δC (125 MHz; CDCl3) 41.8 (CH2), 55.4 
(OCH3), 56.1 (OCH3), 60.7 (OCH3), 61.3 (CH), 102.4 (CH), 114.2 (CH), 123.9 (Cq), 127.7 
(CH), 128.4 (CH), 130.0 (CH), 130.9 (CH), 134.5 (Cq), 137.3 (Cq), 137.7 (Cq), 153.6 (Cq), 
154.6 (Cq), 161.4 (Cq) and 166.3 (Cq); MS m/z (ES+) Found 447.1997 (MH+) and 
469.1819 (MNa+), C26H26N2O5 (MH
+) requires 447.1920 and C26H26N2O5Na (MNa
+) 
requires 469.1739; Elemental Analysis Found C (69.83%) H (5.95%) N (6.17%) 
requires C (69.94%) H (5.87%) N (6.27%);    HPLC (analytical, system 2) tR = 18.1 min. 
 
(74+) HPLC (semipreparative, system 3); NMR data consistent with above;             αD 
20 
+70 (0.001, EtOAc); HPLC (analytical, system 4) tR = 8.5 min, 99% ee. 
 
(74-) HPLC (semipreparative, system 3); NMR data consistent with above;            αD
20 -
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Following Method J, except using 1.8 mmol chalcone (60), pyrazoline (75A) was 
obtained as a pale yellow solid (0.75 g, 80%). 
 
Rf [PE-EtOAc 4:6] 0.65; Mp 75-77 
oC; IR νmax(film)/cm
-1 1230, 1660 and 710; 1H NMR 
δH (500 MHz; CDCl3) 3.17 (1 H, dd, J 17.5 and 5.0 Hz, pyrazoline CH), 3.74 (1 H, dd, J 
17.5 and 11.5 Hz, pyrazoline CH), 3.78 (3 H, s,  OCH3), 3.82 (6 H, s, OCH3), 5.11 (2 H, s, 
Bn CH2), 5.73 (1 H, dd, J 11.5 and 4.5 Hz, pyrazoline CH), 6.52 (2 H, s, Ar CH), 6.98 (2 H, 
d, J 8.5 Hz, Ar CH), 7.32-7.51 (8 H, m, Ar CH), 7.65 (2 H, d, J 8.5 Hz, Ar CH) and 8.02 (2 
H, d, J 7.0 Hz, Ar CH); 13C NMR δC (125 MHz; CDCl3) 41.8 (CH2), 56.1 (OCH3), 60.7 
(OCH3), 61.3 (CH), 70.1 (CH2), 102.3 (CH), 115.1 (CH), 124.1 (Cq), 127.4 (CH), 127.7 
(CH), 128.2 (CH), 128.4 (CH), 128.7 (CH), 130.0 (CH), 130.9 (CH), 134.4 (Cq), 136.4 
(Cq), 137.3 (Cq), 137.7 (Cq), 153.7 (Cq), 154.5 (Cq), 160.6 (Cq) and 166.3 (Cq); MS m/z 
(ES+) Found 545.2201 (MNa+), C32H30N2O5Na (MNa
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Pyrazoline (75A) (1.0 mmol) was added to a stirred solution of 10wt% Pd/C (52 mg) in 
EtOAc (10 mL) under 1 atm of H2 and stirring continued at rt for   20 h. The solution 
was filtered through filter paper and the solvent removed under reduced pressure 
affording an oil which was purified by column chromatography with silica gel using 








Rf [PE-EtOAc 4:6] 0.39; Mp 186-187 
oC; IR νmax(film)/cm
-1 3695, 1199 and 685; 1H NMR 
δH (500 MHz; DMSO) 3.15 (1 H, dd, J 18.0 and 5.0 Hz, pyrazoline CH), 3.63 (3 H, s, 
OCH3), 3.74 (6 H, s, OCH3), 3.82 (1 H, dd, J 18.0 and 12.0 Hz, pyrazoline CH), 5.67 (1 H, 
dd, J 11.5 and 5.0 Hz, pyrazoline CH), 6.57 (2 H, s, Ar CH), 6.81 (2 H, d, J 9.0 Hz, Ar CH), 
7.47-7.55 (5 H, m, Ar CH), 7.86 (2 H, d, J 7.5 Hz, Ar CH) and 9.97 (1 H, s, OH); 13C NMR 
δC (125 MHz; DMSO) 41.7 (CH2), 55.8 (OCH3), 59.9 (OCH3), 60.5 (CH), 102.5 (CH), 115.6 
(CH), 121.9 (Cq), 127.8 (CH), 128.6 (CH), 129.3 (CH), 130.6 (CH), 135.0 (Cq), 136.5 (Cq), 
138.2 (Cq), 153.1 (Cq), 155.4 (Cq), 159.6 (Cq) and 165.3 (Cq); MS m/z (ES+) Found 
433.1789 (MH+) and 455.1650 (MNa+), C25H25N2O5 requires 433.1763 and 
C25H24N2O5Na (MNa
+) requires 455.1583; Elemental Analysis Found C (69.49%) H 
(5.67%) N (6.62%) requires C (69.43%) H (5.59%) N (6.48%); HPLC (analytical, system 
2) tR = 9.9 min. 
(3-(4-nitrophenyl)-5-(3,4,5-trimethoxyphenyl)-4,5-dihydro-1H-pyrazol-1-
yl)(phenyl)methanone (76) 
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Following Method J, except using 2.0 mmol chalcone (62), pyrazoline (76) was 
obtained as a yellow solid (0.55 g, 60%). 
 
Rf [PE-EtOAc 4:6] 0.61; Mp 197-199 
oC; IR νmax(film)/cm
-1 1645, 1593, 1428 and 1125; 
1H NMR δH (500 MHz; CDCl3) 3.25 (1 H, dd, J 18.0 and 5.5 Hz, pyrazoline CH), 3.79-3.85 
(10 H, m, OCH3 and pyrazoline CH), 5.82 (1 H, dd, J 12.0 and 5.5 Hz, pyrazoline CH), 
6.52 (2 H, s, Ar CH), 7.47-7.56 (3 H, m, Ar CH), 7.85 (2 H, d, J 9.0 Hz, Ar CH), 7.99 (2 H, 
d, J 7.0 Hz, Ar CH) and 8.27 (2 H, d, J 7.0 Hz, Ar CH); 13C NMR δC (125 MHz; CDCl3) 41.5 
(CH2), 56.1 (OCH3), 60.8 (OCH3), 62.0 (CH), 102.3 (CH), 124.0 (CH), 127.4 (CH), 127.9 
(CH), 129.9 (CH), 131.4 (CH), 133.8 (Cq), 136.9 (Cq), 137.2 (Cq), 137.6 (Cq), 148.5 (Cq), 
152.3 (Cq), 153.8 (Cq) and 166.9 (Cq); MS m/z (ES+) Found 484.1571 (MNa+), 
C25H23N3O6Na (MNa
+) requires 484.1485; Elemental Analysis Found C (65.02%) H 
(5.07%) N (9.10%) requires C (65.07%) H (5.02%) N (9.11%); HPLC (analytical, system 
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Pyrazoline (76) (0.2 mmol) was added to a stirred solution of 10wt% Pd/C (9.0 mg) in 
EtOAc (10 mL) under 1 atm of H2 and stirring continued at 40 
oC for 18 h. The solution 
was filtered through filter paper and the solvent removed under reduced pressure 
affording a residue which was recrystallised from Et2O to afford the desired 









Rf [PE-EtOAc 4:6] 0.48; Mp 104-106 
oC; IR νmax(film)/cm
-1 1589, 1532, 1504 and 1130; 
1H NMR δH (500 MHz; CDCl3) 3.14 (1 H, dd, J 17.5 and 4.5 Hz, pyrazoline CH), 3.71 (1 
H, dd, J 17.5 and 11.5 Hz, pyrazoline CH), 3.80 (3 H, s, OCH3), 3.82 (6 H, s, OCH3), 3.95 
(2 H, s, NH2), 5.71 (1 H, dd, J 11.5 and 4.0 Hz, pyrazoline CH), 6.53 (2 H, s, Ar CH), 6.66 
(2 H, d, J 8.5 Hz, Ar CH), 7.43-7.53 (5 H, m, Ar CH) and 8.04 (2 H, d, J 6.5 Hz, Ar CH); 13C 
NMR δC (125 MHz; CDCl3) 41.8 (CH2), 56.1 (OCH3), 60.7 (OCH3), 61.2 (CH), 102.3 (CH), 
114.6 (CH), 121.3 (Cq), 127.6 (CH), 128.4 (CH), 130.0 (CH), 130.8 (CH), 134.1 (Cq), 
137.2 (Cq), 137.9 (Cq), 148.7 (Cq), 153.6 (Cq), 155.0 (Cq) and 166.5 (Cq); MS m/z (ES+) 
Found 454.1863 (MNa+), C25H25N3O4Na (MNa
+) requires 454.1743; Elemental Analysis 
Found C (69.52%) H (5.91%) N (9.80%) requires C (69.59%) H (5.84%) N (9.74%); HPLC 
(analytical, system 2) tR = 3.9 min. 
Phenyl(3-(pyridin-2-yl)-5-(3,4,5-trimethoxyphenyl)-4,5-dihydro-1H-pyrazol-1-
yl)methanone (78) 
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Following Method J, except using 1.0 mmol chalcone (64), pyrazoline (78) was 
obtained as a white solid (0.30 g, 72%). 
 
Rf [PE-EtOAc 4:6] 0.45; Mp 189-191 
oC (EtOAc); IR νmax(film)/cm
-1 1641, 1598, 1414 
and 1338; 1H NMR δH (500 MHz; CDCl3) 3.43 (1 H, dd, J 18.5 and 5.0 Hz, pyrazoline 
CH), 3.80 (3 H, s, OCH3), 3.82 (6 H, s, OCH3), 3.89 (1 H, dd, J 18.5 and 11.5 Hz, 
pyrazoline CH), 5.78 (1 H, dd, J 12.0 and 5.0 Hz, pyrazoline CH), 6.53 (2 H, s, Ar CH), 
7.28-7.44 (1 H, m, Ar CH), 7.47-7.53 (3 H, m, Ar CH and py CH), 7.70-7.73 (1 H, m, py 
CH), 7.99-8.03 (3 H, m, py CH and Ar CH) and 8.59-8.60 (1 H, m, py CH); 13C NMR δC 
(125 MHz; CDCl3) 41.6 (CH2), 56.1 (CH), 60.7 (OCH3), 61.6 (OCH3), 102.5 (CH), 121.4 
(CH), 124.4 (CH), 127.7 (CH), 129.9 (CH), 131.1 (CH), 134.2 (Cq), 136.2 (CH),137.3 (Cq), 
137.4 (Cq), 149.4 (CH), 150.6 (Cq), 153.6 (Cq), 156.4 (Cq) and 166.9 (Cq); MS m/z (ES+) 
Found 418.1834 (MH+) and 440.1581 (MNa+), C24H24N4O4 (MH
+) requires 418.1767 
and C24H23N4O4Na (MNa
+) requires 440.1586; Elemental Analysis Found C (68.96%) H 
(5.49%) N (10.08%) requires C (69.05%) H (5.55%) N (10.07%); HPLC (analytical, 
system 2) tR = 8.2 min. 
 
(78+) HPLC (semipreparative, system 3); NMR data consistent with above;           αD
20
 
+70 (0.001, EtOAc); HPLC (analytical, system 4) tR = 8.0 min, 98% ee. 
 
(78-) HPLC (semipreparative, system 3); NMR data consistent with above;            αD
20
 -
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Following Method J, except using 1.25 mmol chalcone (65), pyrazoline (79) was 
obtained as a white solid (0.33 g, 65%). 
 
Rf [PE-EtOAc 4:6] 0.70; Mp 126-130
oC (Et2O); IR νmax(film)/cm
-1 1631, 1428 and 1130; 
1H NMR δH (500 MHz; DMSO) 3.10 (1 H, dd, J 18.0 and 5.5 Hz, pyrazoline CH), 3.63 (3 
H, s, OCH3), 3.74 (6 H, s, OCH3), 3.81 (1 H, dd, J 18.0 and 12.0 Hz, pyrazoline CH), 5.68 
(1 H, dd, J 12.0 and 5.5 Hz, pyrazoline CH), 6.57 (2 H, s, Ar CH), 6.64 (1 H, dd, J 3.5 and 
1.5 Hz, furan CH), 6.97 (1 H, dd, J 3.5 and 0.5 Hz, furan CH), 7.47-7.52 (3 H, m, Ar CH), 
7.81 (2 H, d, J 7.0 Hz, Ar CH) and 7.86 (1 H, dd, J 1.5 and 0.5 Hz, furan CH); 13C NMR δC 
(125 MHz; DMSO) 41.5 (CH2), 55.9 (OCH3), 60.1 (OCH3), 102.5 (CH), 112.2 (CH), 114.5 
(CH), 127.4 (CH), 127.9 (CH), 128.5 (CH), 129.1 (CH), 130.7 (CH), 134.8 (Cq), 136.6 
(Cq), 137.7 (Cq), 145.7 (CH), 146.0 (Cq), 146.6 (Cq), 153.1 (Cq) and 165.8 (Cq); MS m/z 
(ES+) Found 407.1646 (MH+) and 429.1452 (MNa+), C23H23N2O5 (MH
+) requires 
407.1607 and C23H22N2O5Na (MNa
+) requires 429.1426; Elemental Analysis Found C 
(68.03%) H (5.39%) N (6.73%) requires C (67.97%) H (5.46%) N (6.89%); HPLC 
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Following Method J, except using 5.0 mmol chalcone (66), pyrazoline (80) was 
obtained as a white solid (1.28 g, 61%). 
 
Rf [PE-EtOAc 4:6] 0.67; Mp 122-124 
oC (Et2O); IR νmax(film)/cm
-1 1630, 1509, 1452 and 
1132; 1H NMR δH (500 MHz; CDCl3) 3.19 (1 H, dd, J 17.5 and 5.5 Hz, pyrazoline CH), 
3.76-3.83 ( 10 H, m, OCH3 and pyrazoline CH), 5.75 (1 H, dd, J 11.5 and 5.0 Hz, 
pyrazoline CH), 6.52 (2 H, s, Ar CH), 7.07 (1 H, dd, J 5.0 and 4.0 Hz, thiophene CH), 
7.25 (1 H, dd, J 4.0 and 1.0 Hz, thiophene CH), 7.42 (1 H, dd J 5.0 and 1.0, thiophene 
CH), 7.44-7.51 (3 H, m, Ar CH) and 8.02 (2 H, d, J 7.0 Hz, Ar CH); 13C NMR δC (125 MHz; 
CDCl3) 42.4 (CH2), 56.1 (CH), 60.7 (OCH3), 61.6 (OCH3), 102.3 (CH), 127.6 (CH), 127.7 
(CH), 128.8 (CH), 128.9 (CH), 130.1 (CH), 131.1 (CH), 134.8 (Cq), 134.9 (Cq), 137.3 (Cq), 
137.4 (Cq), 150.3 (Cq), 153.7 (Cq) and 166.2 (Cq); MS m/z (ES+) Found 423.1454 (MH+) 
and 445.1278 (MNa+), C23H23N2O4S  (MH
+) requires 423.1379 and C23H22N2O4SNa 
(MNa+) requires 445.1198; Elemental Analysis Found C (65.48%) H (4.99%) N (6.59%) 
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Following Method J, except using 2.0 mmol chalcone (67), pyrazoline (81) was 
obtained as a white solid (0.54, 58%). 
 
Rf [PE-EtOAc 4:6] 0.76; Mp 188-189 
oC; IR νmax(film)/cm
-1 1655, 1231 and 692; 1H NMR 
δH (500 MHz; CDCl3) 3.36 (1 H, dd, J 17.5 and 5.0 Hz, pyrazoline CH), 3.81 (3 H, s, 
OCH3), 3.83 (6 H, s, OCH3), 3.90 (1 H, dd, J 17.5 and 11.5 Hz, pyrazoline CH), 5.81 (1 H, 
dd J 11.5 and 5.0 Hz, pyrazoline CH), 6.57 (2 H, s, Ar CH), 7.48-7.55 (5 H, m, Ar CH) and 
7.83-7.94 (7 H, m, Ar CH); 13C NMR δC (125 MHz; CDCl3) 41.7 (CH2), 56.1 (OCH3), 60.8 
(OCH3) 61.6 (CH),77.2 (CH), 102.4 (CH), 123.4 (CH), 126.8 (CH), 127.4 (CH), 127.8 (CH), 
127.9 (CH), 128.4 (CH), 128.5 (CH), 128.9 (Cq), 130.1 (CH), 131.1 (CH), 132.9 (Cq), 
134.2 (Cq), 134.3 (Cq), 137.4 (Cq), 137.6 (Cq), 153.7 (Cq), 154.8 (Cq) and 166.6 (Cq); 
MS m/z (ES+) Found 489.1886 (MNa+), C29H26N2O4Na (MNa
+) requires 489.1790; 
Elemental Analysis Found C (74.72%) H (5.59%) N (6.04%) requires C (74.66%) H 




To a stirred solution of chalcone (58) (0.6 g, 2 mmol) in EtOH (10 mL) at rt was added 
hydrazine hydrate (0.26 g, 8 mmol) and the solution heated to    80 oC for 3 h. The 
solvent was then removed under reduced pressure to afford an orange residue which 
was ground together with 10mol% Pd/C     (0.2 g) and heated at 200 oC for 2 h under 
nitrogen. The flask was then allowed to cool to rt and the residue the dissolved in 
EtOAc (50 mL) and filtered through celite. The solvent was then removed under 
reduced pressure and the pale brown solid obtained was dissolved in EtOAc (10 mL) 
followed by dropwise addition of benzoyl chloride (0.84 g, 6 mmol) and NEt3 (0.6 g, 6 
mmol) and the solution allowed to stir at 50 oC for 18 h. After 18 h the solvent was 
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removed under reduced pressure to afford a mixture of 69:31 (85:85A) as a white 
solid (0.57 g, 69%). 
 
Phenyl(3-phenyl-5-(3,4,5-trimethoxyphenyl)-1H-pyrazol-1-yl)methanone & 





-1 1708, 1580, 1427 and 1326; 1H NMR δH (500 MHz; CDCl3); 3.87 (6 H, 
s, (85) CH3), 3.89-3.91 (10 H, m, (85 and 85A) CH3), 6.71 (2 H, s, (85) Ar CH), 6.83 (0.6 
H, s, pyrazole (85A) CH), 6.86 (1 H, s, pyrazole (85) CH), 7.09 (1.2 H, s, (85A) CH), 7.39-
7.45 (5 H, m, (85A) CH), 7.48-7.53 (5 H, m, 85 CH), 7.61-7.65 (2 H, m, CH), 7.87 (2 H, d, 
J 7.0, (85) CH), 8. 11-8.13 (3.5 H, t, J 7.0, CH); 13C NMR δC (125 MHz; CDCl3); 56.2 (CH3), 
56.3 (CH3), 60.9 (CH3), 61.0 (CH3), 103.6 (CH), 106.1 (CH), 108.8 (CH), 108.9 (CH), 126.2 
(Cq), 126.3 (Cq), 127.4 (Cq), 128.0 (CH), 128.0 (CH), 128.3 (CH), 128.5 (CH), 128.8 (CH), 
128.8 (CH), 129.1 (CH), 130.7 (Cq), 131.7 (CH), 131.9 (CH), 132.0 (CH), 132.4 (Cq), 
132.5 (Cq), 133.2 (CH), 138.6 (Cq), 139.1 (Cq), 148.5 (Cq), 148.7 (Cq), 153.0 (Cq), 153.4 
(Cq), 153.5 (Cq), 153.5 (Cq), 167.4 (Cq); MS m/z (ES+) Found 415.1703 (MH+), 
C25H23N2O4 (MH







To a solution of pyrazoline (75) (50 mg, 0.12 mmol) in THF (10 mL) was added acetyl 
chloride (36 mg, 0.46 mmol) followed by NEt3 (23 mg, 0.23 mmol) and the solution 
allowed to stir at rt for 2 h. After 2 h the solvent was removed under reduced 
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pressure to afford a white solid which was recrysalised from Et2O to give pyrazoline 






Mp 158-160 oC (Et2O); IR νmax(film)/cm
-1 1660, 1625, 1452; 1H NMR δH (500 MHz; 
CDCl3) 2.32 (3 H, s, CH3), 3.19 (1 H, dd, J 17.5 and 5.0 Hz, pyrazoline CH), 3.77 (1 H, dd, 
J 18.0 and 12.0 Hz, pyrazoline CH), 3.80 (3 H, s, OCH3), 3.82 (6 H, s, OCH3), 5.76 (1 H, 
dd, J 12.0 and 5.0 Hz, pyrazoline CH), 6.52 (2 H, s, Ar CH), 7.14 (2 H, d, J 8.5 Hz, Ar CH), 
7.44-7.52 (3 H, m, Ar CH), 7.73 (2 H, d, J 8.5 Hz, Ar CH) and 8.00 (2 H, d, J 7.0 Hz, Ar 
CH); 13C NMR δC (125 MHz; CDCl3) 21.1 (CH3), 41.8 (CH2), 56.1 (CH3), 60.7 (CH3), 61.6 
(CH), 102.3 (CH), 122.0 (CH), 127.7 (CH), 128.0 (CH), 129.0 (Cq), 130.0 (CH), 131.0 
(CH), 134.3 (Cq), 137.4 (Cq), 137.5 (Cq), 152.2 (Cq), 153.7 (Cq), 153.8 (Cq), 166.5 (Cq) 









To a solution of pyrazoline (77) (20 mg, 0.046 mmol) in THF (5 mL) was added acetyl 
chloride (14 mg, 0.09 mmol) and the solution stirred at rt for 2.5 h. After 2.5 h the 
solvent was removed under reduced pressure to afford a yellow solid which was 
recrystallised from EtOAc to give pyrazoline (87) as a yellow solid (21 mg, 95%). 






Mp >230 oC (EtOAc); IR νmax(film)/cm
-1 1634, 1602, 1411; 1H NMR δH (500 MHz; CDCl3) 
2.17 (3 H, s, CH3), 3.18 (1 H, dd, J 17.5 and 5.0 Hz, pyrazoline CH), 3.75 (1 H, dd, J 17.5 
and 12.0 Hz, pyrazoline CH), 3.78 (3 H, s, OCH3), 3.81 (6 H, s, OCH3), 5.75 (1 H, dd, J 
12.0 and 5.0 Hz, pyrazoline CH), 6.52 (2 H, s, Ar CH), 7.44-7.50 (3 H, m, Ar CH), 7.56 (2 
H, d, J 8.0 Hz, Ar CH), 7.65 (2 H, d, J 8.0 Hz, Ar CH) and 8.01 (2 H, d, J 6.0 Hz, Ar CH); 13C 
NMR δC (125 MHz; CDCl3) 24.7 (CH3), 41.7 (CH2), 56.1 (CH3), 60.7 (CH3), 61.4 (CH), 
102.3 (CH), 119.4 (CH), 126.9 (Cq), 127.7 (CH), 130.0 (CH), 131.0 (CH), 134.3 (Cq), 
137.3 (Cq), 137.6 (Cq), 140.0 (Cq), 153.7 (Cq), 154.3 (Cq), 166.5 (Cq) and 168.3 (Cq); 
MS m/z (ES+) Found 474.2079 (MH+), C27H28N3O5 (MH









Following the procedure previously reported,102 2-acetylpyridine (1.33 g, 11.0 mmol) 
and benzaldehyde (1.06 g, 1.02 mL, 10.0 mmol) were added to distilled water (100 
mL) cooled to 4 oC and shaken thoroughly forming a fine emulsion. 10 mL of 10% of 
NaOH aqueous solution was then added and shaken again for 30 seconds and the 
reaction left at 4 oC. After 24 h the solid product was filtered, dried and recrystallised 
from EtOH to give the chalcone (2.02 g, 97%) as pale green crystals.  







Rf [PE-EtOAc 4:6] 0.88; Mp 72-74 
oC (EtOH); IR νmax(film)/cm
-1 1667, 1601, 1337 and 
1030; 1H NMR δH (500 MHz; CDCl3) 7.40-7.49 (4 H, m, Ph CH), 7.72-7.73 (2 H, m, Ph CH 
and py CH), 7.85-7.88 (1 H, m, py CH), 7.94 (1 H, d, J 16.0 Hz, COCH=CH), 8.18-8.19 (1 
H, m, py CH), 8.30 (1 H, d, J 16.0 Hz, COCH=CH) and 8.74-8.76 (1 H, m, py CH); 13C 
NMR δC (125 MHz; CDCl3) 120.9 (CH), 122.9 (CH), 126.9 (CH), 128.8 (CH), 128.9 (CH), 
130.6 (CH), 135.2 (Cq), 137.0 (CH), 144.8 (CH), 148.9 (CH), 154.3 (Cq) and 189.5 (Cq); 
MS m/z (ES+) Found 232.0749 (MNa+), C14H11N1NaO (MNa









Chalcone (96) (0.418 g, 2.0 mmol) was dissolved in EtOH (10 mL) and stirred for 10 
min at rt until fully dissolved then methylhydrazine (0.368 g, 0.42 mL, 8.0 mmol) was 
added dropwise and stirred continued at room temperature for 3 h. The solvent was 
removed under reduced pressure and the resulting yellow oil purified by column 
chromatography with silica gel using PE:EtOAc 60:40 to afford pyrazoline (97) (0.34 g, 
72%) as a yellow oil, which solidified upon cooling and was recrystallised from Et2O to 
give pale yellow crystals. 
 





Rf [PE-EtOAc 4:6] 0.82; Mp 52-55 
oC (Et2O);  IR νmax(film)/cm
-1 2971, 1570, 1456 and 
1122; 1H NMR δH (500 MHz; CDCl3) 2.88 (3 H, s, CH3), 3.08 (1 H, dd, J 16.5 and 14.5 Hz, 
pyrazoline CH), 3.71 (1 H, dd, J 16.5 and 10.5 Hz, pyrazoline CH), 4.21 (1 H, dd, J 14.5 
and 10.5 Hz, pyrazoline CH), 7.18 (1 H, dd, J 7.5 and 5.0 Hz, py CH), 7.29-7.34 (1 H, m, 
Ph CH), 7.35-7.40 (2 H, m, Ph CH), 7.45-7.48 (2 H, m, Ph), 7.66 (1 H, td, J 7.5 and 1.0 
Hz, py CH), 7.91 (1 H, dt, J 8.0 and 1.0 Hz, py CH) and 8.56 (1 H, br.d, J 5.0 Hz, py CH); 
13C NMR δC (125 MHz; CDCl3) 41.1 (CH3), 42.6 (CH2), 73.5 (CH), 120.4 (CH), 122.6 (CH), 
127.4 (CH), 127.8 (CH), 128.6 (CH), 136.0 (CH), 140.2 (Cq), 149.1 (CH), 150.4 (Cq) and 
152.1 (Cq); MS m/z (ES+) Found 260.1158 (MNa+), C15H15N3Na (MNa
+)  requires 







Following the procedure previously reported for the oxidation of a 1,2,3,4-tetrahydro- 
β-carboline,103 pyrazoline (97) (0.79 g, 3.4 mmol) was thoroughly ground together 
with 10 wt. % loading Pd/C (10 mol%, 0.36 g), placed under nitrogen and gradually 
heated to 200 oC and kept at 200 oC for 4 h. After 4 h the flask was cooled to rt and 50 
mL of toluene added, heated and vigorously stirred for 10 min., the solution was then 
filtered through fluted filter paper and cotton wool. The solvent was removed under 
reduced pressure to give a brown oil which was purified by column chromatography 
with silica gel using PE:EtOAc 60:40 to afford pyrazole (98) (0.63 g, 80%) as a pale 
yellow solid, which was recrystallised from Et2O to give pale yellow crystals. 







Rf [PE-EtOAc 4:6] 0.61; Mp 108-110 
oC (Et2O); IR νmax(film)/cm
-1 1598, 1477 and 1199; 
1H NMR δH (500 MHz; CDCl3) 3.97 (3 H, s, CH3), 6.94 (1 H, s, pyrazole CH), 7.21 (1 H, 
ddd, J 7.5, 4.5 and 1.0 Hz, py CH), 7.42-7.49 (5 H, m, Ph CH), 7.73 (1 H, td, J 7.5 and 1.5 
Hz, py CH), 7.95 (1 H, dt, J  8.0 and 1.0 Hz, py CH) and 8.64 (1 H, ddd, J 5.0, 1.5 and 1.0 
Hz, py CH); 13C NMR δC (125 MHz; CDCl3) 37.9 (CH3), 104.6 (CH), 119.9 (CH), 122.4 
(CH), 128.6 (CH), 128.7 (2 x CH), 130.5 (Cq), 136.6 (CH), 145.2 (Cq), 149.4 (CH), 150.6 










Following method J, except using 5.0 mmol of chalcone (96), 20.0 mmol hydrazine 
monohydrate and 10.0 mmol acetyl chloride, pyrazoline (100) was obtained as a 
white solid (0.95 g, 72%). 
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Rf [PE-EtOAc 4:6] 0.23; Mp 120-121 
oC (EtOAc); IR νmax(film)/cm
-1 1655, 1580, 1413 
and 1335; 1H NMR δH (500 MHz; CDCl3) 2.43 (3 H, s, CH3), 3.38 (1 H, dd, J 18.5 and 5.0 
Hz, pyrazoline CH), 3.84 (1 H, dd, J 18.5 and 12.0 Hz, pyrazoline CH), 5.60 (1 H, dd, J 
12.0 and 5.0 Hz, pyrazoline CH), 7.21-7.31 (6 H, m, Ph CH and py CH), 7.71-7.75 (1 H, 
td, J 8.0 and 2.0 Hz, py CH), 8.08 (1 H, d, J 8.0 Hz, py CH) and 8.58 (1 H, d, J 5.0 Hz,  py 
CH); 13C NMR δC (125 MHz; CDCl3) 21.8 (CH3), 42.0 (CH2), 60.1 (CH), 121.1 (CH), 124.2 
(CH), 125.5 (CH), 127.5 (CH), 128.7 (CH), 136.2 (CH), 141.6 (CH), 149.3 (Cq), 150.6 
(Cq), 155.3 (Cq) and 168.9 (Cq); MS m/z (ES+) Found 288.1166 (MNa+), C16H15N3ONa 

















Following method J, except using 2.5 mmol of chalcone (96), 10.0 mmol hydrazine 
monohydrate and 7.5 mmol trifluoroacetic anhydride, pyrazoline (101) was obtained 
as a pale green solid (0.52 g, 65%). 
 
Rf [PE-EtOAc 4:6] 0.87; Mp 143-145 
oC (EtOH); IR νmax(film)/cm
-1 1701, 1587, 1463 and 
1171; 1H NMR δH (500 MHz; CDCl3) 3.50 (1 H, dd, J 19.0 and 5.0 Hz, pyrazoline CH), 
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3.92 (1 H, dd, J 19.0 and 11.5 Hz, pyrazoline CH), 5.64 (1 H, dd, J 11.5 and 4.5 Hz, 
pyrazoline CH), 7.24-7.38 (6 H, m, Ph CH and py CH), 7.80 (1 H, td, J 7.5 and 2.0 Hz, py 
CH),  8.19 (1 H, d, J 7.0 Hz, py CH) and 8.62 (1 H, d, J 6.0 Hz, py CH); 13C NMR δC (125 
MHz; CDCl3) 41.7 (CH2), 61.8 (CH), 122.0 (CH), 125.1 (CH), 125.7 (CH), 128.4 (CH), 
129.1 (CH), 136.5 (CH), 139.5 (Cq), 149.5 (Cq), 149.7 (CH), 154.0 (Cq), 154.3 (Cq) and 
159.6 (Cq); MS m/z (ES+) Found 320.1066 (MH+) and 342.0888 (MNa+), C16H13F3N3O 
(MH+) requires 320.1011 and C16H12F3N3ONa (MNa
+) requires 342.0831; HPLC 






Following the procedure reported, chalcone (96) (5.0 mmol) and thiosemicarbazide 
(7.5 mmol) were added to EtOH (50 mL) followed by a solution of sodium hydroxide 
(5.0 mmol, 0.28 g) in water (10 mL) and refluxed for 6 h. The solvent was then 







Rf [PE-EtOAc 4:6] 0.55; Mp 185-189 
oC (EtOH); IR νmax(film)/cm
-1 3523, 3395, 1569, 
1349 and 1195; 1H NMR δH (400 MHz; CDCl3) 3.45 (1 H, dd, J 20.0 and 4.0 Hz, 
pyrazoline CH), 3.96 (1 H, dd, J 20.0 and 12.0 Hz, pyrazoline CH), 6.10 (1 H, dd, J 12.0 
and 4.0 Hz, pyrazoline CH), 6.30 (1 H, broad s, NH), 7.17 (1 H, broad S, NH), 7.26-7.35 
(6 H, m, Ph CH and py CH), 7.78 (1 H, td, J 8.0 and 4.0 Hz, py CH), 8.07 (1 H, d, J 8.0 Hz, 
CH) and 8.64 (1 H, d, J 8.0 Hz, py CH); 13C NMR δC (100 MHz; CDCl3) 39.8 (CH2), 63.1 
(CH), 121.5 (Py CH), 124.8 (Ar CH), 125.2 (Ar CH), 126.9 (Ar CH), 128.5 (Py CH), 136.7 
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(Py CH), 149.5 (Py CH) and 193.0 (C=S); MS m/z (ES+) Found 283.1004 (MH+) and 
305.0824 (MNa+), C15H15N4S (MH
+) requires 283.1017 and C15H14N4SNa (MNa
+) 








Pyrazoline (102) (1.4 mmol) was added to a solution of potassium hydroxide (4.2 
mmol) in THF (20 ml) and stirred for 15 min, methyl iodide (4.2 mmol) was then 
added and stirring continued for 2 h. Water (100 ml) was then added and stirring 
continued for 2 h resulting in the formation of a precipitate which was collected by 
filtration and recrystallised from EtOAc to afford pyrazoline (103) as yellow crystals 







Rf [PE-EtOAc 4:6] 0.15; Mp 157-158 
oC (EtOH); IR νmax(film)/cm
-1 1604, 1566, 1320 and 
1399; 1H NMR δH (500 MHz; CDCl3) 2.30 (3 H, s, CH3), 3.34 (1 H, dd, J 18.5 and 6.0 Hz, 
pyrazoline CH), 3.93 (1 H, dd, J 18.5 and 12.0 Hz, pyrazoline CH), 5.63 (1 H, dd, J 12.0 
and 6.0 Hz, pyrazoline CH), 7.24-7.35 (6 H, m, Ph CH and py CH), 7.71 (1 H, td, J 7.5 
and 1.5 Hz, py CH), 8.12 (1 H, d, J 7.5 Hz, py CH) and 8.55 (1 H, d, J 7.5 Hz, py CH); 13C 
NMR δC (125 MHz; CDCl3) 13.1 (CH3), 42.8 (CH2), 63.3 (CH), 121.1 (CH), 123.7 (CH), 
125.5 (CH), 127.6 (CH), 128.9 (CH), 136.1 (CH), 149.1 (CH), 149.2 (Cq) 151.0 (Cq), 
152.3 (Cq) and 160.0 (Cq); MS m/z (ES+) Found 297.1182 (MH+), C16H17N4S (MH
+) 
requires 297.1174; HPLC (analytical, system 2) tR = 5.6 min. 





Following method J, except using 5.0 mmol of chalcone (96), 20.0 mmol hydrazine 
monohydrate and 10.0 mmol of benzoyl chloride, pyrazoline (104) was obtained as a 
white solid (1.24 g, 76%). 
 
Rf [PE-EtOAc 4:6] 0.76; Mp 139-140 
oC (EtOAc); IR νmax(film)/cm
-1 1641, 1577, 1413 
and 1338; 1H NMR δH (500 MHz; CDCl3) 3.44 (1 H, dd, J 18.5 and 5.0 Hz, pyrazoline 
CH), 3.91 (1 H, dd, J 18.5 and 12.0 Hz, pyrazoline CH) 5.85 (1 H, dd, J 12.0 and 5.0 Hz, 
pyrazoline CH), 7.27-7.35 (6 H, m, Ph CH and py CH), 7.43-7.50 (3 H, m, Ar CH), 7.70 (1 
H, td, J 7.5 and 1.5 Hz, py CH), 8.01-8.04 (3 H, m, CH) and 8.59 (1 H, d, J 7.5 Hz, py CH); 
13C NMR δC (125 MHz; CDCl3) 41.4 (CH2), 61.5 (CH), 121.4 (CH), 124.3 (CH), 125.7 (CH), 
127.5 (CH), 127.6 (CH), 128.8 (CH), 129.9 (CH), 130.9 (CH), 134.2 (Cq), 136.2 (CH), 
141.6 (Cq), 149.3 (CH), 150.7 (Cq), 156.2 (Cq) and 166.6 (Cq); MS m/z (ES+) Found 
350.1282 (MNa+), C21H17N3ONa (MNa
+) requires 350.1269; HPLC (analytical, system 2) 
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Following method J, except using 5.0 mmol of chalcone (96), 20.0 mmol hydrazine 
monohydrate and 10.0 mmol of 3,4,5-trimethoxybenzoyl chloride, pyrazoline (105) 
was obtained as a white solid (1.56 g, 75%). 
 
Rf [PE-EtOAc 4:6] 0.55; Mp 173-175 
oC (EtOAc); IR νmax(film)/cm
-1 1643, 1579, 1412 
and 1341; 1H NMR δH (500 MHz; CDCl3) 3.44 (1 H, dd, J 18.5 and 5.0 Hz, pyrazoline 
CH), 3.88-3.94 (10 H, m, OCH3 and CH), 5.82 (1 H, dd, J 12.0 and 5.0 Hz, pyrazoline 
CH), 7.25-7.33 (6 H, m, Ph CH and py CH), 7.404 (2 H, s, Ar CH), 7.74 (1 H, td, J 8.0 and 
2.0 Hz, py CH), 8.05 (1 H, d, J 8.0 Hz, py CH) and 8.61 (1 H, d, J 7.5 Hz, py CH); 13C NMR 
δC (125 MHz; CDCl3) 41.2 (CH2), 56.2 (CH), 60.9 (OCH3), 62.0 (OCH3), 108.0 (CH), 121.0 
(CH), 124.4 (CH), 125.7 (CH), 127.6 (CH), 128.9 (CH), 136.2 (CH), 140.7 (Cq), 141.6 
(Cq), 149.5 (CH), 150.8 (Cq), 152.3 (Cq),156.0 (Cq), 156.5 (Cq) and 165.6 (Cq); MS m/z 
(ES+) Found 418.1776 (MH+) and 440.1587 (MNa+), C24H24N3O4 (MH
+) requires 
418.1767 and C24H23N3O4Na (MNa
+) requires 440.1586; Elemental Analysis Found C 
(69.15%) H (5.37%) N (9.92%) requires C (69.05%) H (5.55%) N (10.07%); HPLC 







Following method J, except using 2.0 mmol of chalcone (64), 8.0 mmol hydrazine 
monohydrate and 4.0 mmol 3,4,5-trimethoxybenzoyl chloride, pyrazoline (106) was 
obtained as a white solid (0.85 g, 84%). 
 
Rf [PE-EtOAc 4:6] 0.41; Mp 174-175 
oC (EtOH); IR νmax(film)/cm
-1 1641, 1580, 1416 and 
1128; 1H NMR δH (500 MHz; CDCl3) 3.42 (1 H, dd, J 19.0 and 5.0 Hz, pyrazoline CH), 
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3.81 (3 H, s, OCH3), 3.82 (6 H, s, OCH3), 3.85-3.93 (10 H, m, OCH3 and pyrazoline CH), 
5.75 (1 H, dd, J 12.0 and 5.0 Hz, pyrazoline CH), 6.52 (2 H, s, Ar CH), 7.32 (1 H, td, J 5.0 
and 1.0 Hz, py CH), 7.40 (2 H, s, Ar CH), 7.74 (1 H, dt, J 7.5 and 1.5 Hz, py CH), 8.04 (1 
H, d, J 8.0 Hz, py CH) and 8.61 (1 H, d, J 5.5 Hz, py CH); 13C NMR δC (125 MHz; CDCl3) 
41.4 (CH2), 56.1 (OCH3), 56.2 (OCH3), 56.3 (OCH3) 60.7 (OCH3), 62.2 (Ar CH), 102.5 (Ar 
CH), 108.0 (Ar CH), 121.1 (Ar CH), 124.5 (Ar CH), 128.9 (Ar CH), 136.3 (Ar CH), 137.4 
(Cq), 137.5 (Cq), 140.9 (Cq), 149.6 (Cq), 150.7 (Cq), 152.5 (Cq), 153.6 (Cq), 156.7 (Cq) 
and 165.8 (C=O); MS m/z (ES+) Found 508.2078 (MH+) and 530.1898 (MNa+), 
C27H30N3O7 (MH
+) requires 508.2084 and C27H29N3O7Na (MNa
+) requires 530.1903; 










Following method J, except using 4.0 mmol of chalcone (64), 8.0 mmol hydrazine 
monohydrate and 8.0 mmol of acetyl chloride, pyrazoline (107) was obtained as a 
yellow solid (1.14 g, 80%). 
 
Rf [PE-EtOAc 4:6] 0.24; Mp 173-174 
oC (EtOH); IR νmax(film)/cm
-1 1662, 1594, 1416, 
1327 and 1132; 1H NMR δH (500 MHz; CDCl3)  2.43 (3 H, s, OCH3), 3.34 (1 H, dd, J 18.5 
and 5.0 Hz, pyrazoline CH), 3.77 (3 H, s, OCH3), 3.79-3.87 (7 H, m, CH3 and pyrazoline 
CH), 5.51 (1 H, dd, J 12.0 and 5.0 Hz, pyrazoline CH), 6.40 (2 H, s, Ar CH), 7.26-7.30 (1 
H, m, py CH), 7.73(1 H, td, J 7.5 and 1.5 Hz, py CH), 8.06 (1 H, d, J 8.0 Hz, py CH) and 
8.57 (1 H, d, J 4.5 Hz, py CH); 13C NMR δC (125 MHz; CDCl3) 21.8 (OCH3), 42.2 (CH2), 
56.0 (CH), 60.3 (OCH3), 60.6 (CH3), 102.3 (CH), 121.1 (CH), 124.3 (CH), 136.2 (CH), 
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137.2 (Cq), 137.4  (Cq), 149.4 (CH), 150.5 (Cq), 153.4 (Cq), 155.4 (Cq) and 169.1 (Cq); 
MS m/z (ES+) Found 378.1481 (MNa+), C19H21N3O4Na (MNa
+) requires 378.1430; HPLC 


















Following method L, except using 2.5 mmol of chalcone (64) and 5.0 mmol of phenyl 
hydrazine, pyrazoline (108) was obtained as a yellow solid (0.33 g, 34%). 
 
Rf [PE-EtOAc 4:6] 0.70; Mp 75-77 
oC (EtOAc); IR νmax(film)/cm
-1 1601, 1502, 1214 and 
1128; 1H NMR δH (500 MHz; CDCl3) 3.33 (1 H, dd, J 18.0 and 7.5 Hz, pyrazoline CH), 
3.79 (6 H, s, OCH3), 3.82 (3 H, s, OCH3), 3.98 (1 H, dd, J 18.0 and 12.5 Hz, pyrazoline 
CH), 5.24 (1 H, dd, J 12.5 and 7.5 Hz, pyrazoline CH), 6.51 (2 H, s, Ar CH), 6.85 (1 H, td, 
J 7.0 and 1.0 Hz, py CH), 7.12 (2 H, d, J 8.5 Hz, Ar CH), 7.20-7.24 (3 H, m, Ar CH), 7.71 
(1 H, td, J 7.5 and 1.5 Hz, py CH), 8.14 (1 H, d, J 8.0 Hz, Ar CH) and 8.54-8.55 (1 H, d, J 
7.5 Hz, py CH); 13C NMR δC (125 MHz; CDCl3) 43.3 (CH2), 56.1 (CH), 60.8 (CH), 65.2 
(CH), 102.4 (CH), 113.7 (CH), 119.8 (CH), 120.7 (CH), 122.7 (CH), 128.9 (CH), 130.0 
(Cq), 137.1 (Cq), 138.1 (Cq),140.3 (Cq) 144.6 (Cq) and 153.8 (Cq); MS m/z (ES+) Found 
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390.1882 (MH+) and 412.1649 (MNa+), C23H24N3O3 (MH
+) requires 390.1818 and 
C23H23N3O3Na (MNa










Following the procedure reported,115 to a stirred solution of maltol (92) (17.8 g, 0.14 
mol) in MeOH (180 mL) was added sodium hydroxide (6 g, 0.15 mol) in water (20 mL) 
followed by benzyl chloride (20.9 g, 0.16 mol), and the mixture was heated to reflux 
for 12 h. The solvent was reduced under reduced pressure to afford orange oil which 
was taken up in CH2Cl2 (80 mL) and washed with 5% (w/v) aqueous sodium hydroxide 
(5 x 30 mL) and water (2 x 50 mL). The organic fraction was dried over anhydrous 
sodium sulfate and filtered. The solvent was removed by rotary evaporation to give 
product (114) as a pale yellow oil (26.3 g, 87%). 
 





Rf [PE-EtOAc 4:6] 0.65; IR νmax(film)/cm
-1 1633, 1431 and 1173; 1H NMR δH (500 MHz; 
CDCl3) 2.09 (3 H, s, CH3), 5.16 (2 H, s, Bn CH2), 6.36 (1 H, d, J 5.0 Hz, COCH=CH), 7.33-
7.39 (5 H, m, Ph CH) and 7.59 (1 H, d, J 5.0, COCH=CH); 13C NMR δC (125 MHz; CDCl3); 
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14.8 (CH3), 73.6 (CH2), 117.2 (CH), 128.3 (CH), 128.4 (CH), 129.0 (CH), 136.9 (Cq), 
143.8 (Cq), 153.4 (Cq), 159.7 (CH) and 175.1 (Cq); MS m/z (ES+) Found 217.0861 
(MH+), C13H13O3 (MH







Following the procedure reported,115 to a stirred solution of benzylated maltol (114) 
(8.5 g, 39.4 mmol) in EtOH (100 mL) and water (100 mL) was added β-alanine (8.7 g, 
97.8 mmol) followed by 10 M sodium hydroxide solution until pH 13 was attained. 
After heating under reflux for 18 h, the solvent was reduced in volume under reduced 
pressure and water was added followed by hydrochloric acid to adjust to pH 4. The 
yellow precipitate was filtered and dried to afford product (115) as a pale yellow solid 
(7.9 g, 70%). 
 
 
Synthesis of 3-(3-(benzyloxy)-2-methyl-4-oxopyridin-1(4H)-yl)propanoic acid (115) 
 
 
Rf [CH2Cl2-MeOH 9:1] 0.21; Mp 172-173 
oC (EtOH); IR νmax(film)/cm
-1 1729, 1625 and 
1550; 1H NMR δH (500 MHz; DMSO) 2.21 (3 H, s, CH3), 2.66 (2 H, t, J 7.0 Hz, NCH2CH2), 
4.11 (2 H, t, J 7.0 Hz, NCH2CH2), 5.00 (2 H, s, Bn CH2), 6.20 (1 H, d, J 7.5 Hz, COCH=CH), 
7.32-7.41 (5 H, m, Ph CH) and 7.66 (1 H, d, J 7.5 Hz, COCH=CH); 13C NMR δC (125 MHz; 
CDCl3); 12.0 (CH3), 34.5 (CH2), 48.6 (CH2), 72.0 (CH2), 115.9 (CH), 122.1 (Cq), 127.9 
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(CH), 128.3 (CH), 128.4 (CH), 137.7 (Cq), 139.8 (CH), 145.0 (Cq), 171.9 (Cq) and 172.0 
(Cq);  MS m/z (ES
+) Found 288.1238 (MH+) and 310.1055 (MNa+), C16H18N1O4 (MH
+) 
requires 288.1236 and C16H17N1O4Na (MNa





Following an adapted literature procedure,115 to a stirred solution of maltol carboxylic 
acid (115)  (5.5 g, 19.1 mmol) in CH2Cl2 (60 mL) at rt was added    N-
hydroxysuccinimide (2.2 g, 19.1 mmol) dissolved in CH2Cl2 (60 mL) followed by N,N'-
dicyclohexylcarbodiimide (3.9 g, 19.1 mmol) dissolved in CH2Cl2      (60 mL) and stirring 
continued at rt for 18 h. After 18 h the white precipitate was filtered and the solvent 
concentrated under reduced pressure to afford a pale yellow solid. Recrysalisation 
from CH2Cl2 and Et2O afforded a white crystalline solid which was collected and dried 
to give the product (116)    (5.1 g, 70%). 
 





Mp 72-74 oC (CH2Cl2/Et2O); IR νmax(film)/cm
-1 1782, 1725 and 1633; 1H NMR δH (500 
MHz; DMSO) 2.22 (3 H, s, CH3), 2.82 (4 H, s, 2 x CH2), 3.19 (2 H, t, J 7.0 Hz, NCH2CH2), 
4.24 (2 H, t, J 7.0 Hz, NCH2CH2), 5.00 (2 H, s, Bn CH2), 6.14 (1 H, d, J 7.5 Hz, COCH=CH), 
7.32-7.42 (5 H, m, Ph CH) and 7.66 (1 H, d, J 7.5 Hz, COCH=CH); 13C NMR δC (125 MHz; 
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DMSO); 11.9 (CH3), 25.5 (CH2), 31.2 (CH2), 47.5 (CH2), 71.9 (CH2), 116.1 (CH), 127.8 
(CH), 128.2 (CH), 128.4 (CH), 137.8 (Cq), 139.6 (CH), 140.8 (Cq), 145.2 (Cq), 166.8 (Cq), 





Maltol activated ester (116) (1.44 g, 3.8 mmol) was dissolved in DMF (5 mL) and 
added dropwise to a stirred solution of ethylenediamine (0.09 g,           1.5 mmol) in 
DMF (2 mL) at rt and stirring continued for 72 h. After 72 h a white precipitate formed 
which was filtered off and the solvent removed under removed pressure to afford a 
pale yellow oil which was purified by column chromatography with silica gel using 
CH2Cl2:MeOH 8:2 to afford the desired benzylated maltol dimer (117) as a white solid 







Rf [CH2Cl2-MeOH 9:1] 0.08; 
1H NMR δH (500 MHz; CDCl3) 2.12 (6 H, s, CH3), 2.42 (4 H, t, 
J 6.5 Hz, 2 x CH2), 3.23 (4 H, br s, CH2), 4.07 (4 H, t, J 6.5 Hz, 2 x CH2), 5.01 (4 H, s, Bn 
CH2), 6.28 (4 H, d, J 7.5 Hz, COCH=CH), 7.28-7.34 (10 H, m, Ar CH), 7.37 (2 H, d, J 7.5 
Hz, COCH=CH) and 7.89 (2 H, br s, NH); 13C NMR δC (125 MHz; CDCl3); 12.4 (CH3), 36.5 
(CH2), 39.3 (CH2), 50.0 (CH2) 73.2 (CH2), 116.6 (CH), 128.3 (CH), 128.4 (CH), 128.7 (CH), 
136.9 (Cq), 139.4 (CH), 142.1 (Cq), 145.8 (Cq), 169.3 (Cq) and 172.9 (Cq); MS m/z (ES+) 
Found 621.2686 (MNa+), C34H38N4O6Na (MNa
+) requires 621.2689. 
 
 






Benzylated maltol dimer (117) (0.4 g, 0.67 mmol) was added to a stirred solution of 
10wt% Pd/C (40 mg) in MeOH (10 mL) under 1 atm of H2 and stirring continued at rt 
for 20 h. The solution was filtered through filter paper and the solvent removed under 






Rf [CH2Cl2-MeOH 8:2] 0.1; 
1H NMR δH (500 MHz; DMSO) 2.29 (6 H, s, CH3), 2.49 (4 H, t, 
J 7.5 Hz, 2 x CH2), 3.01 (4 H, br s, CH2), 4.13 (4 H, t, J 7.0 Hz, 2 x CH2), 6.08 (2 H, d, J 7.0 
Hz, COCH=CH), 7.47 (2 H, d, J 7.0 Hz, COCH=CH) and 8.02 (2 H, br s, NH); 13C NMR δC 
(125 MHz; DMSO) 11.3 (CH3), 36.2 (CH2), 38.1 (CH2), 49.1 (CH2), 110.5 (CH), 128.4 
(Cq), 137.6 (CH), 145.4 (Cq), 168.9 (Cq) and 169.1 (Cq); MS m/z (ES+) Found 419.1951 
(MH+) and 441.1759 (MNa+), C20H27N4O6 (MH
+) requires 419.1931 and C20H26N4O6Na 




Maltol activated ester (116) (1.92 g, 5.0 mmol) was dissolved in DMF (5 mL) and 
added dropwise to a stirred solution of tris(2-aminoethyl)amine (0.15 g, 1.0 mmol) in 
DMF (5 mL) at rt and stirring continued for 72 h. After 72 h a white precipitate formed 
which was filtered off and the solvent removed under removed pressure to afford a 
pale yellow oil which was purified by column chromatography with silica gel using 
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CH2Cl2:MeOH 7:3 to afford the desired benzylated maltol trimer (118) as a white solid 






Rf [CH2Cl2-MeOH 8:2] 0.08; 
1H NMR δH (500 MHz; CDCl3) 2.14 (9 H, s, CH3), 2.89 (6 H, t, 
J 6.0 Hz, 3 x CH2), 2.54 (6 H, t, J 6.0 Hz, 3 x CH2), 3.04 (6 H, t, J 6.0 Hz, 3 x CH2), 4.04 (6 
H, t, J 6.5 Hz, 3 x CH2), 5.05 (6 H, s, Bn CH2), 6.20 (3 H, d, J 7.5 Hz, COCH=CH), 7.26-7.36 
(18 H, m, COCH=CH and Ph CH) and 8.00 (3 H, br s, NH); 13C NMR δC (125 MHz; CDCl3) 
12.3 (CH3), 36.5 (CH2), 37.8 (CH2), 49.9 (CH2), 54.2 (CH2), 72.9 (CH2), 116.8 (CH), 128.2 
(CH), 128.4 (CH), 128.7 (CH), 137.2 (Cq), 139.2 (CH), 141.5 (Cq), 146.0 (Cq), 169.2 (Cq) 






Benzylated maltol trimer (118) (0.34 g, 0.36 mmol) was added to a stirred solution of 
10wt% Pd/C (34 mg) in MeOH (10 mL) under 1 atm of H2 and stirring continued at rt 
for 72 h. The solution was filtered through filter paper and the solvent removed under 
reduced pressure affording a mixture of partially deprotected maltol trimer (112) and 
unreacted benzylated maltol trimer (118)  (0.116 g, 34%). 
 
Method AD 
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Acetyl chloride (0.23 g, 3.0 mmol) was added dropwise to a stirred solution of MeOH 
(5.0 mL) on ice, the solution was then allowed to warm to rt. Maltol carboxylic acid 
(115) (0.57 g, 2.0 mmol) was dissolved in MeOH (5 mL) and added dropwise to the 
solution and the reaction heated to 70 oC for 1 h. After 1 h the solvent was removed 
under reduced pressure to afford methyl ester maltol (119) as a white solid (0.59 g, 
98%). 
 




Rf [CH2Cl2-MeOH 9:1] 0.61; Mp 144-145 
oC (MeOH); IR νmax(film)/cm
-1 1742, 1633, 
1186; 1H NMR δH (500 MHz; CDCl3); 2.09 (3 H, s, CH3), 2.63 (2 H, t, J 7.0 Hz, NCH2CH2), 
3.70 (3 H, s, OCH3), 4.08 (2 H, t, J 7.0 Hz, NCH2CH2), 5.21 (2 H, s, Bn CH2), 6.42 (1 H, d, J 
7.5 Hz, COCH=CH) and 7.27-7.40 (6 H, m, Ph CH and COCH=CH); 13C NMR δC (125 MHz; 
CDCl3); 12.4 (CH3), 34.8 (CH2), 48.9 (CH2), 52.3 (OCH3), 73.0 (CH2), 117.5 (CH), 128.0 
(CH), 128.2 (CH), 129.1 (CH), 137.5 (Cq), 138.4 (CH), 140.2 (Cq), 146.2 (Cq), 170.3 (Cq) 
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Hydrazine monohydrate (0.64 g, 20.0 mmol) was added to a stirred solution of methyl 
ester maltol (119) (1.5 g, 5.0 mmol) in MeOH (10 mL) and rt and heated to 70 oC for 
18 h. After 18 h the solvent was removed under reduced pressure and the residue 
purified by column chromatography with silica gel using CH2Cl2:MeOH 2:8 solvent 
system to afford the product (120) as a pale yellow solid (0.93 g, 62%). 
 





Rf [CH2Cl2-MeOH 9:1] 0.09; M.p 76-78 
oC (MeOH); IR νmax(film)/cm
-1 1664, 1629 and 
1127; 1H NMR δH (400 MHz; DMSO); 2.27 (3 H, s, CH3), 2.48 (2 H, t, J 7.0 Hz, NCH2CH2), 
4.15 (2 H, t, J 7.0 Hz, NCH2CH2), 4.38 (1 H, br s, NH), 5.07 (2 H, s, Bn CH2), 6.18 (1 H, d, 
J 7.5 Hz, COCH=CH), 7.37-7.48 (5 H, m, Ph CH), 7.57 (1 H, d, J 7.5 Hz, COCH=CH) and 
9.16 (1 H, s, NH);  13C NMR δC (125 MHz; DMSO);  11.9 (CH3), 34.3 (CH2), 49.2 (CH2), 
71.9 (CH2), 116.0 (CH), 116.1 (CH), 127.9 (CH), 128.3 (CH), 137.8 (Cq), 139.6 (CH), 
140.7 (Cq), 140.8 (Cq), 145.3 (Cq), 168.2 (Cq) and 171.8 (Cq); MS m/z (ES+) Found 
302.1480 (MH+) and 324.1310 (MNa+), C16H20N3O3 (MH
+) requires 302.1505 and 
C16H19N3O3Na (MNa
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Benzyl protected maltol hydrazide (120) (0.93 g, 3.1 mmol) was added to a stirred 
solution of 20 mol% Pd/C (0.62 mg) in MeOH (10 mL) under 1.0 atm of H2 and stirring 
continued at rt for 24 h. The solution was filtered through filter paper and the solvent 
removed under reduced pressure to give maltol hydrazide (121) as a beige coloured 
solid (0.55g, 82%).  
 




Rf [CH2Cl2-MeOH 9:1] 0.06; Mp 102-104
oC (MeOH); IR νmax(film)/cm
-1 3616, 1668 and 
1626; 1H NMR δH (500 MHz; DMSO); 2.35 (3H, s, CH3), 2.56 (2 H, t, J 7.0 Hz, NCH2CH2), 
4.26 (2 H, t, J 7.0 Hz, NCH2CH2), 6.38 (1 H, d, J 7.0 Hz, COCH=CH), 7.65 (1 H, d, J 7.0 Hz, 
COCH=CH) and 9.71 (1 H, br s, OH); 13C NMR δc (125 MHz; DMSO); 11.6 (CH3), 34.1 
(CH2), 49.8 (CH2), 110.7 (CH), 131.8 (Cq), 137.9 (CH), 144.8 (Cq), 166.6 (Cq) and 168.2 
(Cq); MS m/z (ES+) Found 212.1033 (MH+) and 234.0838 (MNa+), C9H14N3O3 (MH
+) 
requires 212.1035 and C9H13N3O3Na  (MNa





















LNCaP Human Prostate Carcinoma 















































































































































































































































































































































































































Pyrazoline (85 and 85A) 
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Appendix A: NCI Data 
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Appendix B: X-Ray Crystallographic Data 
 
 




Ortep3 representations, showing the four independent structures. Right – highlighting the 
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Table 1.  Crystal data and structure refinement for pyrazole (99) Zn
2+
 Complex. 
                                                                                                                         
 Identification code k12farm1 
 Empirical formula C60 H52 Cl8 N12 Zn4 
 Formula weight 1486.22 
 Temperature 150(2) K 
 Wavelength 0.71073 Å 
 Crystal system Monoclinic 
 Space group P21/c 
 Unit cell dimensions a = 14.2600(2)Å alpha = 90
o
 
       b = 26.1400(4)Å beta = 101.476(1)
o
 
       c = 16.8220(2)Å gamma = 90
o
 
 Volume 6145.15(15) Å
3
 
 Z 4 
 Density (calculated) 1.606 Mg/m
3
 
 Absorption coefficient 1.941 mm
-1
 
 F(000) 3008 
 Crystal size 0.40 x 0.25 x 0.14 mm 
 Theta range for data collection 3.51 to 27.47
o
 
 Index ranges -18<=h<=18; -33<=k<=33; -21<=l<=21 
 Reflections collected 99814 
 Independent reflections 14032 [R(int) = 0.0737] 
 Reflections observed (>2sigma) 9917 
 Data Completeness 0.997 
 Absorption correction Semi-empirical from equivalents 
 Max. and min. transmission 0.565 and 0.457 
 Refinement method Full-matrix least-squares on F
2
 
 Data / restraints / parameters 14032 / 0 / 761 
 Goodness-of-fit on F
2
 1.031 
 Final R indices [I>2sigma(I)] R1 = 0.0452   wR2 = 0.1015 
 R indices (all data) R1 = 0.0782  wR2 = 0.1156 






4 independent molecules in the asymmetric unit. Largest residual peak in difference Fourier electron 
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Table 2.  Atomic coordinates ( x 10
4





1.U(eq) is defined  as one third of the trace of the orthogonalized Uij tensor. 
                                                                                                                         
                                                                                                                         
  Atom   x   y   z  U(eq) 
                                                                                                                           
Zn(1) 1522(1) 3005(1) 4492(1) 34(1) 
Cl(1) 184(1) 3211(1) 4892(1) 50(1) 
Cl(2) 2821(1) 2998(1) 5450(1) 46(1) 
N(1) 1540(2) 2451(1) 3607(1) 29(1) 
N(2) 1582(2) 3462(1) 3500(1) 29(1) 
N(3) 1565(2) 3963(1) 3307(1) 28(1) 
C(1) 1583(2) 1943(1) 3708(2) 33(1) 
C(2) 1606(2) 1608(1) 3074(2) 35(1) 
C(3) 1577(2) 1804(1) 2309(2) 36(1) 
C(4) 1545(2) 2325(1) 2197(2) 31(1) 
C(5) 1536(2) 2641(1) 2854(2) 28(1) 
C(6) 1536(2) 3202(1) 2806(2) 28(1) 
C(7) 1503(2) 3539(1) 2163(2) 28(1) 
C(8) 1528(2) 4027(1) 2493(2) 28(1) 
C(9) 1500(2) 4522(1) 2074(2) 30(1) 
C(10) 1826(2) 4980(1) 2452(2) 33(1) 
C(11) 1761(2) 5432(1) 2013(2) 39(1) 
C(12) 1394(3) 5430(2) 1191(2) 48(1) 
C(13) 1097(3) 4974(2) 808(2) 54(1) 
C(14) 1139(3) 4523(1) 1237(2) 40(1) 
C(15) 1549(3) 4332(1) 3955(2) 40(1) 
Zn(1A) 4005(1) 4683(1) 458(1) 33(1) 
Cl(1A) 5541(1) 4459(1) 390(1) 36(1) 
Cl(2A) 2798(1) 4447(1) -528(1) 39(1) 
N(1A) 4013(2) 5165(1) 1446(1) 28(1) 
N(2A) 3841(2) 4157(1) 1413(1) 30(1) 
N(3A) 3807(2) 3645(1) 1534(1) 30(1) 
C(1A) 3987(2) 5677(1) 1428(2) 34(1) 
C(2A) 4093(2) 5972(1) 2122(2) 35(1) 
C(3A) 4237(2) 5729(1) 2866(2) 33(1) 
C(4A) 4249(2) 5201(1) 2899(2) 29(1) 
C(5A) 4122(2) 4929(1) 2177(2) 26(1) 
C(6A) 4063(2) 4369(1) 2148(2) 28(1) 
C(7A) 4171(2) 3997(1) 2750(2) 28(1) 
C(8A) 4001(2) 3531(1) 2345(2) 28(1) 
C(9A) 4034(2) 3014(1) 2690(2) 29(1) 
C(10A) 4252(2) 2576(1) 2286(2) 32(1) 
C(11A) 4301(2) 2101(1) 2655(2) 38(1) 
C(12A) 4148(2) 2052(1) 3440(2) 40(1) 
C(13A) 3941(2) 2482(1) 3847(2) 39(1) 
C(14A) 3880(2) 2958(1) 3486(2) 34(1) 
C(15A) 3457(3) 3320(1) 829(2) 40(1) 
Zn(1B) 6478(1) 4369(1) 4600(1) 29(1) 
Cl(1B) 5060(1) 4224(1) 4899(1) 43(1) 
Cl(2B) 7730(1) 4325(1) 5602(1) 44(1) 
N(1B) 6581(2) 4960(1) 3800(1) 26(1) 
N(2B) 6571(2) 3955(1) 3576(1) 26(1) 
N(3B) 6526(2) 3464(1) 3323(1) 25(1) 
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C(1B) 6628(2) 5462(1) 3950(2) 30(1) 
C(2B) 6702(2) 5825(1) 3373(2) 34(1) 
C(3B) 6710(2) 5660(1) 2593(2) 35(1) 
C(4B) 6664(2) 5143(1) 2420(2) 29(1) 
C(5B) 6613(2) 4800(1) 3037(2) 25(1) 
C(6B) 6596(2) 4243(1) 2926(2) 25(1) 
C(7B) 6582(2) 3941(1) 2252(2) 25(1) 
C(8B) 6531(2) 3440(1) 2513(2) 24(1) 
C(9B) 6462(2) 2964(1) 2032(2) 26(1) 
C(10B) 6781(2) 2490(1) 2355(2) 27(1) 
C(11B) 6654(2) 2060(1) 1863(2) 35(1) 
C(12B) 6225(3) 2096(1) 1050(2) 38(1) 
C(13B) 5945(3) 2567(1) 724(2) 38(1) 
C(14B) 6064(2) 3000(1) 1200(2) 31(1) 
C(15B) 6413(3) 3065(1) 3900(2) 37(1) 
Zn(1C) 8769(1) 3081(1) 472(1) 34(1) 
Cl(1C) 7528(1) 3147(1) -539(1) 50(1) 
Cl(2C) 10158(1) 3263(1) 124(1) 53(1) 
N(1C) 8853(2) 2515(1) 1360(2) 30(1) 
N(2C) 8725(2) 3519(1) 1490(1) 28(1) 
N(3C) 8748(2) 4018(1) 1684(1) 28(1) 
C(1C) 8811(2) 2007(1) 1261(2) 34(1) 
C(2C) 8945(2) 1666(1) 1908(2) 36(1) 
C(3C) 9139(2) 1859(1) 2690(2) 36(1) 
C(4C) 9168(2) 2384(1) 2806(2) 30(1) 
C(5C) 9014(2) 2701(1) 2128(2) 26(1) 
C(6C) 8979(2) 3261(1) 2186(2) 27(1) 
C(7C) 9155(2) 3596(1) 2837(2) 27(1) 
C(8C) 9009(2) 4081(1) 2507(2) 27(1) 
C(9C) 9111(2) 4574(1) 2925(2) 29(1) 
C(10C) 9417(2) 5018(1) 2594(2) 33(1) 
C(11C) 9545(2) 5470(1) 3039(2) 40(1) 
C(12C) 9371(3) 5485(1) 3819(2) 45(1) 
C(13C) 9067(2) 5046(1) 4155(2) 40(1) 
C(14C) 8936(2) 4597(1) 3715(2) 32(1) 
C(15C) 8418(3) 4386(1) 1042(2) 39(1) 
                                                                                                                         
 Table 3.   Bond lengths [Å] and angles [
o
] for 1. 
   
Zn(1)-N(2) 2.066(2) Zn(1)-N(1) 2.081(2) 
Zn(1)-Cl(2) 2.2012(9)  Zn(1)-Cl(1) 2.2124(10) 
N(1)-C(1) 1.338(4) N(1)-C(5) 1.359(4) 
N(2)-C(6) 1.341(4) N(2)-N(3) 1.349(3) 
N(3)-C(8) 1.371(4)  N(3)-C(15) 1.459(4) 
C(1)-C(2) 1.387(4) C(2)-C(3) 1.379(4) 
C(3)-C(4) 1.373(4) C(4)-C(5) 1.384(4) 
C(5)-C(6) 1.469(4) C(6)-C(7) 1.389(4) 
C(7)-C(8) 1.388(4) C(8)-C(9) 1.470(4) 
C(9)-C(10) 1.391(4) C(9)-C(14) 1.399(4) 
C(10)-C(11) 1.386(4) C(11)-C(12) 1.379(5) 
C(12)-C(13) 1.381(5) C(13)-C(14) 1.378(5) 
Zn(1A)-N(1A) 2.084(2) Zn(1A)-N(2A) 2.162(2) 
Zn(1A)-Cl(2A) 2.2261(9) Zn(1A)-Cl(1A) 2.2932(9) 
Zn(1A)-Cl(1A)#1 2.8025(9) Cl(1A)-Zn(1A)#1 2.8026(9) 
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N(1A)-C(1A) 1.339(4) N(1A)-C(5A) 1.358(4) 
N(2A)-C(6A) 1.335(4) N(2A)-N(3A) 1.356(3) 
N(3A)-C(8A) 1.369(4)  N(3A)-C(15A) 1.465(4) 
C(1A)-C(2A) 1.382(4) C(2A)-C(3A) 1.380(4) 
C(3A)-C(4A) 1.382(4) C(4A)-C(5A) 1.389(4) 
C(5A)-C(6A) 1.466(4) C(6A)-C(7A) 1.390(4) 
C(7A)-C(8A) 1.391(4) C(8A)-C(9A) 1.469(4) 
C(9A)-C(10A) 1.397(4) C(9A)-C(14A) 1.408(4) 
C(10A)-C(11A) 1.383(4) C(11A)-C(12A) 1.386(5) 
C(12A)-C(13A) 1.378(5) C(13A)-C(14A) 1.379(4) 
Zn(1B)-N(2B) 2.062(2) Zn(1B)-N(1B) 2.072(2) 
Zn(1B)-Cl(2B) 2.2002(9) Zn(1B)-Cl(1B) 2.2107(9) 
N(1B)-C(1B) 1.337(4) N(1B)-C(5B) 1.359(3) 
N(2B)-C(6B) 1.333(4) N(2B)-N(3B) 1.349(3) 
N(3B)-C(8B) 1.365(3)  N(3B)-C(15B) 1.457(4) 
C(1B)-C(2B) 1.375(4) C(2B)-C(3B) 1.383(4) 
C(3B)-C(4B) 1.382(4) C(4B)-C(5B) 1.384(4) 
C(5B)-C(6B) 1.467(4) C(6B)-C(7B) 1.379(4) 
C(7B)-C(8B) 1.387(4) C(8B)-C(9B) 1.475(4) 
C(9B)-C(10B) 1.393(4) C(9B)-C(14B) 1.406(4) 
C(10B)-C(11B) 1.388(4) C(11B)-C(12B) 1.385(5) 
C(12B)-C(13B) 1.375(5) C(13B)-C(14B) 1.376(4) 
Zn(1C)-N(2C) 2.071(2) Zn(1C)-N(1C) 2.089(3) 
Zn(1C)-Cl(1C) 2.2032(9)  Zn(1C)-Cl(2C) 2.2259(10) 
N(1C)-C(1C) 1.338(4) N(1C)-C(5C) 1.355(4) 
N(2C)-C(6C) 1.338(4) N(2C)-N(3C) 1.344(3) 
N(3C)-C(8C) 1.370(4)  N(3C)-C(15C) 1.453(4) 
C(1C)-C(2C) 1.390(4) C(2C)-C(3C) 1.385(5) 
C(3C)-C(4C) 1.385(4) C(4C)-C(5C) 1.392(4) 
C(5C)-C(6C) 1.469(4) C(6C)-C(7C) 1.387(4) 
C(7C)-C(8C) 1.383(4) C(8C)-C(9C) 1.463(4) 
C(9C)-C(10C) 1.393(4) C(9C)-C(14C) 1.400(4) 
C(10C)-C(11C) 1.393(4) C(11C)-C(12C) 1.385(5) 
C(12C)-C(13C) 1.386(5) C(13C)-C(14C) 1.379(4) 
                                                                                                                          
N(2)-Zn(1)-N(1) 79.45(10) N(2)-Zn(1)-Cl(2) 115.60(8) 
N(1)-Zn(1)-Cl(2) 112.91(7) N(2)-Zn(1)-Cl(1) 106.41(7) 
N(1)-Zn(1)-Cl(1) 121.40(8) Cl(2)-Zn(1)-Cl(1) 115.48(4) 
C(1)-N(1)-C(5) 118.3(3) C(1)-N(1)-Zn(1) 127.3(2) 
C(5)-N(1)-Zn(1) 114.4(2) C(6)-N(2)-N(3) 106.6(2) 
C(6)-N(2)-Zn(1) 114.0(2) N(3)-N(2)-Zn(1) 138.94(19) 
N(2)-N(3)-C(8) 110.7(2) N(2)-N(3)-C(15) 117.7(2) 
C(8)-N(3)-C(15) 131.5(3) N(1)-C(1)-C(2) 122.5(3) 
C(3)-C(2)-C(1) 118.8(3) C(4)-C(3)-C(2) 119.5(3) 
C(3)-C(4)-C(5) 119.2(3) N(1)-C(5)-C(4) 121.8(3) 
N(1)-C(5)-C(6) 114.6(3) C(4)-C(5)-C(6) 123.6(3) 
N(2)-C(6)-C(7) 110.2(3) N(2)-C(6)-C(5) 117.3(3) 
C(7)-C(6)-C(5) 132.5(3) C(8)-C(7)-C(6) 106.0(3) 
N(3)-C(8)-C(7) 106.3(3) N(3)-C(8)-C(9) 125.3(3) 
C(7)-C(8)-C(9) 128.4(3) C(10)-C(9)-C(14) 118.8(3) 
C(10)-C(9)-C(8) 124.3(3) C(14)-C(9)-C(8) 116.9(3) 
C(11)-C(10)-C(9) 120.5(3) C(12)-C(11)-C(10) 120.3(3) 
C(11)-C(12)-C(13) 119.3(3) C(14)-C(13)-C(12) 121.2(3) 
C(13)-C(14)-C(9) 119.8(3) N(1A)-Zn(1A)-N(2A) 77.08(9) 
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N(1A)-Zn(1A)-Cl(2A) 130.00(7) N(2A)-Zn(1A)-Cl(2A) 101.27(7) 
N(1A)-Zn(1A)-Cl(1A) 109.91(7) N(2A)-Zn(1A)-Cl(1A) 96.89(7) 
Cl(2A)-Zn(1A)-Cl(1A) 119.76(3) N(1A)-Zn(1A)-Cl(1A)#1 87.49(7) 
N(2A)-Zn(1A)-Cl(1A)#1 163.17(7) Cl(2A)-Zn(1A)-Cl(1A)#1 93.76(3) 
Cl(1A)-Zn(1A)-Cl(1A)#1 81.93(3) Zn(1A)-Cl(1A)-Zn(1A)#1 98.06(3) 
C(1A)-N(1A)-C(5A) 118.3(3) C(1A)-N(1A)-Zn(1A) 126.2(2) 
C(5A)-N(1A)-Zn(1A) 115.3(2) C(6A)-N(2A)-N(3A) 106.1(2) 
C(6A)-N(2A)-Zn(1A) 112.6(2) N(3A)-N(2A)-Zn(1A) 138.77(18) 
N(2A)-N(3A)-C(8A) 111.0(2) N(2A)-N(3A)-C(15A) 117.9(2) 
C(8A)-N(3A)-C(15A) 130.5(3) N(1A)-C(1A)-C(2A) 122.6(3) 
C(3A)-C(2A)-C(1A) 118.8(3) C(2A)-C(3A)-C(4A) 119.6(3) 
C(3A)-C(4A)-C(5A) 118.6(3) N(1A)-C(5A)-C(4A) 122.0(3) 
N(1A)-C(5A)-C(6A) 115.5(2) C(4A)-C(5A)-C(6A) 122.5(3) 
N(2A)-C(6A)-C(7A) 110.9(3) N(2A)-C(6A)-C(5A) 116.4(3) 
C(7A)-C(6A)-C(5A) 132.7(3) C(6A)-C(7A)-C(8A) 105.8(3) 
N(3A)-C(8A)-C(7A) 106.2(3) N(3A)-C(8A)-C(9A) 125.3(3) 
C(7A)-C(8A)-C(9A) 128.6(3) C(10A)-C(9A)-C(14A) 118.0(3) 
C(10A)-C(9A)-C(8A) 123.8(3) C(14A)-C(9A)-C(8A) 118.2(3) 
C(11A)-C(10A)-C(9A) 120.8(3) C(10A)-C(11A)-C(12A) 120.5(3) 
C(13A)-C(12A)-C(11A) 119.3(3) C(12A)-C(13A)-C(14A) 121.1(3) 
C(13A)-C(14A)-C(9A) 120.4(3) N(2B)-Zn(1B)-N(1B) 79.84(9) 
N(2B)-Zn(1B)-Cl(2B) 115.82(7) N(1B)-Zn(1B)-Cl(2B) 112.65(7) 
N(2B)-Zn(1B)-Cl(1B) 108.29(7) N(1B)-Zn(1B)-Cl(1B) 117.44(7) 
Cl(2B)-Zn(1B)-Cl(1B) 117.15(4) C(1B)-N(1B)-C(5B) 118.0(3) 
C(1B)-N(1B)-Zn(1B) 128.2(2) C(5B)-N(1B)-Zn(1B) 113.86(19) 
C(6B)-N(2B)-N(3B) 106.6(2) C(6B)-N(2B)-Zn(1B) 113.92(19) 
N(3B)-N(2B)-Zn(1B) 139.10(18) N(2B)-N(3B)-C(8B) 110.5(2) 
N(2B)-N(3B)-C(15B) 118.4(2) C(8B)-N(3B)-C(15B) 130.9(2) 
N(1B)-C(1B)-C(2B) 123.6(3) C(1B)-C(2B)-C(3B) 118.1(3) 
C(4B)-C(3B)-C(2B) 119.6(3) C(3B)-C(4B)-C(5B) 118.9(3) 
N(1B)-C(5B)-C(4B) 121.7(3) N(1B)-C(5B)-C(6B) 115.0(2) 
C(4B)-C(5B)-C(6B) 123.3(3) N(2B)-C(6B)-C(7B) 110.6(3) 
N(2B)-C(6B)-C(5B) 117.3(2) C(7B)-C(6B)-C(5B) 132.1(3) 
C(6B)-C(7B)-C(8B) 105.9(2) N(3B)-C(8B)-C(7B) 106.4(2) 
N(3B)-C(8B)-C(9B) 125.0(3) C(7B)-C(8B)-C(9B) 128.6(3) 
C(10B)-C(9B)-C(14B) 118.8(3) C(10B)-C(9B)-C(8B) 123.7(3) 
C(14B)-C(9B)-C(8B) 117.4(3) C(11B)-C(10B)-C(9B) 119.7(3) 
C(12B)-C(11B)-C(10B) 120.8(3) C(13B)-C(12B)-C(11B) 119.5(3) 
C(12B)-C(13B)-C(14B) 120.7(3) C(13B)-C(14B)-C(9B) 120.3(3) 
N(2C)-Zn(1C)-N(1C) 78.90(10) N(2C)-Zn(1C)-Cl(1C) 116.30(8) 
N(1C)-Zn(1C)-Cl(1C) 122.03(7) N(2C)-Zn(1C)-Cl(2C) 105.88(7) 
N(1C)-Zn(1C)-Cl(2C) 114.33(8) Cl(1C)-Zn(1C)-Cl(2C) 113.61(4) 
C(1C)-N(1C)-C(5C) 118.0(3) C(1C)-N(1C)-Zn(1C) 128.3(2) 
C(5C)-N(1C)-Zn(1C) 113.7(2) C(6C)-N(2C)-N(3C) 106.7(2) 
C(6C)-N(2C)-Zn(1C) 113.4(2) N(3C)-N(2C)-Zn(1C) 137.31(19) 
N(2C)-N(3C)-C(8C) 110.5(2) N(2C)-N(3C)-C(15C) 118.2(2) 
C(8C)-N(3C)-C(15C) 130.9(3) N(1C)-C(1C)-C(2C) 122.9(3) 
C(3C)-C(2C)-C(1C) 118.7(3) C(2C)-C(3C)-C(4C) 119.3(3) 
C(3C)-C(4C)-C(5C) 118.6(3) N(1C)-C(5C)-C(4C) 122.4(3) 
N(1C)-C(5C)-C(6C) 114.8(3) C(4C)-C(5C)-C(6C) 122.7(3) 
N(2C)-C(6C)-C(7C) 110.4(3) N(2C)-C(6C)-C(5C) 116.8(3) 
C(7C)-C(6C)-C(5C) 132.8(3) C(8C)-C(7C)-C(6C) 105.8(3) 
N(3C)-C(8C)-C(7C) 106.6(3) N(3C)-C(8C)-C(9C) 124.9(3) 
C(7C)-C(8C)-C(9C) 128.5(3) C(10C)-C(9C)-C(14C) 118.2(3) 
   - 317 -   
C(10C)-C(9C)-C(8C) 123.4(3) C(14C)-C(9C)-C(8C) 118.3(3) 
C(11C)-C(10C)-C(9C) 120.6(3) C(12C)-C(11C)-C(10C) 120.3(3) 
C(11C)-C(12C)-C(13C) 119.5(3) C(14C)-C(13C)-C(12C) 120.4(3) 
C(13C)-C(14C)-C(9C) 121.0(3)   
   
Symmetry transformations used to generate equivalent atoms: 
           #1 -x+1,-y+1,-z 
 
 




) for 1. The anisotropic displacement 






 U11 + ... + 2 h k a* b* U 
                                                                                                                         
  Atom  U11  U22  U33  U23  U13  U12 
                                                                                                                            
Zn(1) 43(1) 39(1) 20(1) 2(1) 6(1) 12(1) 
Cl(1) 59(1) 58(1) 40(1) 10(1) 27(1) 15(1) 
Cl(2) 61(1) 44(1) 27(1) -4(1) -7(1) 11(1) 
N(1) 26(1) 34(2) 26(1) 1(1) 5(1) 4(1) 
N(2) 32(2) 34(2) 22(1) 0(1) 5(1) 6(1) 
N(3) 30(2) 31(1) 23(1) 2(1) 4(1) 5(1) 
C(1) 24(2) 42(2) 32(2) 5(1) 6(1) 0(1) 
C(2) 31(2) 33(2) 43(2) 1(2) 11(2) 1(1) 
C(3) 37(2) 36(2) 36(2) -8(2) 10(2) -2(2) 
C(4) 31(2) 40(2) 23(2) 0(1) 6(1) 1(1) 
C(5) 23(2) 36(2) 23(1) 1(1) 5(1) 1(1) 
C(6) 24(2) 35(2) 24(2) -2(1) 6(1) 1(1) 
C(7) 25(2) 40(2) 20(1) -1(1) 5(1) 2(1) 
C(8) 22(2) 37(2) 23(1) -2(1) 3(1) 2(1) 
C(9) 22(2) 41(2) 27(2) 4(1) 7(1) 2(1) 
C(10) 27(2) 42(2) 30(2) -3(1) 6(1) 0(1) 
C(11) 35(2) 38(2) 45(2) 1(2) 15(2) -4(2) 
C(12) 58(3) 42(2) 48(2) 10(2) 17(2) -2(2) 
C(13) 72(3) 54(2) 32(2) 11(2) 6(2) -6(2) 
C(14) 50(2) 41(2) 28(2) 3(2) 5(2) -5(2) 
C(15) 57(2) 37(2) 27(2) -4(1) 8(2) 6(2) 
Zn(1A) 35(1) 41(1) 21(1) -5(1) 2(1) 7(1) 
Cl(1A) 40(1) 42(1) 27(1) 8(1) 10(1) 12(1) 
Cl(2A) 45(1) 42(1) 25(1) 2(1) -4(1) -5(1) 
N(1A) 29(1) 35(2) 20(1) -1(1) 6(1) 4(1) 
N(2A) 35(2) 30(2) 23(1) -2(1) 4(1) 3(1) 
N(3A) 33(2) 31(2) 24(1) -2(1) 2(1) 2(1) 
C(1A) 41(2) 34(2) 28(2) 4(1) 9(1) 5(2) 
C(2A) 38(2) 34(2) 34(2) 0(1) 10(2) 1(2) 
C(3A) 34(2) 36(2) 27(2) -8(1) 5(1) -1(1) 
C(4A) 28(2) 36(2) 21(1) 1(1) 6(1) 2(1) 
C(5A) 22(2) 36(2) 22(1) -1(1) 5(1) 3(1) 
C(6A) 23(2) 37(2) 23(1) -1(1) 5(1) 1(1) 
C(7A) 24(2) 36(2) 23(1) 0(1) 5(1) 3(1) 
C(8A) 22(2) 36(2) 26(2) -1(1) 2(1) 1(1) 
C(9A) 18(2) 36(2) 32(2) -1(1) 0(1) -2(1) 
C(10A) 26(2) 37(2) 32(2) -2(1) 5(1) -2(1) 
C(11A) 30(2) 39(2) 45(2) -4(2) 4(2) 0(2) 
C(12A) 30(2) 40(2) 49(2) 8(2) 3(2) -3(2) 
C(13A) 31(2) 52(2) 33(2) 7(2) 4(1) -2(2) 
C(14A) 28(2) 41(2) 32(2) -1(1) 6(1) 2(1) 
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C(15A) 52(2) 34(2) 30(2) -7(1) -6(2) 2(2) 
Zn(1B) 33(1) 35(1) 18(1) 0(1) 3(1) -1(1) 
Cl(1B) 41(1) 63(1) 28(1) -4(1) 13(1) -6(1) 
Cl(2B) 49(1) 47(1) 29(1) 1(1) -11(1) 1(1) 
N(1B) 23(1) 30(1) 23(1) 0(1) 3(1) -1(1) 
N(2B) 28(1) 27(1) 21(1) 2(1) 3(1) -2(1) 
N(3B) 27(1) 28(1) 20(1) 1(1) 4(1) -1(1) 
C(1B) 22(2) 37(2) 30(2) -4(1) 3(1) 2(1) 
C(2B) 32(2) 27(2) 42(2) -3(1) 6(2) 0(1) 
C(3B) 35(2) 30(2) 41(2) 5(1) 11(2) 0(1) 
C(4B) 28(2) 35(2) 26(2) 2(1) 8(1) -1(1) 
C(5B) 21(2) 31(2) 23(1) -3(1) 5(1) 0(1) 
C(6B) 22(2) 33(2) 21(1) 3(1) 5(1) 0(1) 
C(7B) 24(2) 31(2) 20(1) 2(1) 5(1) 1(1) 
C(8B) 21(2) 30(2) 21(1) 0(1) 5(1) -1(1) 
C(9B) 22(2) 35(2) 24(2) 1(1) 10(1) -2(1) 
C(10B) 21(2) 33(2) 28(2) 1(1) 7(1) -2(1) 
C(11B) 34(2) 32(2) 42(2) 1(1) 18(2) -2(1) 
C(12B) 46(2) 34(2) 37(2) -9(2) 19(2) -7(2) 
C(13B) 47(2) 47(2) 21(2) -6(1) 8(2) -1(2) 
C(14B) 35(2) 34(2) 25(2) 1(1) 9(1) 1(1) 
C(15B) 53(2) 33(2) 26(2) 5(1) 10(2) -1(2) 
Zn(1C) 40(1) 40(1) 23(1) -4(1) 8(1) -12(1) 
Cl(1C) 60(1) 52(1) 31(1) 1(1) -5(1) -12(1) 
Cl(2C) 56(1) 66(1) 45(1) -16(1) 28(1) -22(1) 
N(1C) 27(1) 33(2) 30(1) -5(1) 9(1) -5(1) 
N(2C) 30(1) 30(1) 26(1) 1(1) 8(1) -3(1) 
N(3C) 28(1) 31(1) 26(1) 2(1) 4(1) -3(1) 
C(1C) 30(2) 37(2) 38(2) -7(2) 12(1) -4(1) 
C(2C) 31(2) 28(2) 49(2) -4(2) 9(2) 1(1) 
C(3C) 29(2) 35(2) 42(2) 4(2) 4(2) 0(1) 
C(4C) 28(2) 35(2) 29(2) -2(1) 6(1) -2(1) 
C(5C) 21(2) 32(2) 27(2) -2(1) 6(1) -4(1) 
C(6C) 24(2) 33(2) 25(2) 1(1) 7(1) -2(1) 
C(7C) 24(2) 34(2) 24(2) -1(1) 7(1) -1(1) 
C(8C) 22(2) 33(2) 26(2) -1(1) 6(1) -2(1) 
C(9C) 18(2) 32(2) 35(2) -2(1) 2(1) 2(1) 
C(10C) 24(2) 34(2) 40(2) 0(2) 4(1) 2(1) 
C(11C) 32(2) 32(2) 55(2) -1(2) 3(2) -1(1) 
C(12C) 36(2) 34(2) 58(2) -17(2) -2(2) 3(2) 
C(13C) 33(2) 47(2) 37(2) -12(2) 1(2) 5(2) 
C(14C) 24(2) 36(2) 35(2) -6(1) 3(1) 0(1) 
C(15C) 43(2) 38(2) 33(2) 9(2) 2(2) 0(2) 
                                                                   
                                                                                                                         
 Table 5.   Hydrogen coordinates ( x 10
4
) and isotropic displacement 




) for 1. 
                                                                                                                         
  Atom   x   y   z  U(eq) 
                                                                                                                             
H(1) 1597 1808 4235 39 
H(2) 1642 1249 3165 42 
H(3) 1578 1582 1863 43 
H(4) 1528 2466 1674 38 
H(7) 1470 3453 1609 34 
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H(10) 2096 4983 3016 39 
H(11) 1971 5743 2280 46 
H(12) 1346 5740 890 58 
H(13) 860 4971 239 64 
H(14) 922 4214 966 48 
H(15A) 1287 4169 4388 61 
H(15B) 1147 4624 3738 61 
H(15C) 2201 4451 4172 61 
H(1A) 3891 5845 917 41 
H(2A) 4067 6334 2089 42 
H(3A) 4328 5924 3352 39 
H(4A) 4342 5028 3406 34 
H(7A) 4328 4049 3320 33 
H(10A) 4367 2604 1751 38 
H(11A) 4440 1807 2369 46 
H(12A) 4185 1726 3693 48 
H(13A) 3839 2450 4386 47 
H(14A) 3733 3249 3776 40 
H(15D) 4002 3174 633 60 
H(15E) 3069 3525 397 60 
H(15F) 3066 3043 984 60 
H(1B) 6609 5575 4483 36 
H(2B) 6746 6178 3506 41 
H(3B) 6747 5901 2178 41 
H(4B) 6666 5024 1887 35 
H(7B) 6602 4052 1718 30 
H(10B) 7085 2462 2910 33 
H(11B) 6864 1736 2086 42 
H(12B) 6124 1798 721 45 
H(13B) 5667 2595 163 46 
H(14B) 5876 3324 965 37 
H(15G) 7044 2934 4159 55 
H(15H) 6028 2785 3615 55 
H(15I) 6091 3206 4315 55 
H(1C) 8683 1873 725 41 
H(2C) 8904 1307 1815 43 
H(3C) 9252 1634 3143 43 
H(4C) 9290 2524 3337 37 
H(7C) 9338 3510 3396 33 
H(10C) 9540 5011 2059 40 
H(11C) 9753 5770 2805 48 
H(12C) 9460 5794 4123 53 
H(13C) 8947 5054 4690 48 
H(14C) 8725 4300 3951 38 
H(15J) 8960 4499 808 58 
H(15K) 8135 4681 1265 58 
H(15L) 7936 4225 619 58 
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 Table 6.   Dihedral angles [
o
] for 1. 
                                                                                                                         
  Atom1  -  Atom2  -  Atom3  -  Atom4  Dihedral 
                                                                                                                         
N(2) - Zn(1) - N(1) - C(1) 175.1(3) 
Cl(2) - Zn(1) - N(1) - C(1) 61.6(3) 
Cl(1) - Zn(1) - N(1) - C(1) -82.1(3) 
N(2) - Zn(1) - N(1) - C(5) -2.8(2) 
Cl(2) - Zn(1) - N(1) - C(5) -116.25(19) 
Cl(1) - Zn(1) - N(1) - C(5) 100.1(2) 
N(1) - Zn(1) - N(2) - C(6) 4.3(2) 
Cl(2) - Zn(1) - N(2) - C(6) 114.8(2) 
Cl(1) - Zn(1) - N(2) - C(6) -115.5(2) 
N(1) - Zn(1) - N(2) - N(3) 176.1(3) 
Cl(2) - Zn(1) - N(2) - N(3) -73.4(3) 
Cl(1) - Zn(1) - N(2) - N(3) 56.3(3) 
C(6) - N(2) - N(3) - C(8) -1.2(3) 
Zn(1) - N(2) - N(3) - C(8) -173.4(2) 
C(6) - N(2) - N(3) - C(15) 176.3(3) 
Zn(1) - N(2) - N(3) - C(15) 4.1(4) 
C(5) - N(1) - C(1) - C(2) -1.2(4) 
Zn(1) - N(1) - C(1) - C(2) -178.9(2) 
N(1) - C(1) - C(2) - C(3) -0.5(5) 
C(1) - C(2) - C(3) - C(4) 1.3(5) 
C(2) - C(3) - C(4) - C(5) -0.4(5) 
C(1) - N(1) - C(5) - C(4) 2.1(4) 
Zn(1) - N(1) - C(5) - C(4) -179.8(2) 
C(1) - N(1) - C(5) - C(6) -177.1(3) 
Zn(1) - N(1) - C(5) - C(6) 0.9(3) 
C(3) - C(4) - C(5) - N(1) -1.4(5) 
C(3) - C(4) - C(5) - C(6) 177.8(3) 
N(3) - N(2) - C(6) - C(7) 0.8(3) 
Zn(1) - N(2) - C(6) - C(7) 175.2(2) 
N(3) - N(2) - C(6) - C(5) -179.6(2) 
Zn(1) - N(2) - C(6) - C(5) -5.2(3) 
N(1) - C(5) - C(6) - N(2) 2.9(4) 
C(4) - C(5) - C(6) - N(2) -176.4(3) 
N(1) - C(5) - C(6) - C(7) -177.6(3) 
C(4) - C(5) - C(6) - C(7) 3.1(5) 
N(2) - C(6) - C(7) - C(8) -0.2(3) 
C(5) - C(6) - C(7) - C(8) -179.7(3) 
N(2) - N(3) - C(8) - C(7) 1.1(3) 
C(15) - N(3) - C(8) - C(7) -176.0(3) 
N(2) - N(3) - C(8) - C(9) 179.9(3) 
C(15) - N(3) - C(8) - C(9) 2.9(5) 
C(6) - C(7) - C(8) - N(3) -0.5(3) 
C(6) - C(7) - C(8) - C(9) -179.3(3) 
N(3) - C(8) - C(9) - C(10) 22.9(5) 
C(7) - C(8) - C(9) - C(10) -158.6(3) 
N(3) - C(8) - C(9) - C(14) -158.5(3) 
C(7) - C(8) - C(9) - C(14) 20.0(5) 
C(14) - C(9) - C(10) - C(11) 2.3(5) 
C(8) - C(9) - C(10) - C(11) -179.1(3) 
C(9) - C(10) - C(11) - C(12) -1.6(5) 
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C(10) - C(11) - C(12) - C(13) -0.4(6) 
C(11) - C(12) - C(13) - C(14) 1.7(6) 
C(12) - C(13) - C(14) - C(9) -1.0(6) 
C(10) - C(9) - C(14) - C(13) -1.0(5) 
C(8) - C(9) - C(14) - C(13) -179.7(3) 
N(1A) - Zn(1A) - Cl(1A) - Zn(1A)#1 -84.35(8) 
N(2A) - Zn(1A) - Cl(1A) - Zn(1A)#1 -163.07(7) 
Cl(2A) - Zn(1A) - Cl(1A) - Zn(1A)#1 89.73(4) 
Cl(1A)#1 - Zn(1A) - Cl(1A) - Zn(1A)#1 0.0 
N(2A) - Zn(1A) - N(1A) - C(1A) -171.5(3) 
Cl(2A) - Zn(1A) - N(1A) - C(1A) -77.5(3) 
Cl(1A) - Zn(1A) - N(1A) - C(1A) 95.8(3) 
Cl(1A)#1 - Zn(1A) - N(1A) - C(1A) 15.3(3) 
N(2A) - Zn(1A) - N(1A) - C(5A) 13.3(2) 
Cl(2A) - Zn(1A) - N(1A) - C(5A) 107.2(2) 
Cl(1A) - Zn(1A) - N(1A) - C(5A) -79.5(2) 
Cl(1A)#1 - Zn(1A) - N(1A) - C(5A) -160.0(2) 
N(1A) - Zn(1A) - N(2A) - C(6A) -15.6(2) 
Cl(2A) - Zn(1A) - N(2A) - C(6A) -144.4(2) 
Cl(1A) - Zn(1A) - N(2A) - C(6A) 93.3(2) 
Cl(1A)#1 - Zn(1A) - N(2A) - C(6A) 8.4(4) 
N(1A) - Zn(1A) - N(2A) - N(3A) -174.4(3) 
Cl(2A) - Zn(1A) - N(2A) - N(3A) 56.8(3) 
Cl(1A) - Zn(1A) - N(2A) - N(3A) -65.5(3) 
Cl(1A)#1 - Zn(1A) - N(2A) - N(3A) -150.4(2) 
C(6A) - N(2A) - N(3A) - C(8A) 0.3(3) 
Zn(1A) - N(2A) - N(3A) - C(8A) 160.0(2) 
C(6A) - N(2A) - N(3A) - C(15A) 172.4(3) 
Zn(1A) - N(2A) - N(3A) - C(15A) -27.9(4) 
C(5A) - N(1A) - C(1A) - C(2A) 1.9(5) 
Zn(1A) - N(1A) - C(1A) - C(2A) -173.2(2) 
N(1A) - C(1A) - C(2A) - C(3A) 0.3(5) 
C(1A) - C(2A) - C(3A) - C(4A) -1.6(5) 
C(2A) - C(3A) - C(4A) - C(5A) 0.5(5) 
C(1A) - N(1A) - C(5A) - C(4A) -3.0(4) 
Zn(1A) - N(1A) - C(5A) - C(4A) 172.6(2) 
C(1A) - N(1A) - C(5A) - C(6A) 175.0(3) 
Zn(1A) - N(1A) - C(5A) - C(6A) -9.4(3) 
C(3A) - C(4A) - C(5A) - N(1A) 1.8(4) 
C(3A) - C(4A) - C(5A) - C(6A) -176.0(3) 
N(3A) - N(2A) - C(6A) - C(7A) -0.2(3) 
Zn(1A) - N(2A) - C(6A) - C(7A) -165.8(2) 
N(3A) - N(2A) - C(6A) - C(5A) -178.6(2) 
Zn(1A) - N(2A) - C(6A) - C(5A) 15.7(3) 
N(1A) - C(5A) - C(6A) - N(2A) -4.8(4) 
C(4A) - C(5A) - C(6A) - N(2A) 173.2(3) 
N(1A) - C(5A) - C(6A) - C(7A) 177.2(3) 
C(4A) - C(5A) - C(6A) - C(7A) -4.8(5) 
N(2A) - C(6A) - C(7A) - C(8A) 0.0(3) 
C(5A) - C(6A) - C(7A) - C(8A) 178.1(3) 
N(2A) - N(3A) - C(8A) - C(7A) -0.4(3) 
C(15A) - N(3A) - C(8A) - C(7A) -171.1(3) 
N(2A) - N(3A) - C(8A) - C(9A) -179.3(3) 
C(15A) - N(3A) - C(8A) - C(9A) 10.0(5) 
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C(6A) - C(7A) - C(8A) - N(3A) 0.2(3) 
C(6A) - C(7A) - C(8A) - C(9A) 179.1(3) 
N(3A) - C(8A) - C(9A) - C(10A) 26.7(5) 
C(7A) - C(8A) - C(9A) - C(10A) -152.0(3) 
N(3A) - C(8A) - C(9A) - C(14A) -156.3(3) 
C(7A) - C(8A) - C(9A) - C(14A) 25.1(5) 
C(14A) - C(9A) - C(10A) - C(11A) 0.9(4) 
C(8A) - C(9A) - C(10A) - C(11A) 177.9(3) 
C(9A) - C(10A) - C(11A) - C(12A) -0.9(5) 
C(10A) - C(11A) - C(12A) - C(13A) 0.3(5) 
C(11A) - C(12A) - C(13A) - C(14A) 0.3(5) 
C(12A) - C(13A) - C(14A) - C(9A) -0.3(5) 
C(10A) - C(9A) - C(14A) - C(13A) -0.2(4) 
C(8A) - C(9A) - C(14A) - C(13A) -177.5(3) 
N(2B) - Zn(1B) - N(1B) - C(1B) -176.6(3) 
Cl(2B) - Zn(1B) - N(1B) - C(1B) -62.7(3) 
Cl(1B) - Zn(1B) - N(1B) - C(1B) 78.0(2) 
N(2B) - Zn(1B) - N(1B) - C(5B) 2.60(19) 
Cl(2B) - Zn(1B) - N(1B) - C(5B) 116.47(18) 
Cl(1B) - Zn(1B) - N(1B) - C(5B) -102.84(19) 
N(1B) - Zn(1B) - N(2B) - C(6B) -3.3(2) 
Cl(2B) - Zn(1B) - N(2B) - C(6B) -113.66(19) 
Cl(1B) - Zn(1B) - N(2B) - C(6B) 112.41(19) 
N(1B) - Zn(1B) - N(2B) - N(3B) -175.1(3) 
Cl(2B) - Zn(1B) - N(2B) - N(3B) 74.5(3) 
Cl(1B) - Zn(1B) - N(2B) - N(3B) -59.4(3) 
C(6B) - N(2B) - N(3B) - C(8B) 0.6(3) 
Zn(1B) - N(2B) - N(3B) - C(8B) 172.7(2) 
C(6B) - N(2B) - N(3B) - C(15B) -175.2(3) 
Zn(1B) - N(2B) - N(3B) - C(15B) -3.0(4) 
C(5B) - N(1B) - C(1B) - C(2B) 0.4(4) 
Zn(1B) - N(1B) - C(1B) - C(2B) 179.5(2) 
N(1B) - C(1B) - C(2B) - C(3B) 1.2(5) 
C(1B) - C(2B) - C(3B) - C(4B) -1.3(5) 
C(2B) - C(3B) - C(4B) - C(5B) -0.2(5) 
C(1B) - N(1B) - C(5B) - C(4B) -2.0(4) 
Zn(1B) - N(1B) - C(5B) - C(4B) 178.7(2) 
C(1B) - N(1B) - C(5B) - C(6B) 177.7(3) 
Zn(1B) - N(1B) - C(5B) - C(6B) -1.6(3) 
C(3B) - C(4B) - C(5B) - N(1B) 1.9(4) 
C(3B) - C(4B) - C(5B) - C(6B) -177.8(3) 
N(3B) - N(2B) - C(6B) - C(7B) -0.9(3) 
Zn(1B) - N(2B) - C(6B) - C(7B) -175.26(19) 
N(3B) - N(2B) - C(6B) - C(5B) 177.9(2) 
Zn(1B) - N(2B) - C(6B) - C(5B) 3.5(3) 
N(1B) - C(5B) - C(6B) - N(2B) -1.3(4) 
C(4B) - C(5B) - C(6B) - N(2B) 178.4(3) 
N(1B) - C(5B) - C(6B) - C(7B) 177.1(3) 
C(4B) - C(5B) - C(6B) - C(7B) -3.2(5) 
N(2B) - C(6B) - C(7B) - C(8B) 0.8(3) 
C(5B) - C(6B) - C(7B) - C(8B) -177.7(3) 
N(2B) - N(3B) - C(8B) - C(7B) 0.0(3) 
C(15B) - N(3B) - C(8B) - C(7B) 175.0(3) 
N(2B) - N(3B) - C(8B) - C(9B) -178.2(3) 
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C(15B) - N(3B) - C(8B) - C(9B) -3.1(5) 
C(6B) - C(7B) - C(8B) - N(3B) -0.5(3) 
C(6B) - C(7B) - C(8B) - C(9B) 177.6(3) 
N(3B) - C(8B) - C(9B) - C(10B) -28.5(4) 
C(7B) - C(8B) - C(9B) - C(10B) 153.8(3) 
N(3B) - C(8B) - C(9B) - C(14B) 152.6(3) 
C(7B) - C(8B) - C(9B) - C(14B) -25.1(4) 
C(14B) - C(9B) - C(10B) - C(11B) -3.5(4) 
C(8B) - C(9B) - C(10B) - C(11B) 177.6(3) 
C(9B) - C(10B) - C(11B) - C(12B) 0.9(5) 
C(10B) - C(11B) - C(12B) - C(13B) 1.8(5) 
C(11B) - C(12B) - C(13B) - C(14B) -1.8(5) 
C(12B) - C(13B) - C(14B) - C(9B) -0.9(5) 
C(10B) - C(9B) - C(14B) - C(13B) 3.5(5) 
C(8B) - C(9B) - C(14B) - C(13B) -177.5(3) 
N(2C) - Zn(1C) - N(1C) - C(1C) 171.8(3) 
Cl(1C) - Zn(1C) - N(1C) - C(1C) 57.6(3) 
Cl(2C) - Zn(1C) - N(1C) - C(1C) -85.6(3) 
N(2C) - Zn(1C) - N(1C) - C(5C) -11.3(2) 
Cl(1C) - Zn(1C) - N(1C) - C(5C) -125.54(19) 
Cl(2C) - Zn(1C) - N(1C) - C(5C) 91.2(2) 
N(1C) - Zn(1C) - N(2C) - C(6C) 14.0(2) 
Cl(1C) - Zn(1C) - N(2C) - C(6C) 134.34(19) 
Cl(2C) - Zn(1C) - N(2C) - C(6C) -98.4(2) 
N(1C) - Zn(1C) - N(2C) - N(3C) 172.6(3) 
Cl(1C) - Zn(1C) - N(2C) - N(3C) -67.0(3) 
Cl(2C) - Zn(1C) - N(2C) - N(3C) 60.2(3) 
C(6C) - N(2C) - N(3C) - C(8C) -0.5(3) 
Zn(1C) - N(2C) - N(3C) - C(8C) -160.0(2) 
C(6C) - N(2C) - N(3C) - C(15C) -174.6(3) 
Zn(1C) - N(2C) - N(3C) - C(15C) 25.8(4) 
C(5C) - N(1C) - C(1C) - C(2C) -1.5(5) 
Zn(1C) - N(1C) - C(1C) - C(2C) 175.2(2) 
N(1C) - C(1C) - C(2C) - C(3C) -0.5(5) 
C(1C) - C(2C) - C(3C) - C(4C) 1.8(5) 
C(2C) - C(3C) - C(4C) - C(5C) -1.0(5) 
C(1C) - N(1C) - C(5C) - C(4C) 2.4(4) 
Zn(1C) - N(1C) - C(5C) - C(4C) -174.8(2) 
C(1C) - N(1C) - C(5C) - C(6C) -175.6(3) 
Zn(1C) - N(1C) - C(5C) - C(6C) 7.2(3) 
C(3C) - C(4C) - C(5C) - N(1C) -1.1(4) 
C(3C) - C(4C) - C(5C) - C(6C) 176.7(3) 
N(3C) - N(2C) - C(6C) - C(7C) 0.8(3) 
Zn(1C) - N(2C) - C(6C) - C(7C) 165.9(2) 
N(3C) - N(2C) - C(6C) - C(5C) -179.6(2) 
Zn(1C) - N(2C) - C(6C) - C(5C) -14.6(3) 
N(1C) - C(5C) - C(6C) - N(2C) 4.9(4) 
C(4C) - C(5C) - C(6C) - N(2C) -173.1(3) 
N(1C) - C(5C) - C(6C) - C(7C) -175.6(3) 
C(4C) - C(5C) - C(6C) - C(7C) 6.4(5) 
N(2C) - C(6C) - C(7C) - C(8C) -0.8(3) 
C(5C) - C(6C) - C(7C) - C(8C) 179.7(3) 
N(2C) - N(3C) - C(8C) - C(7C) 0.0(3) 
C(15C) - N(3C) - C(8C) - C(7C) 173.1(3) 
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N(2C) - N(3C) - C(8C) - C(9C) 179.5(3) 
C(15C) - N(3C) - C(8C) - C(9C) -7.3(5) 
C(6C) - C(7C) - C(8C) - N(3C) 0.5(3) 
C(6C) - C(7C) - C(8C) - C(9C) -179.0(3) 
N(3C) - C(8C) - C(9C) - C(10C) -32.7(5) 
C(7C) - C(8C) - C(9C) - C(10C) 146.7(3) 
N(3C) - C(8C) - C(9C) - C(14C) 150.4(3) 
C(7C) - C(8C) - C(9C) - C(14C) -30.1(5) 
C(14C) - C(9C) - C(10C) - C(11C) 0.0(4) 
C(8C) - C(9C) - C(10C) - C(11C) -176.8(3) 
C(9C) - C(10C) - C(11C) - C(12C) 0.2(5) 
C(10C) - C(11C) - C(12C) - C(13C) -0.2(5) 
C(11C) - C(12C) - C(13C) - C(14C) 0.0(5) 
C(12C) - C(13C) - C(14C) - C(9C) 0.2(5) 
C(10C) - C(9C) - C(14C) - C(13C) -0.2(5) 
C(8C) - C(9C) - C(14C) - C(13C) 176.8(3) 
                                                                                                                         
                                                                                                                       
X-ray Structure Determination of Pyrazoline (102) 
 
 
Table 1.  Crystal data and structure refinement for pyrazoline (102). 
                                                        
 Identification code k10farm2 
 Empirical formula C14 H15 N4 S 
 Formula weight 271.36 
 Temperature 150(2) K 
 Wavelength 0.71073 Å 
 Crystal system Monoclinic 
 Space group P21/n 
 Unit cell dimensions a = 9.7950(2)Å  = 90
o
 
       b = 14.7280(3)Å  = 107.768(1)
o
 
       c = 10.0360(2)Å  = 90
o
 
 Volume 1378.74(5) Å
3
 
 Z 4 
   - 325 -   
 Density (calculated) 1.307 Mg/m
3
 
 Absorption coefficient 0.227 mm
-1
 
 F(000) 572 
 Crystal size .35 x .35 x .12 mm 
 Theta range for data collection 3.52 to 27.52
o
 
 Index ranges -12<=h<=12; -19<=k<=19; -13<=l<=13 
 Reflections collected 24456 
 Independent reflections 3152 [R(int) = 0.0669] 
  2385 
 Data Completeness 0.996 
 Absorption correction Semi-empirical from equivalents 
 Max. and min. transmission 0.938 and 0.716 
 Refinement method Full-matrix least-squares on F
2
 
 Data / restraints / parameters 3152 / 2 / 190 
 Goodness-of-fit on F
2
 1.025 
  R1 = 0.0388   wR2 = 0.0882 
 R indices (all data) R1 = 0.0604  wR2 = 0.0977 






H1A and H1B located and refined at a distance of 0.98Å from N1. 
 
Hydrogen bonding in the lattice. 
 
Hydrogen bonds with  H..A < r(A) + 2.000 Angstroms  and  <DHA > 110 deg. 
 
 D-H           d(D-H)   d(H..A)   <DHA    d(D..A)   A 
 
 N1-H1A         0.974    2.131   151.06    3.020    N4 [ x-1/2, -y+1/2, z+1/2 ] 
 
 N1-H1B         0.973    2.685   153.02    3.579    S1 [ x-1/2, -y+1/2, z-1/2 ] 
 
 
Table 2.  Atomic coordinates ( x 10
4





1.U(eq) is defined as one third of the trace of the orthogonalized Uij tensor. 
                                                             
                                                             
  Atom   x   y   z  U(eq) 
                                  
S(1) 4628(1) 1778(1) 10745(1) 31(1) 
N(1) 2367(2) 2474(1) 8805(2) 29(1) 
N(2) 4541(1) 2782(1) 8521(1) 22(1) 
N(3) 3811(1) 3255(1) 7308(1) 21(1) 
N(4) 4898(1) 3550(1) 4307(1) 24(1) 
C(1) 3790(2) 2369(1) 9288(2) 22(1) 
C(2) 6091(2) 2733(1) 8703(2) 21(1) 
C(3) 6924(2) 3463(1) 9689(2) 21(1) 
C(4) 6280(2) 4048(1) 10399(2) 27(1) 
C(5) 7078(2) 4704(1) 11299(2) 35(1) 
C(6) 8530(2) 4781(1) 11503(2) 39(1) 
C(7) 9185(2) 4210(1) 10789(2) 36(1) 
C(8) 8388(2) 3558(1) 9887(2) 27(1) 
C(9) 6100(2) 2885(1) 7186(2) 22(1) 
C(10) 4676(2) 3346(1) 6575(2) 19(1) 
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C(11) 4195(2) 3800(1) 5208(2) 19(1) 
C(12) 4427(2) 3897(1) 3010(2) 28(1) 
C(13) 3310(2) 4510(1) 2582(2) 28(1) 
C(14) 2626(2) 4782(1) 3531(2) 27(1) 
C(15) 3063(2) 4417(1) 4866(2) 24(1) 
                                    
 
 Table 3.   Bond lengths [Å] and angles [
o
] for 1. 
  
S(1)-C(1) 1.6842(16) N(1)-C(1) 1.338(2) 
N(1)-H(1A) 0.974(5) N(1)-H(1B) 0.973(5) 
N(2)-C(1) 1.359(2) N(2)-N(3) 1.3960(17) 
N(2)-C(2) 1.4748(19) N(3)-C(10) 1.2870(19) 
N(4)-C(12) 1.343(2) N(4)-C(11) 1.3440(19) 
C(2)-C(3) 1.519(2) C(2)-C(9) 1.541(2) 
C(2)-H(2) 1.0000 C(3)-C(4) 1.386(2) 
C(3)-C(8) 1.393(2) C(4)-C(5) 1.390(2) 
C(4)-H(4) 0.9500 C(5)-C(6) 1.379(3) 
C(5)-H(5) 0.9500 C(6)-C(7) 1.384(3) 
C(6)-H(6) 0.9500 C(7)-C(8) 1.385(2) 
C(7)-H(7) 0.9500 C(8)-H(8) 0.9500 
C(9)-C(10) 1.504(2) C(9)-H(9A) 0.9900 
C(9)-H(9B) 0.9900 C(10)-C(11) 1.468(2) 
C(11)-C(15) 1.394(2) C(12)-C(13) 1.382(2) 
C(12)-H(12) 0.9500 C(13)-C(14) 1.380(2) 
C(13)-H(13) 0.9500 C(14)-C(15) 1.384(2) 
C(14)-H(14) 0.9500 C(15)-H(15) 0.9500 
                                         
C(1)-N(1)-H(1A) 117.5(13) C(1)-N(1)-H(1B) 120.9(12) 
H(1A)-N(1)-H(1B) 120.4(17) C(1)-N(2)-N(3) 119.74(12) 
C(1)-N(2)-C(2) 128.48(13) N(3)-N(2)-C(2) 111.48(11) 
C(10)-N(3)-N(2) 107.42(12) C(12)-N(4)-C(11) 116.95(14) 
N(1)-C(1)-N(2) 115.28(14) N(1)-C(1)-S(1) 123.48(12) 
N(2)-C(1)-S(1) 121.23(12) N(2)-C(2)-C(3) 111.95(12) 
N(2)-C(2)-C(9) 100.77(11) C(3)-C(2)-C(9) 112.13(12) 
N(2)-C(2)-H(2) 110.5 C(3)-C(2)-H(2) 110.5 
C(9)-C(2)-H(2) 110.5 C(4)-C(3)-C(8) 118.34(15) 
C(4)-C(3)-C(2) 122.43(14) C(8)-C(3)-C(2) 119.23(14) 
C(3)-C(4)-C(5) 120.80(16) C(3)-C(4)-H(4) 119.6 
C(5)-C(4)-H(4) 119.6 C(6)-C(5)-C(4) 120.29(17) 
C(6)-C(5)-H(5) 119.9 C(4)-C(5)-H(5) 119.9 
C(5)-C(6)-C(7) 119.55(17) C(5)-C(6)-H(6) 120.2 
C(7)-C(6)-H(6) 120.2 C(6)-C(7)-C(8) 120.13(16) 
C(6)-C(7)-H(7) 119.9 C(8)-C(7)-H(7) 119.9 
C(7)-C(8)-C(3) 120.87(16) C(7)-C(8)-H(8) 119.6 
C(3)-C(8)-H(8) 119.6 C(10)-C(9)-C(2) 100.62(12) 
C(10)-C(9)-H(9A) 111.6 C(2)-C(9)-H(9A) 111.6 
C(10)-C(9)-H(9B) 111.6 C(2)-C(9)-H(9B) 111.6 
H(9A)-C(9)-H(9B) 109.4 N(3)-C(10)-C(11) 120.13(13) 
N(3)-C(10)-C(9) 114.22(13) C(11)-C(10)-C(9) 125.43(13) 
N(4)-C(11)-C(15) 123.04(14) N(4)-C(11)-C(10) 114.83(13) 
C(15)-C(11)-C(10) 122.10(13) N(4)-C(12)-C(13) 123.74(15) 
N(4)-C(12)-H(12) 118.1 C(13)-C(12)-H(12) 118.1 
C(14)-C(13)-C(12) 118.66(15) C(14)-C(13)-H(13) 120.7 
C(12)-C(13)-H(13) 120.7 C(13)-C(14)-C(15) 118.95(15) 
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C(13)-C(14)-H(14) 120.5 C(15)-C(14)-H(14) 120.5 
C(14)-C(15)-C(11) 118.61(14) C(14)-C(15)-H(15) 120.7 
C(11)-C(15)-H(15) 120.7   
  
                                                            




) for 1. The anisotropic displacement factor 






 U11 + ... + 2 h k a* b* U 
                                                                                 
  Atom  U11  U22  U33  U23  U13  U12 
                                                
S(1) 28(1) 36(1) 25(1) 10(1) 4(1) -5(1) 
N(1) 21(1) 42(1) 25(1) 8(1) 8(1) -4(1) 
N(2) 17(1) 28(1) 20(1) 4(1) 5(1) -1(1) 
N(3) 21(1) 23(1) 16(1) 0(1) 4(1) -2(1) 
N(4) 25(1) 28(1) 20(1) 1(1) 11(1) 0(1) 
C(1) 22(1) 25(1) 20(1) -1(1) 7(1) -5(1) 
C(2) 17(1) 23(1) 22(1) 3(1) 6(1) 1(1) 
C(3) 22(1) 23(1) 17(1) 6(1) 4(1) 1(1) 
C(4) 28(1) 33(1) 21(1) 1(1) 9(1) -2(1) 
C(5) 43(1) 36(1) 26(1) -7(1) 11(1) -1(1) 
C(6) 40(1) 34(1) 35(1) -5(1) -1(1) -8(1) 
C(7) 24(1) 32(1) 44(1) 2(1) -1(1) -4(1) 
C(8) 24(1) 24(1) 33(1) 3(1) 6(1) 2(1) 
C(9) 21(1) 25(1) 21(1) -2(1) 7(1) 0(1) 
C(10) 20(1) 20(1) 18(1) -3(1) 7(1) -2(1) 
C(11) 19(1) 20(1) 17(1) -3(1) 7(1) -5(1) 
C(12) 33(1) 34(1) 21(1) 1(1) 13(1) 0(1) 
C(13) 31(1) 29(1) 21(1) 7(1) 4(1) -3(1) 
C(14) 23(1) 24(1) 29(1) 2(1) 3(1) 1(1) 
C(15) 24(1) 24(1) 25(1) -3(1) 9(1) -1(1) 
  
 Table 5.   Hydrogen coordinates ( x 10
4




) for 1. 
                                     
  Atom   x   y   z  U(eq) 
                                  
H(2) 6473 2117 9040 25 
H(4) 5280 3999 10268 32 
H(5) 6621 5101 11775 42 
H(6) 9078 5224 12130 47 
H(7) 10184 4264 10918 43 
H(8) 8845 3171 9396 33 
H(9A) 6905 3280 7147 27 
H(9B) 6150 2303 6708 27 
H(12) 4889 3712 2349 34 
H(13) 3018 4739 1653 33 
H(14) 1868 5212 3272 32 
H(15) 2600 4585 5535 28 
H(1A) 1791(19) 2159(13) 9300(20) 55(6) 
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Table 6.   Dihedral angles [
o
] for 1. 
                                         
  Atom1  -  Atom2  -  Atom3  -  Atom4  Dihedral 
                                                  
C(1) - N(2) - N(3) - C(10) -161.42(14) 
C(2) - N(2) - N(3) - C(10) 12.75(16) 
N(3) - N(2) - C(1) - N(1) -1.3(2) 
C(2) - N(2) - C(1) - N(1) -174.40(14) 
N(3) - N(2) - C(1) - S(1) 179.10(11) 
C(2) - N(2) - C(1) - S(1) 6.0(2) 
C(1) - N(2) - C(2) - C(3) -89.28(18) 
N(3) - N(2) - C(2) - C(3) 97.19(14) 
C(1) - N(2) - C(2) - C(9) 151.37(15) 
N(3) - N(2) - C(2) - C(9) -22.16(15) 
N(2) - C(2) - C(3) - C(4) 4.7(2) 
C(9) - C(2) - C(3) - C(4) 117.11(16) 
N(2) - C(2) - C(3) - C(8) -174.86(13) 
C(9) - C(2) - C(3) - C(8) -62.44(18) 
C(8) - C(3) - C(4) - C(5) -0.8(2) 
C(2) - C(3) - C(4) - C(5) 179.62(15) 
C(3) - C(4) - C(5) - C(6) -0.2(3) 
C(4) - C(5) - C(6) - C(7) 1.0(3) 
C(5) - C(6) - C(7) - C(8) -0.7(3) 
C(6) - C(7) - C(8) - C(3) -0.4(3) 
C(4) - C(3) - C(8) - C(7) 1.2(2) 
C(2) - C(3) - C(8) - C(7) -179.28(15) 
N(2) - C(2) - C(9) - C(10) 21.41(14) 
C(3) - C(2) - C(9) - C(10) -97.81(14) 
N(2) - N(3) - C(10) - C(11) 178.38(12) 
N(2) - N(3) - C(10) - C(9) 3.41(17) 
C(2) - C(9) - C(10) - N(3) -16.74(16) 
C(2) - C(9) - C(10) - C(11) 168.61(13) 
C(12) - N(4) - C(11) - C(15) -2.5(2) 
C(12) - N(4) - C(11) - C(10) 175.33(13) 
N(3) - C(10) - C(11) - N(4) -154.21(14) 
C(9) - C(10) - C(11) - N(4) 20.1(2) 
N(3) - C(10) - C(11) - C(15) 23.7(2) 
C(9) - C(10) - C(11) - C(15) -161.97(14) 
C(11) - N(4) - C(12) - C(13) 2.2(2) 
N(4) - C(12) - C(13) - C(14) -0.3(3) 
C(12) - C(13) - C(14) - C(15) -1.4(2) 
C(13) - C(14) - C(15) - C(11) 1.0(2) 
N(4) - C(11) - C(15) - C(14) 1.0(2) 
C(10) - C(11) - C(15) - C(14) -176.75(14) 
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Table 1.  Crystal data and structure refinement for  pyrazoline (105). 
                                                        
 Identification code k11farm1 
 Empirical formula C24 H23 N3 O4 
 Formula weight 417.45 
 Temperature 150(2) K 
 Wavelength 0.71073 Å 
 Crystal system Orthorhombic 
 Space group Pbca 
 Unit cell dimensions 
o
 
       b = 22.0950(2)Å 
o
 
       
o
 
 Volume 4100.73(8) Å
3
 
 Z 8 
 Density (calculated) 1.352 Mg/m
3
 
 Absorption coefficient 0.093 mm
-1
 
 F(000) 1760 
 Crystal size 0.40 x 0.25 x 0.25 mm 
 Theta range for data collection 3.54 to 27.47
o
 
 Index ranges -8<=h<=9; -28<=k<=27; -34<=l<=34 
 Reflections collected 56599 
 Independent reflections 4679 [R(int) = 0.0645] 
  3531 
 Data Completeness 0.997 
 Absorption correction Semi-empirical from equivalents 
 Max. and min. transmission 0.982 and 0.893 
 Refinement method Full-matrix least-squares on F
2
 
 Data / restraints / parameters 4679 / 0 / 283 
 Goodness-of-fit on F
2
 1.051 
  R1 = 0.0422   wR2 = 0.0882 
 R indices (all data) R1 = 0.0649  wR2 = 0.0991 
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 Table 2.  Atomic coordinates ( x 10
4





1.U(eq) is defined  as one third of the trace of the orthogonalized Uij tensor. 
                                                             
                                                            
  Atom   x   y   z  U(eq) 
                                  
O(1) 8672(2) 1985(1) 7146(1) 34(1) 
O(2) 13646(1) 441(1) 6698(1) 32(1) 
O(3) 12242(1) -195(1) 5936(1) 29(1) 
O(4) 8769(2) 32(1) 5556(1) 36(1) 
N(1) 6394(2) 2016(1) 6564(1) 25(1) 
N(2) 5409(2) 1815(1) 6142(1) 25(1) 
N(3) 982(2) 2382(1) 5679(1) 31(1) 
C(1) 8030(2) 1763(1) 6756(1) 25(1) 
C(2) 9030(2) 1235(1) 6514(1) 23(1) 
C(3) 10824(2) 1096(1) 6719(1) 24(1) 
C(4) 11870(2) 613(1) 6532(1) 23(1) 
C(5) 11148(2) 263(1) 6140(1) 24(1) 
C(6) 9351(2) 399(1) 5941(1) 26(1) 
C(7) 8287(2) 882(1) 6126(1) 26(1) 
C(8) 14362(2) 728(1) 7139(1) 32(1) 
C(9) 11790(2) -777(1) 6138(1) 38(1) 
C(10) 6969(2) 171(1) 5328(1) 41(1) 
C(11) 5385(2) 2514(1) 6834(1) 24(1) 
C(12) 3449(2) 2530(1) 6551(1) 26(1) 
C(13) 3785(2) 2096(1) 6126(1) 24(1) 
C(14) 2400(2) 1975(1) 5720(1) 25(1) 
C(15) 2544(2) 1469(1) 5410(1) 29(1) 
C(16) 1184(2) 1382(1) 5039(1) 34(1) 
C(17) -269(2) 1802(1) 4988(1) 34(1) 
C(18) -314(2) 2286(1) 5315(1) 35(1) 
C(19) 6439(2) 3111(1) 6804(1) 26(1) 
C(20) 7541(2) 3265(1) 6388(1) 37(1) 
C(21) 8358(2) 3836(1) 6354(1) 51(1) 
C(22) 8092(3) 4255(1) 6730(1) 58(1) 
C(23) 7013(3) 4104(1) 7147(1) 55(1) 
C(24) 6190(2) 3533(1) 7187(1) 38(1) 







 Table 3.   Bond lengths [Å] and angles [
o
] for 1. 
  
O(1)-C(1) 1.2310(17) O(2)-C(4) 1.3690(17) 
O(2)-C(8) 1.4238(18) O(3)-C(5) 1.3787(16) 
O(3)-C(9) 1.4294(18) O(4)-C(6) 1.3670(17) 
O(4)-C(10) 1.4276(19) N(1)-C(1) 1.3705(18) 
N(1)-N(2) 1.3873(16) N(1)-C(11) 1.4921(17) 
N(2)-C(13) 1.2918(18) N(3)-C(18) 1.341(2) 
N(3)-C(14) 1.3421(18) C(1)-C(2) 1.5041(19) 
C(2)-C(7) 1.393(2) C(2)-C(3) 1.400(2) 
C(3)-C(4) 1.3843(19) C(3)-H(3) 0.9500 
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C(4)-C(5) 1.394(2) C(5)-C(6) 1.394(2) 
C(6)-C(7) 1.389(2) C(7)-H(7) 0.9500 
C(8)-H(8A) 0.9800 C(8)-H(8B) 0.9800 
C(8)-H(8C) 0.9800 C(9)-H(9A) 0.9800 
C(9)-H(9B) 0.9800 C(9)-H(9C) 0.9800 
C(10)-H(10A) 0.9800 C(10)-H(10B) 0.9800 
C(10)-H(10C) 0.9800 C(11)-C(19) 1.5117(19) 
C(11)-C(12) 1.5468(19) C(11)-H(11) 1.0000 
C(12)-C(13) 1.500(2) C(12)-H(12A) 0.9900 
C(12)-H(12B) 0.9900 C(13)-C(14) 1.473(2) 
C(14)-C(15) 1.395(2) C(15)-C(16) 1.381(2) 
C(15)-H(15) 0.9500 C(16)-C(17) 1.380(2) 
C(16)-H(16) 0.9500 C(17)-C(18) 1.379(2) 
C(17)-H(17) 0.9500 C(18)-H(18) 0.9500 
C(19)-C(20) 1.389(2) C(19)-C(24) 1.391(2) 
C(20)-C(21) 1.387(2) C(20)-H(20) 0.9500 
C(21)-C(22) 1.375(3) C(21)-H(21) 0.9500 
C(22)-C(23) 1.382(3) C(22)-H(22) 0.9500 
C(23)-C(24) 1.391(3) C(23)-H(23) 0.9500 
C(24)-H(24) 0.9500   
     
C(4)-O(2)-C(8) 117.34(11) C(5)-O(3)-C(9) 113.00(11) 
C(6)-O(4)-C(10) 116.84(11) C(1)-N(1)-N(2) 125.76(11) 
C(1)-N(1)-C(11) 120.92(11) N(2)-N(1)-C(11) 113.05(11) 
C(13)-N(2)-N(1) 107.96(11) C(18)-N(3)-C(14) 116.80(13) 
O(1)-C(1)-N(1) 117.08(12) O(1)-C(1)-C(2) 120.08(13) 
N(1)-C(1)-C(2) 122.84(12) C(7)-C(2)-C(3) 119.87(13) 
C(7)-C(2)-C(1) 125.41(13) C(3)-C(2)-C(1) 114.70(12) 
C(4)-C(3)-C(2) 120.04(13) C(4)-C(3)-H(3) 120.0 
C(2)-C(3)-H(3) 120.0 O(2)-C(4)-C(3) 125.15(13) 
O(2)-C(4)-C(5) 114.44(12) C(3)-C(4)-C(5) 120.40(13) 
O(3)-C(5)-C(4) 120.14(12) O(3)-C(5)-C(6) 120.46(13) 
C(4)-C(5)-C(6) 119.33(12) O(4)-C(6)-C(7) 124.25(13) 
O(4)-C(6)-C(5) 115.03(12) C(7)-C(6)-C(5) 120.71(13) 
C(6)-C(7)-C(2) 119.63(13) C(6)-C(7)-H(7) 120.2 
C(2)-C(7)-H(7) 120.2 O(2)-C(8)-H(8A) 109.5 
O(2)-C(8)-H(8B) 109.5 H(8A)-C(8)-H(8B) 109.5 
O(2)-C(8)-H(8C) 109.5 H(8A)-C(8)-H(8C) 109.5 
H(8B)-C(8)-H(8C) 109.5 O(3)-C(9)-H(9A) 109.5 
O(3)-C(9)-H(9B) 109.5 H(9A)-C(9)-H(9B) 109.5 
O(3)-C(9)-H(9C) 109.5 H(9A)-C(9)-H(9C) 109.5 
H(9B)-C(9)-H(9C) 109.5 O(4)-C(10)-H(10A) 109.5 
O(4)-C(10)-H(10B) 109.5 H(10A)-C(10)-H(10B) 109.5 
O(4)-C(10)-H(10C) 109.5 H(10A)-C(10)-H(10C) 109.5 
H(10B)-C(10)-H(10C) 109.5 N(1)-C(11)-C(19) 112.84(11) 
N(1)-C(11)-C(12) 101.14(11) C(19)-C(11)-C(12) 112.32(11) 
N(1)-C(11)-H(11) 110.1 C(19)-C(11)-H(11) 110.1 
C(12)-C(11)-H(11) 110.1 C(13)-C(12)-C(11) 102.50(11) 
C(13)-C(12)-H(12A) 111.3 C(11)-C(12)-H(12A) 111.3 
C(13)-C(12)-H(12B) 111.3 C(11)-C(12)-H(12B) 111.3 
H(12A)-C(12)-H(12B) 109.2 N(2)-C(13)-C(14) 120.86(13) 
N(2)-C(13)-C(12) 114.72(12) C(14)-C(13)-C(12) 124.40(12) 
N(3)-C(14)-C(15) 122.79(13) N(3)-C(14)-C(13) 115.03(13) 
C(15)-C(14)-C(13) 122.17(13) C(16)-C(15)-C(14) 118.97(14) 
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C(16)-C(15)-H(15) 120.5 C(14)-C(15)-H(15) 120.5 
C(17)-C(16)-C(15) 118.79(14) C(17)-C(16)-H(16) 120.6 
C(15)-C(16)-H(16) 120.6 C(18)-C(17)-C(16) 118.43(14) 
C(18)-C(17)-H(17) 120.8 C(16)-C(17)-H(17) 120.8 
N(3)-C(18)-C(17) 124.20(14) N(3)-C(18)-H(18) 117.9 
C(17)-C(18)-H(18) 117.9 C(20)-C(19)-C(24) 119.25(14) 
C(20)-C(19)-C(11) 121.66(13) C(24)-C(19)-C(11) 118.94(14) 
C(21)-C(20)-C(19) 120.06(17) C(21)-C(20)-H(20) 120.0 
C(19)-C(20)-H(20) 120.0 C(22)-C(21)-C(20) 120.71(19) 
C(22)-C(21)-H(21) 119.6 C(20)-C(21)-H(21) 119.6 
C(21)-C(22)-C(23) 119.58(17) C(21)-C(22)-H(22) 120.2 
C(23)-C(22)-H(22) 120.2 C(22)-C(23)-C(24) 120.34(18) 
C(22)-C(23)-H(23) 119.8 C(24)-C(23)-H(23) 119.8 
C(19)-C(24)-C(23) 120.05(18) C(19)-C(24)-H(24) 120.0 
C(23)-C(24)-H(24) 120.0   
  
                                                            




) for 1. The anisotropic displacement 






 U11 + ... + 2 h k a* b* U 
                                                                                 
  Atom  U11  U22  U33  U23  U13  U12 
                                                
O(1) 36(1) 34(1) 32(1) -10(1) -10(1) 9(1) 
O(2) 22(1) 35(1) 39(1) -10(1) -7(1) 7(1) 
O(3) 26(1) 28(1) 33(1) -4(1) 3(1) 5(1) 
O(4) 34(1) 37(1) 37(1) -15(1) -14(1) 11(1) 
N(1) 24(1) 22(1) 28(1) -4(1) -3(1) 3(1) 
N(2) 25(1) 24(1) 24(1) 1(1) -3(1) 1(1) 
N(3) 31(1) 33(1) 29(1) 1(1) -4(1) 9(1) 
C(1) 25(1) 22(1) 26(1) 0(1) -2(1) 1(1) 
C(2) 24(1) 21(1) 24(1) 2(1) 0(1) 0(1) 
C(3) 23(1) 23(1) 25(1) 0(1) -1(1) -2(1) 
C(4) 18(1) 25(1) 26(1) 3(1) 0(1) 0(1) 
C(5) 23(1) 23(1) 26(1) 0(1) 4(1) 2(1) 
C(6) 28(1) 25(1) 25(1) -2(1) -2(1) 0(1) 
C(7) 25(1) 25(1) 28(1) -1(1) -4(1) 4(1) 
C(8) 22(1) 36(1) 38(1) -6(1) -5(1) 1(1) 
C(9) 31(1) 25(1) 59(1) -3(1) -1(1) 3(1) 
C(10) 38(1) 44(1) 42(1) -15(1) -18(1) 11(1) 
C(11) 23(1) 23(1) 27(1) -1(1) 3(1) 3(1) 
C(12) 23(1) 22(1) 33(1) -2(1) 0(1) 0(1) 
C(13) 23(1) 21(1) 27(1) 4(1) 2(1) 0(1) 
C(14) 23(1) 25(1) 26(1) 6(1) 2(1) 1(1) 
C(15) 28(1) 26(1) 35(1) 1(1) -3(1) 3(1) 
C(16) 37(1) 29(1) 36(1) -2(1) -5(1) 0(1) 
C(17) 32(1) 38(1) 31(1) 2(1) -9(1) 2(1) 
C(18) 34(1) 40(1) 32(1) 1(1) -6(1) 12(1) 
C(19) 20(1) 23(1) 34(1) -1(1) -4(1) 3(1) 
C(20) 28(1) 32(1) 50(1) 3(1) 8(1) 1(1) 
C(21) 28(1) 43(1) 82(2) 19(1) 2(1) -7(1) 
C(22) 43(1) 29(1) 103(2) 7(1) -26(1) -11(1) 
C(23) 58(1) 30(1) 77(2) -17(1) -26(1) 3(1) 
C(24) 39(1) 32(1) 43(1) -11(1) -7(1) 5(1) 
 
 Table 5.   Hydrogen coordinates ( x 10
4




) for 1. 
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  Atom   x   y   z  U(eq) 
                                  
H(3) 11325 1333 6987 28 
H(7) 7060 970 5990 31 
H(8A) 14436 1166 7083 48 
H(8B) 15643 571 7215 48 
H(8C) 13502 645 7422 48 
H(9A) 12140 -789 6495 57 
H(9B) 12509 -1089 5956 57 
H(9C) 10413 -853 6103 57 
H(10A) 5941 115 5575 62 
H(10B) 6755 -100 5042 62 
H(10C) 6975 591 5212 62 
H(11) 5175 2400 7194 29 
H(12A) 2385 2393 6769 32 
H(12B) 3162 2941 6424 32 
H(15) 3561 1187 5452 35 
H(16) 1248 1040 4823 40 
H(17) -1215 1758 4734 41 
H(18) -1328 2570 5280 42 
H(20) 7736 2978 6126 44 
H(21) 9110 3938 6069 61 
H(22) 8646 4646 6702 70 
H(23) 6833 4391 7408 66 
H(24) 5456 3430 7475 46 
  
 
Table 6.   Dihedral angles [
o
] for 1. 
                                         
  Atom1  -  Atom2  -  Atom3  -  Atom4  Dihedral 
                                                  
C(1) - N(1) - N(2) - C(13) 169.20(13) 
C(11) - N(1) - N(2) - C(13) -4.79(15) 
N(2) - N(1) - C(1) - O(1) -177.09(13) 
C(11) - N(1) - C(1) - O(1) -3.5(2) 
N(2) - N(1) - C(1) - C(2) 2.6(2) 
C(11) - N(1) - C(1) - C(2) 176.19(12) 
O(1) - C(1) - C(2) - C(7) 168.54(14) 
N(1) - C(1) - C(2) - C(7) -11.2(2) 
O(1) - C(1) - C(2) - C(3) -9.42(19) 
N(1) - C(1) - C(2) - C(3) 170.87(13) 
C(7) - C(2) - C(3) - C(4) 0.9(2) 
C(1) - C(2) - C(3) - C(4) 179.01(12) 
C(8) - O(2) - C(4) - C(3) 8.8(2) 
C(8) - O(2) - C(4) - C(5) -172.17(12) 
C(2) - C(3) - C(4) - O(2) 179.03(13) 
C(2) - C(3) - C(4) - C(5) 0.0(2) 
C(9) - O(3) - C(5) - C(4) 97.25(16) 
C(9) - O(3) - C(5) - C(6) -85.70(16) 
O(2) - C(4) - C(5) - O(3) -2.82(19) 
C(3) - C(4) - C(5) - O(3) 176.28(12) 
O(2) - C(4) - C(5) - C(6) -179.90(12) 
C(3) - C(4) - C(5) - C(6) -0.8(2) 
C(10) - O(4) - C(6) - C(7) 1.5(2) 
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C(10) - O(4) - C(6) - C(5) -177.62(14) 
O(3) - C(5) - C(6) - O(4) 2.7(2) 
C(4) - C(5) - C(6) - O(4) 179.79(13) 
O(3) - C(5) - C(6) - C(7) -176.46(13) 
C(4) - C(5) - C(6) - C(7) 0.6(2) 
O(4) - C(6) - C(7) - C(2) -178.76(14) 
C(5) - C(6) - C(7) - C(2) 0.3(2) 
C(3) - C(2) - C(7) - C(6) -1.1(2) 
C(1) - C(2) - C(7) - C(6) -178.97(13) 
C(1) - N(1) - C(11) - C(19) 73.16(16) 
N(2) - N(1) - C(11) - C(19) -112.52(13) 
C(1) - N(1) - C(11) - C(12) -166.64(12) 
N(2) - N(1) - C(11) - C(12) 7.68(14) 
N(1) - C(11) - C(12) - C(13) -7.14(13) 
C(19) - C(11) - C(12) - C(13) 113.43(13) 
N(1) - N(2) - C(13) - C(14) -179.52(12) 
N(1) - N(2) - C(13) - C(12) -0.65(16) 
C(11) - C(12) - C(13) - N(2) 5.34(16) 
C(11) - C(12) - C(13) - C(14) -175.84(12) 
C(18) - N(3) - C(14) - C(15) -0.7(2) 
C(18) - N(3) - C(14) - C(13) -179.71(13) 
N(2) - C(13) - C(14) - N(3) -165.69(13) 
C(12) - C(13) - C(14) - N(3) 15.6(2) 
N(2) - C(13) - C(14) - C(15) 15.3(2) 
C(12) - C(13) - C(14) - C(15) -163.49(14) 
N(3) - C(14) - C(15) - C(16) 0.6(2) 
C(13) - C(14) - C(15) - C(16) 179.55(14) 
C(14) - C(15) - C(16) - C(17) 0.2(2) 
C(15) - C(16) - C(17) - C(18) -0.8(2) 
C(14) - N(3) - C(18) - C(17) 0.0(2) 
C(16) - C(17) - C(18) - N(3) 0.8(3) 
N(1) - C(11) - C(19) - C(20) 31.53(19) 
C(12) - C(11) - C(19) - C(20) -82.02(17) 
N(1) - C(11) - C(19) - C(24) -153.00(13) 
C(12) - C(11) - C(19) - C(24) 93.45(16) 
C(24) - C(19) - C(20) - C(21) -0.8(2) 
C(11) - C(19) - C(20) - C(21) 174.63(15) 
C(19) - C(20) - C(21) - C(22) 0.0(3) 
C(20) - C(21) - C(22) - C(23) 0.6(3) 
C(21) - C(22) - C(23) - C(24) -0.4(3) 
C(20) - C(19) - C(24) - C(23) 1.0(2) 
C(11) - C(19) - C(24) - C(23) -174.57(15) 
C(22) - C(23) - C(24) - C(19) -0.4(3) 
  
 
 
 
 
 
 
 
 
